610 Medizin und Gesundheit
Refine
Year of publication
- 2020 (867) (remove)
Document Type
- Article (678)
- Doctoral Thesis (103)
- Preprint (66)
- Contribution to a Periodical (10)
- Part of Periodical (6)
- Book (3)
- Master's Thesis (1)
Has Fulltext
- yes (867)
Keywords
- COVID-19 (20)
- inflammation (17)
- SARS-CoV-2 (11)
- quality of life (8)
- Quality of life (7)
- biomarker (7)
- cancer (7)
- macrophage (7)
- obesity (7)
- ADHD (6)
- depression (6)
- MRI (5)
- Machine learning (5)
- immunotherapy (5)
- pain (5)
- polytrauma (5)
- stroke (5)
- ACLF (4)
- EEG (4)
- Epilepsy (4)
- HIV (4)
- Inflammation (4)
- Rare diseases (4)
- Stroke (4)
- TAVI (4)
- aortic stenosis (4)
- autophagy (4)
- bipolar disorder (4)
- bladder cancer (4)
- breast cancer (4)
- cognition (4)
- coronavirus (4)
- cytokines (4)
- drug resistance (4)
- exercise (4)
- portal hypertension (4)
- schizophrenia (4)
- tumor microenvironment (4)
- Abdominal aortic aneurysm (3)
- Aortic stenosis (3)
- Biomarkers (3)
- Cardiovascular magnetic resonance (3)
- Cirrhosis (3)
- DNA methylation (3)
- Diagnostics (3)
- Diagnostik (3)
- Endovascular repair (3)
- Gesundheitsökonomie (3)
- Health economics (3)
- Heart failure (3)
- Human behaviour (3)
- Hypoxia (3)
- Infections (3)
- Macrophages (3)
- Magnetic resonance imaging (3)
- Mortality (3)
- NASH (3)
- Offene Versorgung (3)
- Open repair (3)
- Peri-implantitis (3)
- Postural control (3)
- Register (3)
- Registries (3)
- Registry (3)
- Strength training (3)
- Treatment (3)
- acute-on-chronic liver failure (3)
- apoptosis (3)
- attention (3)
- child (3)
- chimeric antigen receptor (3)
- complications (3)
- cytotoxicity (3)
- epilepsy (3)
- glioblastoma (3)
- glioma (3)
- hippocampus (3)
- integrins (3)
- iron (3)
- machine learning (3)
- macrophages (3)
- mesenchymal stromal cells (3)
- miRNA (3)
- microRNA (3)
- microbiome (3)
- migration (3)
- neuroblastoma (3)
- neurodegeneration (3)
- outcome (3)
- ovarian cancer (3)
- physical activity (3)
- precision medicine (3)
- prevalence (3)
- prevention (3)
- proliferation (3)
- prostate cancer (3)
- proteostasis (3)
- psoriasis (3)
- reactive oxygen species (3)
- sulforaphane (3)
- toxicity (3)
- 3D printing (2)
- 3D rapid prototyping (2)
- AML (2)
- ATP (2)
- Abdominelles Aortenaneurysma (2)
- Alzheimer’s disease (2)
- Artificial intelligence (2)
- Ascites (2)
- Ataxia telangiectasia (2)
- Autism spectrum disorder (2)
- BMI (2)
- Bibliometrics (2)
- Bladder cancer (2)
- Borrelia (2)
- CD19 (2)
- CD44 (2)
- CNN (2)
- Cancer (2)
- Cardiology (2)
- Cerebrospinal fluid (2)
- Children (2)
- Clinical decision support systems (2)
- Cohort studies (2)
- Computer-assisted diagnosis (2)
- Critical care (2)
- DTI (2)
- Database searching (2)
- Datenschutz (2)
- Dementia (2)
- Depression (2)
- Emergency room (2)
- Endoscopy (2)
- Endovaskuläre Behandlung (2)
- Epidemiology (2)
- Erweiterter Suizid (2)
- Europe (2)
- Extended suicide (2)
- Gemeinschaftliche Selbsttötung (2)
- Gene expression (2)
- Gene regulation (2)
- General practice (2)
- Genetics (2)
- Germany (2)
- Glioma (2)
- HIV-1 (2)
- Healthy adults (2)
- Hepatocellular carcinoma (2)
- IDH mutation (2)
- IL-10 (2)
- Immunohistochemistry (2)
- Immunological methods (2)
- Immunologische Methoden (2)
- Immunology (2)
- In vitro (2)
- Klebsiella pneumoniae (2)
- Klinische Ergebnisse (2)
- Knochenersatzmaterial (2)
- Krankheit (2)
- Language (2)
- Lebensqualität (2)
- Liver diseases (2)
- Liver transplantation (2)
- Long-term potentiation (2)
- MSD (2)
- Medical research (2)
- Metaanalysis (2)
- Morbidity (2)
- Morphology (2)
- Multiple sclerosis (2)
- Myocardial perfusion (2)
- NADPH oxidase (2)
- NAFLD (2)
- Neurology (2)
- Neurons (2)
- Notaufnahme (2)
- Object vision (2)
- Outcome (2)
- PCR (2)
- Patient blood management (2)
- Patients (2)
- Pneumonia (2)
- Preventive medicine (2)
- Public health (2)
- Radiomics (2)
- Remuneration (2)
- Seizure (2)
- Suicide pact (2)
- Survey (2)
- Transfusion (2)
- Treatment outcome (2)
- Validation (2)
- Vergütung (2)
- Wearable cardioverter-defibrillator (2)
- Women (2)
- acute lymphoblastic leukemia (2)
- adaptation (2)
- adolescents (2)
- adult (2)
- aging (2)
- alveolar ridge augmentation (2)
- animal experiment (2)
- antiepileptic drugs (2)
- augmentation (2)
- bibliometrics (2)
- biomarkers (2)
- body mass index (2)
- cardiac surgery (2)
- cerebral hemorrhage (2)
- cerebral venous thrombosis (2)
- chemoresistance (2)
- children (2)
- cirrhosis (2)
- cleaning (2)
- clinical studies (2)
- coagulopathy (2)
- combination therapy (2)
- complement (2)
- connective tissue (2)
- continuous performance test (2)
- curcumin (2)
- cystic fibrosis (2)
- cytomegalovirus (2)
- data science (2)
- decompensated liver cirrhosis (2)
- delirium (2)
- dental education (2)
- dental implants (2)
- dental profession (2)
- dentoalveolar surgery (2)
- diabetes mellitus (2)
- direct-acting antivirals (2)
- drug discovery (2)
- elderly (2)
- electroencephalography (2)
- environmental tobacco smoke (2)
- evolution (2)
- fascia (2)
- fibroblasts (2)
- fibrosis (2)
- flow cytometry (2)
- gait analysis (2)
- growth (2)
- hepatic encephalopathy (2)
- hepatocellular carcinoma (2)
- histology (2)
- hyperactivity (2)
- hypoxia (2)
- immunity (2)
- immunosuppression (2)
- impulsivity (2)
- infection (2)
- innate immunity (2)
- integrin (2)
- joint contact forces (2)
- kidney (2)
- liver (2)
- liver cirrhosis (2)
- lung cancer (2)
- lung function (2)
- lymphocytes (2)
- mTOR (2)
- mass spectrometry (2)
- metformin (2)
- mitochondria (2)
- multiple sclerosis (2)
- musculoskeletal disorders (2)
- musculoskeletal modeling (2)
- natural killer cells (2)
- neural oscillations (2)
- neurocognition (2)
- oncology (2)
- oral and maxillofacial surgery (2)
- pancreatic cancer (2)
- patient blood management (2)
- periodontitis (2)
- polygenic risk score (2)
- post-translational modifications (2)
- prognosis (2)
- protein degradation (2)
- protein synthesis (2)
- proteome (2)
- proteomics (2)
- public health (2)
- renal cell carcinoma (2)
- resistance training (2)
- risk factors (2)
- risk prediction (2)
- screening (2)
- sepsis (2)
- severe acute respiratory syndrome coronavirus 2 (2)
- simulation training (2)
- sphingosine 1-phosphate (2)
- sphingosine 1-phosphate receptor (2)
- spinal dural leaks (2)
- stress (2)
- superficial siderosis (2)
- surgery (2)
- survival (2)
- survivin (2)
- thrombosis (2)
- thymus (2)
- transcriptome (2)
- transplantation (2)
- tumor growth (2)
- tumor progression (2)
- von Willebrand factor (2)
- (cardiac) surgery (1)
- 14-3-3 gene family (1)
- 16 segment AHA model (1)
- 16S rRNA sequencing (1)
- 19F MR spectroscopy (1)
- 1H MR spectroscopy (1)
- 2'-deoxyguanosine riboswitch (1)
- 2-hydroxyglutarate (1)
- 2019-nCoV (1)
- 3,4-DCA; biotransformation (1)
- 3-hydroxyanthranilic acid (1)
- 3D printed cell-free scaffold (1)
- 3D-Druck (1)
- 4-fluoroamphetamine (1)
- 9-HODE (1)
- A-FFIP (1)
- A2BP1 (1)
- AAA+ disaggregase (1)
- ABC transporters (1)
- ABCB1 (1)
- ABCC1 (1)
- ACE-Bestimmung (1)
- ADAMTS-13 (1)
- ADAMTS13 (1)
- ADGRE1 (1)
- ADHD differential diagnosis (1)
- ADHS (1)
- AKI (1)
- ALL (1)
- AMH (1)
- AML – acute myeloid leukemia (1)
- ARDS (1)
- ASD-specific (1)
- ASPECTS (1)
- ATP binding (1)
- Abductor pollicis longus (1)
- Ablation (1)
- Abrasion (1)
- Absenteeism (1)
- Absorption modeling (1)
- Abusive head trauma (AHT) (1)
- Access (1)
- Accumulated degree days (1)
- Acellular dermis (1)
- Acoustics (1)
- Action potentials (1)
- Acute HIV infection (1)
- Acute appendicitis (1)
- Acute elbow dislocation (1)
- Acute hospital (1)
- Acute lymphoblastic leukemia (1)
- Acute lymphocytic leukaemia (1)
- Acute-on-chronic subdural hematoma (1)
- Addison’s disease (1)
- Adenosine (1)
- Adherence (1)
- Adipose tissue (1)
- Administrative claims data (1)
- Advanced breast cancer (1)
- Adverse drug reaction (1)
- Afrikanische Schlafkrankheit (1)
- Age determination (1)
- Age determination by skeleton (1)
- Age groups (1)
- Aging (1)
- Albumin ratio (1)
- Algorithms (1)
- Alkaloid (1)
- Allergic rhinitis (1)
- Allgemeinmedizin (1)
- Allogeneic (1)
- Alpha oscillations (1)
- Alzheimer's disease (1)
- Amino acid analysis (1)
- Amisulpride (1)
- Amitriptyline (1)
- Anal cancer (1)
- Anandamide (1)
- Anatomy (1)
- Anderson–Fabry (1)
- Andropogon virginicus (1)
- Angiogenesis (1)
- Angiotensin Converting Enzyme (1)
- Angiotensin-converting enzyme (1)
- Animal model (1)
- Anterior cruciate ligament reconstruction (1)
- Anti-CMV IgG (1)
- Anti-inflammatory (1)
- Anti-rheumatic agents (1)
- Anticholinergic (1)
- Anticoagulant (1)
- Anticoagulant therapy (1)
- Anticoagulants (1)
- Anticoagulation (1)
- Antidepressiva (1)
- Antigens/Peptides/Epitopes (1)
- Antihormone therapy (1)
- Antiviral immune response (1)
- Aortic input function (1)
- Apoptosis (1)
- Appendectomy (1)
- Aquilegia (1)
- Arbeitsgedächtnis (1)
- Arrhythmia syndromes (1)
- Arthroplasty (1)
- Ataxia score (1)
- Athletes (1)
- Atm (1)
- Atrial fibrillation (1)
- Attention deficit (1)
- Auditory cortex (1)
- Auditory midbrain (1)
- Auditory system (1)
- Aufmerksamkeit (1)
- Aufmerksamkeitsleistung (1)
- Autoimmune vasculopathy (1)
- Autologous biomaterial (1)
- Autopsy (1)
- Awareness campaign (1)
- Axiography (1)
- B cells (1)
- B-cell lymphoma (1)
- B-cell receptor (1)
- BAG3 (1)
- BCL6 (1)
- BCX7353 (1)
- BDNF (1)
- BET inhibitor (1)
- BEZ235 (1)
- BFIS (1)
- BG-index (1)
- BIRC5 (1)
- BK channel (1)
- BMC (1)
- BRD4 (1)
- Bacterial abundance (1)
- Bagatelltrauma (1)
- Bakterien (1)
- Bakterientest (1)
- Balloon-expandable TAVI (1)
- Bauchaortenaneurysma (1)
- Bee venom allergy (1)
- Begriffsbestimmung (1)
- Belastung (1)
- Benign enlargement of the subarachnoid spaces (BESS) (1)
- Benign pulmonary diseases (1)
- Benigne Lungenerkrankungen (1)
- Bestimmungsmethoden (1)
- Bestrahlung (1)
- Betriebliche Gesundheitsförderung (1)
- Bewegungsanalyse mit Inertialsensoren (1)
- Bewegungsstörung (1)
- Bildgebung (1)
- BioID (1)
- Bioavailability prediction (1)
- Biomarker (1)
- Biopsy (1)
- Bleeding (1)
- Blocked occlusion (1)
- Blood flow (1)
- Body limbs (1)
- Body measurements (1)
- Body modification (1)
- Body temperature (1)
- Bone defect (1)
- Bone regeneration (1)
- Bone remodelling (1)
- Bone substitute (1)
- Bone tissue engineering (1)
- Brain asymmetry (1)
- Brain injuries (1)
- Brain size I (1)
- Brain structure (1)
- Brain tumor surgery (1)
- Brain tumors (1)
- Brain-stimulus synchrony (1)
- Breast cancer survivers (1)
- Breathing (1)
- Brustkrebs (1)
- Burden (1)
- Burden of illness (1)
- Büroangestellte (1)
- C1 inhibitor (1)
- C2 domain (1)
- CAD/CAM (1)
- CAKUT (1)
- CAR (1)
- CCL2 (1)
- CD107-Assay (1)
- CD3 (1)
- CD34 + cells (1)
- CD4 binding site (1)
- CD41 (1)
- CD49d (1)
- CD62P (1)
- CD8+ T cell (1)
- CDI (1)
- CDK9 (1)
- CEBPD (1)
- CIRS (1)
- CLP (1)
- CMVepidemiology (1)
- COINS (1)
- COMP (1)
- COVID 19 pandemic (1)
- CPT1A (1)
- CRE-dependent transcription (1)
- CRISPR/Cas9 (1)
- CUELA system (1)
- CXCL10 (1)
- CXCR3 (1)
- Callous-unemotional traits (1)
- Calpain (1)
- Cancer check up (1)
- Cancer treatment (1)
- Candida spp (1)
- Cannabidiol (1)
- Capnography (1)
- Cardiac acoustic biomarkers (1)
- Cardiac arrest (1)
- Cardiac masses (1)
- CardioMEMS™ HF system (1)
- Careers (1)
- Caspase-8 (1)
- Cell death and immune response (1)
- Cell staining (1)
- Cell-based therapies (1)
- Cellular neuroscience (1)
- Central nervous system (1)
- Cerebellum (1)
- Cerebral hypoperfusion (1)
- Cerebrovascular disorders (1)
- Checkpoint inhibitor (1)
- Chemoradiation (1)
- Chemoradiotherapy (1)
- Chemotherapie (1)
- Chemotherapy (1)
- Child (1)
- Child abuse (1)
- Child health (1)
- Children and adolescents (1)
- Chimiothérapie (1)
- Chirurgie (1)
- Chromatin accessibility (1)
- Chromatin conformation (1)
- Chronic conditions (1)
- Chronic depression (1)
- Chronic inflammation (1)
- Chronology of disease (1)
- Classification (1)
- Clavien–Dindo classification (1)
- Climate inequity (1)
- Clinical genetics (1)
- Clinical trial (1)
- Clinical trials (1)
- Clostridium (1)
- Clustering coefficients (1)
- Coagulation (1)
- Coagulopathy management (1)
- Cognition (1)
- Cognitive behavioral therapy (1)
- Cognitive impairment (1)
- Cognitive neurology (1)
- Cold hardiness (1)
- Cold tolerance (1)
- Collagen-based biomaterial (1)
- Colonic neoplasms (1)
- Combo® DTS (1)
- Comparators (1)
- Complications (1)
- Compression stocking (1)
- Computed axial tomography (1)
- Computer hardware (1)
- Computer science (1)
- Computer software (1)
- Computer-aided drug design (1)
- Computers (1)
- Concept paper (1)
- Conduct disorder (1)
- Conduct problems (1)
- Confinement (1)
- Congenital CMVinfection (1)
- Congenital anomalies (1)
- Congenital diaphragmatic hernia (1)
- Connectivity (1)
- Conservative treatment (1)
- Constitution (1)
- Continuous Process Verification (1)
- Control (1)
- Cooperation (1)
- Copy number (1)
- Coronary artery disease (1)
- Coronavirus (1)
- Cortical degeneration (1)
- Cortical thickness (1)
- Cp (1)
- Cpk (1)
- Craniomaxillofacial injuries (1)
- Critical Online Reasoning Assessment (1)
- Critical size (1)
- Croatia (1)
- Crohn's disease (1)
- Crohn’s disease (1)
- CspA (1)
- CspZ (1)
- Curriculum (1)
- Cyp46a1 (1)
- CysLTR1 (1)
- Cysteine‐Rich Domain (CRD) (1)
- Cystic fibrosis (1)
- Cytokines (1)
- Cytomegalovirus (CMV) (1)
- DAMPs (1)
- DBS (1)
- DFNB9 (1)
- DILI (1)
- DNA damage (1)
- DNA damage response (1)
- DNA sequence analysis (1)
- DNase1-seq (1)
- DRG (1)
- DST (1)
- DYRK1A (1)
- Darunavir (1)
- Data processing (1)
- Data protection (1)
- Data science (1)
- Datenverarbeitung (1)
- Decision making (1)
- Decontamination (1)
- Deep vein thrombosis (1)
- Defibrillation (1)
- Dehnen (1)
- Delegation (1)
- Demenz (1)
- Density equalizing mapping (1)
- Density-equalizing mapping (1)
- Dental air (1)
- Dental casts (1)
- Dental implant (1)
- Dental implants (1)
- Dental practice (1)
- Dental students (1)
- Determination method (1)
- Developmental disorders (1)
- Diabetes mellitus (1)
- Diagnosis (1)
- Diagnosis related groups (1)
- Diagnostic algorithm (1)
- Diagnostic error (1)
- Diagnostic markers (1)
- Differential diagnosis (1)
- Diffuse large B-cell lymphoma (1)
- Disabilities (1)
- Disaster victim identification (1)
- Disc herniation (1)
- Diseases (1)
- Disintegration (1)
- Distress screening (1)
- Distribution limits (1)
- Dopamine (1)
- Double suicide (1)
- Double-blind placebo-controlled trial (1)
- Douleur (1)
- Downy mildew (1)
- Dravet syndrome (1)
- Drug permeability (1)
- Drug susceptibility testing (1)
- Dural onlays (1)
- Dysphagia (1)
- Désir d’enfant (1)
- E-NTPDase (1)
- E3 ligase (1)
- EBM (1)
- EEG reference choices (1)
- EGFR (1)
- EGFR pathway (1)
- EGFRvIII mutation (1)
- EGR1-dependent transcription (1)
- ELISA (1)
- EMR1 (1)
- EMT (1)
- EQIP (1)
- ERBB2 (HER2/neu) (1)
- ERK3 (1)
- ES (1)
- ESMO-MCBS (1)
- Early intervention (1)
- Ebola virus (1)
- Echovirus-30 (1)
- Ecto-5'-nucleotidase (1)
- Edoxaban (1)
- Education (1)
- Einstellungen (1)
- Einwilligungsfähigkeit (1)
- Eisenmangel (1)
- Ejection fraction (1)
- Elderly (1)
- Electrical stimulation (1)
- Embryos (1)
- Emergency treatment (1)
- Emotions (1)
- End-of-life decisions (1)
- Endocrinology (1)
- Endometrial carcinoma (1)
- Endometriome (1)
- Endométriomes (1)
- Endothelial cells (1)
- Endothelial protein C receptor (1)
- Endovaskuläre Versorgung (1)
- Endpoints (1)
- Enterobacteriaceae (1)
- Entscheidungsassistenz (1)
- Epidemiological data (1)
- Epidural abscess (1)
- Epigenetics (1)
- Epilepsie (1)
- Episodic memory (1)
- Epstein-Barr virus (1)
- Erdnussallergie (1)
- Ergonomic analysis (1)
- Ergonomie am Arbeitsplatz (1)
- Ergonomische Analyse (1)
- Erregerspektrum der Tonsillitis (1)
- Erwachsene (1)
- Evaluation (1)
- Evidence based medicine (1)
- Evidence-based dentistry (1)
- Evidence-based medicine (1)
- Evidenzbasierte Medizin (1)
- Ewing sarcoma (1)
- Exercise challenge (1)
- Exercise therapy (1)
- Exercise-induced asthma (1)
- Exhaled nitric oxide (1)
- External-/self-assessment (1)
- Eye movements (1)
- Eye tracking (1)
- F4/80 (1)
- F508del homozygous (1)
- FBK-R23 (1)
- FDM (1)
- FET (1)
- FEV1 (1)
- FFF (1)
- FHIR (1)
- FLT3-ITD (1)
- FTMT (1)
- Factor H (1)
- Fasting (1)
- Feedback (1)
- Female subjects (1)
- Ferritinophagy (1)
- Ferroptose (1)
- Ferroptosis (1)
- Fertilität (1)
- Fertilité (1)
- Fibromyalgia (1)
- Finevo (1)
- Fingolimod (1)
- First-line regimen (1)
- Five-Konzept (1)
- Fluid therapy (1)
- Forced expiratory volume in 1 s (1)
- Forensic entomology (1)
- Forensic examination (1)
- Fourier analysis (1)
- Fracture (1)
- Fracture type (1)
- Fragebogenentwicklung (1)
- Fresh frozen plasma (1)
- Functional characterization (1)
- Functional clustering (1)
- Functional mitral regurgitation (1)
- G-CSF (1)
- G-protein-coupled receptors (1)
- G2A receptor (1)
- GABA (1)
- GCN (1)
- GFAP (1)
- GHQ-28 (1)
- GIRD (1)
- GLA deficiency (1)
- GPCR (1)
- GWAS (1)
- Gait analysis (1)
- Gas gangrene (1)
- Gastrocnemius muscles (1)
- Gastroschisis (1)
- Gene expression prediction (1)
- Genetic heart disease (1)
- Genetic syndromes (1)
- Geoffrey Burnstock (1)
- Geographical disparities (1)
- Gerontologie (1)
- Geschichte 1663-1748 (1)
- Geschlecht (1)
- Gesundheit (1)
- Gesundheitsamt (1)
- Gesundheitsberichterstattung (1)
- Gesundheitsbildung (1)
- Gesundheitserziehung (1)
- Gesundheitsförderung (1)
- Gesundheitswissenschaften (1)
- Glioblastom (1)
- Global warming (1)
- Graph theory (1)
- Gray matter volume (1)
- Green Tobacco Sickness (GTS) (1)
- Greenhouse effect (1)
- Guided bone regeneration (GBR) (1)
- Guided tissue regeneration (GTR) (1)
- HADS (1)
- HAE (1)
- HBV filaments (1)
- HBV genotypes (1)
- HBV surface protein (1)
- HCC (1)
- HCC recurrence (1)
- HCV (1)
- HDAC (1)
- HDAC and BET inhibitor (1)
- HDAC inhibitor (1)
- HDAC4 (1)
- HEUS (1)
- HEV (1)
- HFrEF (1)
- HHUSD (1)
- HIBCPP cells (1)
- HIFT (1)
- HILI (1)
- HIV-1 escape restriction (1)
- HLA DQ haplotypes (1)
- HLA class I (1)
- HNSCC (1)
- HOSO (1)
- HRM (1)
- Haematocrit (1)
- Haemodynamic monitoring (1)
- Hausarztmangel (1)
- HbA1c (1)
- HeLa cells (1)
- Health care (1)
- Health care sector (1)
- Health education and awareness (1)
- Health literacy (1)
- Health policy (1)
- Health services (1)
- Healthcare costs (1)
- Healthcare resource utilization (1)
- Health‐related quality of life (1)
- Heat shock protein 27 (1)
- Hematologic malignancies (1)
- Hematoxylin staining (1)
- Hemispheric specialization (1)
- Hemodynamics (1)
- Hepatic encephalopathy (1)
- Hepatitis C virus (1)
- Heregulin (1)
- Heterogeneity (1)
- HiC (1)
- HiChIP (1)
- High oblique sagittal osteotomy (1)
- Hippocampal excitability (1)
- Hippocampus (1)
- Histological analysis (1)
- Histology (1)
- Histoplasma qPCR (1)
- History (1)
- Hmox1 (1)
- HoLEP (1)
- Hodgkin lymphoma (1)
- Hodgkin’s lymphoma (1)
- Homicide-suicide (1)
- Homizid-Suizid (1)
- Hospital case volume (1)
- Hospitalization (1)
- House dust mite allergy (1)
- Human (1)
- Human immunodeficiency virus (HIV) (1)
- Hymenoptera venom immunotherapy (1)
- Hyperactivity (1)
- Hyperscanning (1)
- Hyponatremia (1)
- Hypoxia-inducible factor-1α (HIF-1α) (1)
- Höchstrichterliche Rechtsprechung (1)
- ICAM-1 (1)
- ICD (1)
- IDH1 inhibitor (1)
- IDO1 (1)
- IFA (1)
- IFN-γ expression (1)
- IKKε (1)
- IL-1β (1)
- IL-6 (1)
- ISR (1)
- IV iron (1)
- IVD degeneration (IVDD) (1)
- Iatrochemie (1)
- Iatrochemistry (1)
- Identification (1)
- Identifikation (1)
- Identifizierung von Katastrophenopfern (1)
- Idiopathische Dystonie (1)
- IgG (1)
- Image processing (1)
- Image processing (computer-assisted) (1)
- Immune suppression (1)
- Immune system (1)
- Immunomodulatory agents (1)
- Immunotherapy (1)
- Implant osseointegration (1)
- Implementación (1)
- Implementation (1)
- Imrt (1)
- In vivo (1)
- Induced membrane technique (1)
- Inducible nitric oxide synthase (iNOS) (1)
- Induction chemotherapy (1)
- Inertial motion capture (1)
- Infektionen (1)
- Inferior colliculus (1)
- Inflammatory bowel disease (1)
- Inflammatory pattern (1)
- Injury (1)
- Injury Severity Score (ISS) (1)
- Innate immunity (1)
- Integrated Pulmonary Index (1)
- Integration (1)
- IntelliCage (1)
- Intelligence (1)
- Intensive care (1)
- Interferons (1)
- Internet (1)
- Interoperability (1)
- Interposition (1)
- Interstitial pneumonia (1)
- Interview (1)
- Intoxication (1)
- Intoxikation (1)
- Intravenous antibiotic therapy (1)
- Intravenous injections (1)
- Invasive species (1)
- Ireb2 (1)
- Iron (1)
- Isocitrate dehydrogenase (1)
- JNK (1)
- Joint actions (1)
- Joint loading (1)
- Jumping (1)
- K-homology RNA-binding domain (1)
- KOOS IV (1)
- Ki-67/MIB1 (1)
- Ki67 transgenic c‐myc/TGFα mice (1)
- Kidney diseases (1)
- Kidney neoplasm (1)
- Kinder (1)
- Kinderwunsch (1)
- Kinds of diseases (1)
- Kinematic analysis (1)
- Knees (1)
- Kognitive Beeinträchtigungen (1)
- Konzeptpapier (1)
- Krankenhausfallaufkommen (1)
- Krankheitskosten (1)
- Körpermaße (1)
- Körpermodifizierung (1)
- L-DOPA (1)
- LBP (1)
- LIR interaction, (1)
- LPS (1)
- Lactobacillus (1)
- Landarztprogramm (1)
- Langstreckige Knochendefekte (1)
- Language delay (1)
- Late gadolinium enhancement (1)
- Left hemisphere (1)
- Legal considerations (1)
- Legs (1)
- Lennox-Gastaut syndrome (1)
- Leukemia (1)
- Leukämie (1)
- Lipodystrophy (1)
- Liver transplant (1)
- Local IgE (1)
- Local allergic rhinitis (1)
- Locally advanced (1)
- Lockdown (1)
- Loco-regional control (1)
- Long non-coding RNAs (1)
- Longchain polyunsaturated fatty acids (1)
- Loving kindness meditation (1)
- Low-dose ionizing radiation (1)
- Low-dose radiation therapy (1)
- Lower back pain (1)
- Lung cancer (1)
- Lung development (1)
- Lung function (1)
- Lung ultrasound (1)
- Lungenerkrankungen (1)
- Lymph nodes (1)
- Lymphocytes (1)
- Lymphoma (1)
- Lysophosphatidic acids (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MAGGIC score (1)
- MAPK6 (1)
- MCAO (1)
- MHC (1)
- MICA (1)
- MM-121 (1)
- MMP14 (1)
- MODY (1)
- MR-spectroscopy (1)
- MS (1)
- MYC (1)
- Machine learning algorithms (1)
- Machine-learning (1)
- Macroautophagy (1)
- Macrophage polarization (1)
- Malaria (1)
- Mammakarzinom (1)
- Management (1)
- Marker genes (1)
- Market Access (1)
- Masquelet technique (1)
- Mass disaster (1)
- Massenkatastrophe (1)
- Massenspektrometrie (1)
- Master Plan 2020 (1)
- Masterplan 2020 (1)
- Maxillofacial surgery (1)
- Mean erythrocyte volume (1)
- Medical education (1)
- Medical implants (1)
- Medical law (1)
- Medical risk factors (1)
- Medical studies (1)
- Medicinal chemistry (1)
- Medizin (1)
- Medizinrecht (1)
- Medizinstudierende (1)
- Medizinstudium (1)
- Meldepflicht (1)
- Membrane potential (1)
- Memory consolidation (1)
- Memory quality (1)
- Mesenchymal stromal cells (MSC) (1)
- Mesh (1)
- Meta-analysis (1)
- Metabolic diseases (1)
- Metastatic (1)
- Metta (1)
- Michael acceptor (1)
- MicroRNA-181a (1)
- Microbiology (1)
- Microfluidics (1)
- Microglial cells (1)
- Microparticles (1)
- Microphysiological models (1)
- Microstates (1)
- Midwifery (1)
- Mindfulness (1)
- Minimally invasive surgical procedures (1)
- Minor injury (1)
- Mitochondrial dysfunction (1)
- MitraClip (1)
- Mobilization (1)
- Molecular autopsy (1)
- Molecular diagnostic testing (1)
- Molecular neuroscience (1)
- Monetary incentive delay (1)
- Mongolian spot (1)
- Monitoring (1)
- Monocytes (1)
- Morphologie (1)
- Motivational situation (1)
- Motivationslage (1)
- Motor control (1)
- Motor cortex (1)
- Mouse models (1)
- Mucomaix® matrix (1)
- Multidrug-resistance (1)
- Multimedication (1)
- Multimorbidity (1)
- Multiparametric MRI (1)
- Multiplate (1)
- Multiple Sklerose (1)
- Multiple-indication review (1)
- Mundhöhlenkarzinome (1)
- Muscle functions (1)
- Musculoskeletal diseases (1)
- Muskuloskelettale Erkrankungen (1)
- Mutation databases (1)
- Muttermilch (1)
- Mutual information (1)
- Myocardial infarction (MI) (1)
- Myocardial injury (1)
- Myocardial segmentation (1)
- Myonecrosis (1)
- Mφs (1)
- N-glycoproteome (1)
- N2 (1)
- NAFL (1)
- NCOA4 (1)
- NCoR1 (1)
- NDBI (1)
- NF-κB (1)
- NF-κB pathway (1)
- NF-кB (1)
- NIRS (1)
- NK-ZELL-BASIERTER IMMUNTHERAPIE (1)
- NK-ZELLEN (1)
- NKG2D (1)
- NLRP3 inflammasomes (1)
- NMES (1)
- NMR spectroscopy (1)
- NOTCH (1)
- NPH insulin (1)
- NREM sleep (1)
- NS1608 (1)
- NSE (1)
- NTM (1)
- Nachtschattengewächs (1)
- Natural sounds (1)
- Necrotizing fasciitis (1)
- Negative appendectomy rate (1)
- Nek1 (1)
- Neonatal brain damage (1)
- Neonatal surgery outcome (1)
- Nephrectomy (1)
- Nesplora Aquarium (1)
- Network models (1)
- Network motifs (1)
- Neural circuits (1)
- Neural networks (1)
- Neurocognition (1)
- Neurodegeneration (1)
- Neurodevelopmental disorders (1)
- Neuron (1)
- Neuronal plasticity (1)
- Neuropathic pain (1)
- Neurophysiology (1)
- Neuropsychological testing (1)
- Neuropsychology (1)
- Neuroscience (1)
- Neurosurgery (1)
- Neurotransmitter (1)
- Nevus of Ito (1)
- Nevus of Ota (1)
- Next-generation sequencing (1)
- Nicotine (Nicotiana tabacum/ Nicotiana rustica) (1)
- Nicotinic acetylcholine receptors (1)
- Nikotin (Nicotiana tabacum/ Nicotiana rustica) (1)
- Nikotinerge Acetylcholinrezeptoren (1)
- Nivolumab (1)
- Non-abusive head trauma (NAHT) (1)
- Non-allergic-rhinitis (1)
- Non-apoptotic functions (1)
- Non-clear cell renal cell cancer (1)
- Non-small cell lung cancer (1)
- Non-tuberculous mycobacteria (1)
- Non-vitamin K antagonist oral anticoagulants (1)
- Nordic questionnaire (1)
- Normal distribution (1)
- Normative modeling (1)
- NoxO1 (1)
- Number of platelets (1)
- OGTT (1)
- OR time (1)
- OSA (1)
- OTSC Proctology (1)
- Obduktion (1)
- Obstetrics (1)
- Omphalocele (1)
- Oncology (1)
- Open Access (1)
- Opioids (1)
- Oppositional defant disorder (1)
- Optogenetics (1)
- Oral anticoagulation (1)
- Oral cancer (1)
- Organoids (1)
- Orphan nuclear receptor (1)
- Orthognathic surgery (1)
- Oryctolagus cuniculus (1)
- OspE (1)
- Osteoarthritis (1)
- Osteonecrosis (1)
- Outcomes (1)
- Ovarian cancer treatment (1)
- Ovarielle Reserve (1)
- Ovartoxizität (1)
- Overwintering (1)
- Oxygen (1)
- PARK2 (1)
- PBMC (peripheral blood mononuclear cells) (1)
- PBPK (1)
- PD-1 inhibitor (1)
- PDE inhibition (1)
- PDE‐5‐inhibitor (1)
- PEA-15 (1)
- PHGDH (1)
- PI3K/mTor inhibition (1)
- PKD (1)
- PKD/IC (1)
- PLSC (1)
- PRNT (1)
- PROM (1)
- PRRT2 (1)
- PSA screening (1)
- PSA-Screening (1)
- PV loop (1)
- PWI (1)
- PYGL (1)
- Paediatric trauma patients (1)
- Pain (1)
- Pain sensation (1)
- Palliative care (1)
- Parasympathetic (1)
- Parkinson's disease (1)
- Pathogenesis (1)
- Pathologists (1)
- Patient information materials (1)
- Patient outcome assessment (1)
- Patient reported outcomes (1)
- Patient safety (1)
- Patterns of care (1)
- Peanut allergy (1)
- Pediatric patients (1)
- Peer review (1)
- Pelvic (1)
- Percutaneous endoscopic gastrostomy (1)
- Performance Metrics (1)
- Pericardial effusion (1)
- Pericarditis (1)
- Periodontitis grades B and C (1)
- Periprocedural anticoagulation (1)
- Perrault syndrome (1)
- Persistent depressive disorder (1)
- Pgrmc1 (1)
- Phalangeal fractures (1)
- Pharma Management (1)
- Pharmaceutical (1)
- Pharmacology (1)
- Phase I clinical trial (1)
- Phase II trial (1)
- Phase rotors (1)
- Phenotypic plasticity (1)
- Philemon and Baucis (1)
- Philemon und Baucis (1)
- Phosphoproteome (1)
- Phylogeny (1)
- Physical activity (1)
- Physician-assisted suicide (1)
- Physicians (1)
- Pim-1 (1)
- Plantagearbeiter (1)
- Plantation workers (1)
- Plasma transfusion (1)
- Plasma usage (1)
- Platelet-rich fibrin (1)
- Polygenic risk score (1)
- Polypharmacy (1)
- Polysomnography (1)
- Polytrauma (1)
- Portal hypertension (1)
- Portal veins (1)
- Post mortem interval (1)
- Posture (1)
- Pp (1)
- Ppk (1)
- Praktisches Jahr (1)
- PreS1 deletion (1)
- Preclinical drug development (1)
- Prediction (1)
- Premotor cortex (1)
- Pressure distribution (1)
- Pressure measuring plate (1)
- Prevalence (1)
- Prevention (1)
- Pre‐Ligand Assembly Domain (PLAD) (1)
- Primary breast lymphoma (1)
- Primary care (1)
- Primary health care (1)
- Probability density (1)
- Probability distribution (1)
- Procalcitonin (1)
- Procedural skills (1)
- Process Capability (1)
- Process Performance (1)
- Process Validation (1)
- Professions (1)
- Progestatifs synthétiques (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Prostate cancer (1)
- Protease inhibitor therapy (1)
- Proteasome inhibitor (1)
- Protestantism (1)
- Prototypes (1)
- Präanalytik (1)
- Prävention (1)
- Pseudoprogression (1)
- Psycho-oncology (1)
- Psychological stress (1)
- Psychologische Beeinträchtigung (1)
- Psychology (1)
- Psychopharmaka (1)
- Psychosocial impact (1)
- Pteridine (1)
- Pulmonary edema (1)
- Pulmonary embolism (1)
- Pulmonary hypertension (1)
- Pulmonary hypoplasia (1)
- QOL (1)
- Qb-Test (1)
- QbTest® (1)
- Qualitative research (1)
- Quality Control (1)
- Quality indicators (1)
- Qualitätsindikatoren (1)
- Quantitative (q)T2 mapping (1)
- Quantitative magnetic resonance imaging (1)
- Quantitative research (1)
- Quantra (1)
- Quarantine (1)
- Questionnaire (1)
- Questionnaires (1)
- Quinolones (1)
- R406 (1)
- RAS (1)
- RBC (1)
- RBFOX1 (1)
- RDoC (1)
- RIPK1 (1)
- RNA chaperone (1)
- RNA structures (1)
- RNA therapeutics (1)
- RNAseq analysis (1)
- RRMS (1)
- RUCAM (1)
- RULA (1)
- Radiation exposure (1)
- Radical cystectomy (1)
- Radiotherapy (1)
- Radiothérapie (1)
- Ramadan (1)
- Randomised trial (1)
- Randomized controlled trial (1)
- Randomized controlled trials (1)
- Randomized trial (1)
- Rapid diagnostic test (1)
- Ratgeber (1)
- Real-time phase contrast (1)
- Rechtliche Würdigung (1)
- Rectal cancer (1)
- Reference values (1)
- Referenzwerte (1)
- Refractory ALL (1)
- Refractory AML (1)
- RegJoint™ (1)
- Regeneration (1)
- Regret (1)
- Regulatory Affairs (1)
- Relaxometrie (1)
- Reliability (1)
- Renal replacement therapy (1)
- Rescue medication (1)
- Research & Development (1)
- Research investment (1)
- Respiration (1)
- Respiratory distress syndrome (1)
- Resting-state (1)
- Retinal diseases (1)
- Retinoic acid (1)
- Retrospective studies (1)
- Return to work (1)
- Review (1)
- Reward (1)
- Rezidiv (1)
- Rhabdomyosarkom (1)
- Rheumatoid arthritis (1)
- Right hemisphere (1)
- Risk factors (1)
- Risk-stratification (1)
- Robotik (1)
- Roussel Uclaf Causality Assessment Method (1)
- Roux-en-Y gastric bypass (1)
- Running (1)
- Rush protocol (1)
- Récidive (1)
- Réserve ovarienne (1)
- S100b (1)
- S1P lyase (1)
- S1P receptors (1)
- S1P1–5 (1)
- S1PR4 (1)
- SARS‐CoV‐2 (1)
- SCA2 (1)
- SCN5A (1)
- SEAP (1)
- SENP (1)
- SF-36 (1)
- SIDS (1)
- SIRS (1)
- SKI II (1)
- SLC20A1 (1)
- SLUG (1)
- SMAD (1)
- SNORD95 (1)
- SPC (1)
- SPSS (1)
- STAT3 (1)
- SUMO (1)
- Safety (1)
- Sarcoidosis (1)
- Sarcomas (1)
- Sarkoidose (1)
- Saudi Arabia (1)
- Scaffold (1)
- Schlaganfall (1)
- Schmerz (1)
- Schädel-MRT (1)
- Seattle heart failure model (1)
- Second donation (1)
- Secular trend (1)
- Selbstmordpakt (1)
- Self-expandable TAVI (1)
- Seltene Erkrankungen (1)
- Semitendinosus tendon autograft (1)
- Senescence (1)
- Sensorimotor processing (1)
- Sepsis (1)
- Seribantumab (1)
- Serin (1)
- Serious injured children (1)
- Seroconverter (1)
- Seroprevalence (1)
- Serum biomarker (1)
- Sex (1)
- Sharp injuries (1)
- Shoulder injury (1)
- Shoulder luxation (1)
- Sialic acid (1)
- Sialinsäure (1)
- Side effects (1)
- Signal intensity (1)
- Signs and symptoms (1)
- Single-Molecule Localization Microscopy (SMLM) (1)
- Slc11a2 (1)
- Slc25a37 (1)
- Sleep (1)
- Sleep deprivation (1)
- Smac mimetic (1)
- Small molecules (1)
- Social brain (1)
- Social differences (1)
- Social information processing (1)
- Social participation (1)
- Socio-economic analysis (1)
- Socioeconomic analysis (1)
- Socioeconomic indices (1)
- Soft tissue infection (1)
- Software tools (1)
- Solanaceae (1)
- Sozialwissenschaften (1)
- Speech (1)
- Spine fractures (1)
- Spinocerebellar ataxia type 2 (1)
- Sports and exercise medicine (1)
- Stage at presentation (1)
- Standard dataset (1)
- Standard reference values (1)
- Standard value (1)
- State of Control (1)
- Statisitcal Control (1)
- Statisitcal Process Control Chart (1)
- Statistical data (1)
- Status epilepticus (1)
- Stem cell (1)
- Stereoelektroenzephalographie (1)
- Stereotaxie (1)
- Sterols (1)
- Stiffness (1)
- Streptokokken (1)
- Striatum (1)
- Stroke genetics (1)
- Störfaktoren (1)
- Sub-segmentation (1)
- Sub-zero exposure (1)
- Sudden death (1)
- Sudden infant death syndrome (1)
- Sunitinib (1)
- Supported Decision-making (1)
- Supreme court ruling (1)
- Surgeons (1)
- Surgery (1)
- Surgical and invasive medical procedures (1)
- Surgical therapy (1)
- Surveys (1)
- Suspension (1)
- Swallowing (1)
- Syllables (1)
- Sympathetic (1)
- Symptome (1)
- Synaptic plasticity (1)
- Synaptic transmission (1)
- Synthetische Gestagene (1)
- Systematic reviews (1)
- Szientometrie (1)
- Säkularer Trend (1)
- T cell receptor (1)
- T cells (1)
- T-Zellen (1)
- T-cell receptor (1)
- T-tubule system (1)
- T1 and T2 mapping (1)
- T2 (1)
- TAMs (1)
- TAPSE (1)
- TBK1 (1)
- TBSS (1)
- TDM (1)
- TGF-beta (1)
- TGF-β (1)
- TGFβ (1)
- TGR(mREN2)27 (1)
- THV (1)
- TLR2/6 (1)
- TRIMs (1)
- TRPA1 (1)
- TSC22D3 (1)
- TVT (1)
- Tabakkonsum (1)
- Tagging (1)
- Tamponade (1)
- Target validation (1)
- Targeted sequencing (1)
- Temsirolimus (1)
- Tendon incontinence repair (1)
- Tendon transplantation (1)
- Tendons (1)
- Tennis player (1)
- Terminology (1)
- Test assay (1)
- Tfrc (1)
- Therapie (1)
- Therapies (1)
- Therapy (1)
- Thrombotic thrombocytopenic purpura (1)
- Thrombozytenkonzentrat (1)
- Thrombozytentransfusion (1)
- Thumb carpometacarpal joint osteoarthritis (1)
- Tissue engineering (1)
- Tocilizumab (1)
- Todesart (1)
- Toll-like receptor (1)
- Tonsillitis (1)
- Torque (1)
- Total hip arthroplasty (1)
- Touchscreen (1)
- Toxicité ovarienne (1)
- Training history (1)
- Transcatheter Aortic Valve Implantation (1)
- Transcription regulation (1)
- Transcriptional regulatory elements (1)
- Transcriptome analysis (1)
- Transfusion practice (1)
- Transfusionszwischenfall (1)
- Transgenic mice (1)
- Transitional cell carcinoma (1)
- Translation proteomics (1)
- Transportation (1)
- TraumaRegister DGU® (TR-DGU) (1)
- Treatment costs (1)
- Treatment effectiveness (1)
- Treatment modification (1)
- Treatment rates (1)
- Treg (1)
- Treg cell (1)
- Trend Analysis (1)
- Trypanosoma brucei (1)
- Tumor marker (1)
- Tumor microenvironment (1)
- Tumormarker (1)
- Tumormikromilieu (1)
- Type 2 diabetes (1)
- Type of death (1)
- ULK4 (1)
- UPPS (1)
- USP28 (1)
- UV/Vis spectroscopy (1)
- Ubiquitin (1)
- Ubiquitin ligase (1)
- Ubiquitinome (1)
- Ulcerative colitis (1)
- Ultra-rush protocol (1)
- Umfrage (1)
- Unc-51-like kinase (1)
- Uncertainty (1)
- Undergraduate education (1)
- Undergraduates (1)
- Unfälle (1)
- Upper body posture (1)
- Urothelial cancer (1)
- VHH (1)
- VIGALL (1)
- VIM (1)
- VLA4 (1)
- Vascular endothelial growth factor (VEGF) (1)
- Veins (1)
- Venous thromboembolism (1)
- Ventricular arrhythmia (1)
- Ventricular arrhythmias (1)
- Vespid venom allergy (1)
- Videorasterstereography (1)
- Viral infection (1)
- Vmem (1)
- Volume therapy (1)
- Volumetrie (1)
- Volunteer donor (1)
- Vorsorgeuntersuchung (1)
- Voxel-based morphometry (VBM) (1)
- Watertight Dural closure (1)
- Wearable cardioverter‐defibrillator (1)
- Western diet (1)
- Winter survival (1)
- Wissenschaftstheorie (1)
- Workplace ergonomics (1)
- Wound care (1)
- Wound healing (1)
- Wounds (1)
- Wundversorgung (1)
- YM155 (1)
- YWHAE (1)
- YWHAZ (1)
- Year of practical training (1)
- Yellow fluorescent protein (1)
- Zink (1)
- [18F]FET PET (1)
- abnormality detection (1)
- abuse (1)
- abuso (1)
- academic medicine (1)
- acetylation (1)
- acetylcholine (1)
- acetylcholinesterase (1)
- acid dentine lysate (1)
- acidosis (1)
- acoustic emission (1)
- acquired drug resistance (1)
- actin dynamics (1)
- action sounds (1)
- action-effect association (1)
- activated clotting time measurement (1)
- activities of daily life (1)
- activity-based benefits (1)
- acupuncture (1)
- acute coronary syndromes (1)
- acute decompensation (1)
- acute decompensation of cirrhosis (1)
- acute kidney injury (1)
- acute myeloid leukaemia (1)
- acute respiratory distress syndrome (1)
- acute-on-chronic liver failure (ACLF) (1)
- acute‐on‐chronic liver failure (1)
- adaptive cardiac remodelling (1)
- adaptive immunity (1)
- adenovirus (1)
- adhesion (1)
- adiabatic saturation (1)
- adipose-derived mesenchymal stem/stromal cells (1)
- adjuvante Krebstherapie (1)
- adolescentes (1)
- adoptive cancer immunotherapy (1)
- adrenoceptors (1)
- adult and elderly patients (1)
- advanced care planning (1)
- adverse events (1)
- aerobic exercise (1)
- affective disorder (1)
- affective disorders (1)
- affinity purification (1)
- aftercare structures (1)
- age (1)
- aggressiveness (1)
- air flow (1)
- alcohol use disorder (1)
- alcoholic hepatitis (1)
- algorithm (1)
- alirocumab (1)
- alkaloid (1)
- allergy (1)
- allocation (1)
- allogeneic donor (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alpha power (1)
- alpha-galactosidase A deficiency (1)
- alpharetroviral vector (1)
- alternative matrices (1)
- alternative oxidase (1)
- amblyopia (1)
- amino acid PET (1)
- amlexanox (1)
- amyloid beta-peptides (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anaemia walk-in clinic (1)
- anal cancer (1)
- anemia (1)
- angiography (1)
- angiokeratoma diffuse (1)
- animal (1)
- animal model (1)
- annual bleeding rate (1)
- anti-chronic myeloid leukemia (1)
- anti-diabetes (1)
- anti-inflammatory agents (1)
- anti-inflammatory drug (1)
- anti-inflammatory effects (1)
- anti-skin aging (1)
- anti-tumor activity (1)
- antibiotic treatment (1)
- antibody tests (1)
- anticoagulation (1)
- antigen (1)
- antigen processing and presentation (1)
- antigenic variation (1)
- antigens of infectious origin (1)
- antioxidant defense (1)
- antioxidants (1)
- antireflux surgery (1)
- antiresorptive agents (1)
- antiseizure (1)
- antiviral (1)
- antiviral peptide (1)
- anxiety disorder (1)
- aprotinin (1)
- aptamers (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- arousal (1)
- artesunate (ART) (1)
- artificial intelligence (1)
- ascites (1)
- aspiration (1)
- aspirin (1)
- asthma (1)
- asthma phenotypes (1)
- astrogliosis (1)
- asymptomatic (1)
- ataxia telangiectasia (1)
- athletes (1)
- atopy (1)
- attention module (1)
- attention-deficit/hyperactivity disorder (1)
- atypical MAPK kinase (1)
- auditory cortex (1)
- auditory fMRI (1)
- auditory prediction (1)
- auditory processing (1)
- autism (1)
- autism spectrum disorder (1)
- autograft (1)
- autoimmune diabetes (1)
- autoimmune polyglandular syndrome type 2 (1)
- autoimmune thyroiditis (1)
- autoreactivity (1)
- back pain diagnosis (1)
- bacteria (1)
- bacterial translocation (1)
- balloon pulmonary angioplasty (1)
- barbell training (1)
- basal insulin (1)
- behavioral adverse events (1)
- benchmark standards (1)
- berotralstat (1)
- biglycan (1)
- bio imaging (1)
- bio-enabling formulations (1)
- bioactive lipids (1)
- bioavailability (1)
- biobank (1)
- biological maturation (1)
- bioluminescence (1)
- biomarker study (1)
- biopsy naïve (1)
- bipolare Störung (1)
- bladder cancer (BCa) (1)
- bladder exstrophy-epispadias complex (1)
- blinatumomab (1)
- blood (1)
- blood flow recovery (1)
- blood flow restriction (1)
- blood loss (1)
- blood pressure (1)
- blood transfusion (1)
- blood-brain barrier (1)
- blood-cerebrospinal fluid barrier (1)
- body dysmorphic disorder (1)
- body plethysmography (1)
- bone healing (1)
- bone marrow (1)
- bone marrow mononuclear cells (1)
- bone tissue regeneration (1)
- brain (1)
- brain anatomy (1)
- brain function (1)
- brain metastases (1)
- brain shift (1)
- brain tumor (1)
- brain-derived neurotrophic factor (1)
- brainstem (1)
- broad-range qPCR (1)
- broadly neutralizing antibodies (1)
- bronchiolitis obliterans syndrome (1)
- buccal mucosal graft urethroplasty (1)
- bundle (1)
- butyrylcholinesterase (1)
- bypass (1)
- cART (1)
- cBioPortal (1)
- cHL (1)
- caesarean scar (1)
- caesarean section (1)
- calcium handling (1)
- calcium-sensor (1)
- cancer associated fibroblasts (1)
- cancer immunobiology (1)
- cancer information (1)
- cancer specific survival (1)
- candidemia (1)
- canine cancer (1)
- cannabidiol (1)
- cannabinoids (1)
- cannabis (1)
- capsaicin (1)
- carbapenem resistance (1)
- carbapenemase (1)
- carcinoma (1)
- cardiac (1)
- cardiac I/R injury (1)
- cardiac ischaemia‐reperfusion (1)
- cardiac magnetic (1)
- cardiac rehabilitation (1)
- cardiomyopathy (1)
- cardiothoracic surgery (1)
- career promotion (1)
- cartilage oligomeric matrix protein (1)
- catheter (1)
- cell and focal adhesion (1)
- cell death (1)
- cell motility (1)
- cell proliferation (1)
- cell survival (1)
- cell-free expression (1)
- cells (1)
- cellular immunology (1)
- cellular reaction (1)
- cellular therapy (1)
- central nervous system (1)
- ceramides (1)
- cerebellum (1)
- cerumen (1)
- cervical cancer (1)
- cetuximab-bevacizumab therapy sequence (1)
- changes immune activation (1)
- chaperones (1)
- chelation therapy (1)
- chemokine receptor 4 (1)
- chemokines (1)
- chemoprotection (1)
- chemotaxis (1)
- chemotherapeutics-treated (1)
- chemotherapy (1)
- chest trauma (1)
- children and adolescents (1)
- chloroplasts (1)
- cholestasis (1)
- cholesterol (1)
- cholinesterase (1)
- chronic coronary artery disease (1)
- chronic illness (1)
- chronic inflammation (1)
- chronic kidney disease (1)
- chronic liver disease (1)
- chronic low back pain (1)
- chronic metabolic acidosis (1)
- chronic myeloid leukemia (1)
- chronic thromboembolic pulmonary hypertension (1)
- chronic total occlusion (1)
- chronische Niereninsuffizienz (1)
- chronische metabolische Azidose (1)
- circulation (1)
- cisplatin resistance (1)
- cisplatin sensitivity (1)
- classical Hodgkin lymphoma (1)
- clinical (1)
- clinical benefit (1)
- clinical history (1)
- clinical immunology (1)
- clinical pathways (1)
- clinical study (1)
- clinically important restrictions and symptoms (1)
- cloacal malformation (1)
- clock genes (1)
- clopidogrel (1)
- clustering (1)
- co-crystallization (1)
- coagulation (1)
- cochlear implant (1)
- coffee (1)
- cognitive aging (1)
- cognitive decline (1)
- coherence (1)
- collagen type I (1)
- collagen-based matrix (1)
- collateral growth (1)
- colon carcinoma (1)
- colorectal cancer (1)
- colorectal cancer (CRC) (1)
- combined therapy (1)
- common genetic variation (1)
- common variants (1)
- comparative oncology (1)
- comparative pathology (1)
- competition fear (1)
- complement; patients (1)
- complex IV (1)
- computational biology (1)
- computational neuroimaging (1)
- computed tomography (1)
- computer vision (1)
- computer-aided diagnosis (1)
- computer-assisted (1)
- conduct disorder (1)
- confidence (1)
- consolidation treatment (1)
- contact heat evoked potentials (CHEPS) (1)
- contamination (1)
- contralateral delay activity (1)
- coping (1)
- coronary artery bypass surgery (1)
- coronary artery disease (1)
- coronavirus disease 2019 (1)
- cortex (1)
- cortex, gray matter (1)
- cortical folding (1)
- cortisol (1)
- cost-of-illness (1)
- covalent drugs (1)
- covalent inhibitors (1)
- cranberry (1)
- crepitation (1)
- crepitus (1)
- critical care (1)
- cross fitness (1)
- cryogenic electron microscopy (1)
- cyclin Y (1)
- cyclooxygenase 2 (1)
- cyclophosphamide (1)
- cytarabin (1)
- cytokine gene expression (1)
- cytokine storm (1)
- cytokine-induced killer cells (1)
- cytotoxic lymphocytes (1)
- dapagliflozin (1)
- data projection (1)
- day clinic (1)
- debris (1)
- decision making (1)
- decision support systems (1)
- decision-making (1)
- declaration of tobacco ingredients (1)
- decorin (1)
- deep fascia (1)
- deep mutational scanning (1)
- deep sedation (1)
- deferred treatment (1)
- delayed auditory feedback (1)
- delayed treatment (1)
- demineralized bone matrix (1)
- dendritic cells (1)
- dental assistants (1)
- dental emergency treatment (1)
- dentin adhesives (1)
- dentist (1)
- dentistry (1)
- dentists (1)
- depressive symptoms clusters (1)
- detoxification (1)
- deubiquitinating enzyme (1)
- development (1)
- diabetes (1)
- diabetes therapy (1)
- diagnosis (1)
- diagnostic algorithm (1)
- diagnostic test (1)
- diet (1)
- differential scanning fluorimetry (1)
- differentiation (1)
- diffusion tensor imaging (1)
- digital pathology (1)
- dihydroceramide (1)
- disease modelling (1)
- disease models (1)
- dislocation (1)
- distress (1)
- diuretics (1)
- docking studies (1)
- dog study (1)
- donor safety (1)
- drug abstinence (1)
- drug delivery (1)
- drug‐resistant epilepsy (1)
- drug–drug interaction (DDI) (1)
- dual BET/HDAC inhibitor (1)
- dual antiplatelet therapy (1)
- dysbiosis (1)
- dysferlin (1)
- dysferlinopathy (1)
- dysphagia (1)
- e-Health (1)
- e-health (1)
- e-scooter (1)
- eHealth (1)
- early detection (1)
- early myocardial damage (EMD) (1)
- early recognition (1)
- economic burden (1)
- effect mechanism (1)
- effectiveness (1)
- efficacy (1)
- effort (1)
- eight disorders (1)
- elderly patients (1)
- electric scooter (1)
- electroencephalography (EEG), EEG reference choices, event-related potentials (ERP), independent component analysis (ICA), pain research, contact heat evoked potentials (CHEPS) (1)
- electrolytic cleaning (1)
- electromyostimulation (1)
- electron transport chain (1)
- electronic adherence measurement (1)
- electrophilic fatty acids (1)
- elimination rate constant (1)
- embolization (1)
- emergence (1)
- empagliflozin (1)
- encoding (1)
- end of life care (1)
- endocannabinoids (1)
- endolysosomal system (1)
- endometrial cancer (1)
- endothelial cells (1)
- engagement (1)
- enterovirus (1)
- eph receptor tyrosin kinase family (1)
- ephrins (1)
- epidemics (1)
- epidemiology (1)
- epidermal growth factor receptor (1)
- epididymitis (1)
- epigenetic (1)
- epigenetics (1)
- epileptic encephalopathy (1)
- episodic memory (1)
- epithelial cells (1)
- epithelial-to-mesenchymal transition (EMT) (1)
- epithelial‐mesenchymal transition (1)
- epitope mapping (1)
- erectile dysfunction (1)
- ergonomics (1)
- erythropoietin (EPO) (1)
- escape mutations (1)
- essential tremor (1)
- ethyl pyruvate (1)
- euthymic (1)
- event logs (1)
- event-related potentials (1)
- event-related potentials (ERP) (1)
- everolimus (1)
- ex vivo model (1)
- ex-Gaussian analysis (1)
- executive function (1)
- exercise on prescription (1)
- exercise therapy (1)
- exercise treatment (1)
- exertion (1)
- experimental human pain models (1)
- experimental pain models (1)
- expertise (1)
- exposure (1)
- extensively drug-resistant (1)
- external fixation (1)
- external joint moments (1)
- extracellular matrix (1)
- extraction socket healing (1)
- extraversion (1)
- extremity (1)
- eye-tracking (1)
- fMRI (1)
- fMRT (1)
- face inversion effect (1)
- facial nerve functional outcome (1)
- factor VIII (FVIII) (1)
- familial infantile epilepsy (1)
- fasting (1)
- fatigue (1)
- feeder cells (1)
- femoral artery ligation (1)
- fenfluramine (1)
- ferric carboxymaltose (1)
- fibromodulin (1)
- fingolimod (1)
- fixation (1)
- focal cortical dysplasia (1)
- focal seizures (1)
- force transmission (1)
- formalin-fixed paraffin-embedded (FFPE) samples (1)
- fourth (1)
- fractional anisotropy (1)
- fractionation (1)
- fracture (1)
- fragile-X-associated tremor-ataxia syndrome (1)
- fragment-based design (1)
- fragment-based drug design (1)
- free gingival graft (1)
- frontal cortex (1)
- fronto-temporal lobar dementia (1)
- fronto-temporal-lobar-dementia (1)
- fully human (1)
- fumonisin B1 (1)
- functional connectivity (1)
- functional coupling (1)
- functional genetics (1)
- functional imaging (1)
- fundoplication (1)
- furcation involvement (1)
- further education (1)
- fusion (1)
- gap junction protein alpha 4-genotype (1)
- gas chromatography-mass spectrometry (1)
- gastric surgery (1)
- gastrocnemius (1)
- gastroesophageal reflux (1)
- gender (1)
- gender difference (1)
- gene regulation (1)
- gene therapy (1)
- genetic diversity (1)
- genetic generalized epilepsy (1)
- genetic phenotypes (1)
- genetic polymorphisms (1)
- genetic predisposition (1)
- genome-wide association study (1)
- geriatric patients (1)
- geriatrischer Ultraschall (1)
- germ cell tumors (1)
- glioblastoma cells (1)
- glucose (1)
- glucose metabolism (1)
- glycosaminoglycan (1)
- graft (1)
- graph theory (1)
- grey matter volume (1)
- growth inhibition (1)
- gyrification (1)
- haematologic malignancies (1)
- haemophilia A (1)
- haemophilic arthropathy (1)
- haemostasis (1)
- harmine (1)
- health care (1)
- health-related quality of life (1)
- healthcare workers (1)
- healthy subjects (1)
- hearing nerve (1)
- heat stress (1)
- hemadsorption (1)
- hematoma (1)
- hematopoietic stem and progenitor cells (1)
- heme-regulated inhibitory kinase (1)
- hemiplegic migraine (1)
- hemispherotomy (1)
- hemodynamic (1)
- hemodynamic instability (1)
- hemophilia A (1)
- hemorrhage (1)
- hemorrhagic transformation (1)
- hepatic fibrosis (1)
- hepatic stellate cells (1)
- hepatitis C virus (1)
- hepatitis C virus (HCV) (1)
- hepatitis E (1)
- hepatocellular cancer (1)
- hepatocyte nuclear factor 4α (1)
- herb induced liver injury (1)
- hereditary angioedema (1)
- hereditary dystopic lipidosis (1)
- herpes simplex virus (1)
- hiPSC (1)
- high dimensional complex data (1)
- high surgical risk (1)
- high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (1)
- high-throughput nucleotide sequencing (1)
- high-throughput screening (1)
- higher education (1)
- high‐mobility group box‐1 (HMGB1) (1)
- hip joint (1)
- histological outcomes (1)
- histological technic (1)
- histomorphometry (1)
- histone modifications (1)
- histoplasmosis (1)
- home-based (1)
- homeostasis (1)
- hospitalization (1)
- host-pathogen interaction (1)
- huCAR19 (1)
- human decellularized dermis (1)
- human genomics (1)
- human lymph node (1)
- human sera (1)
- humanized mice (1)
- humanized mouse model (1)
- hybrid abutment (1)
- hyperarousal (1)
- hyperexcitability (1)
- hyperglycemia (1)
- hyperhomocysteinemia (1)
- hyperkalemia (1)
- hypertension (1)
- hypoglycaemia (1)
- hypophosphataemia (1)
- iDILI (1)
- iDrug induced liver injury (1)
- image-based risk modelling (1)
- imaging (1)
- immun (1)
- immune checkpoint (1)
- immune checkpoint inhibitors (1)
- immune defense (1)
- immune evasion (1)
- immune response (1)
- immuno-oncotherapy (1)
- immunoprecipitation (1)
- improvement in quality of life (1)
- in vitro (1)
- in vitro in vivo extrapolation (IVIVE) (1)
- in vitro models (1)
- in vivo model of critical size defects (1)
- independent component analysis (ICA) (1)
- indoor air pollution (1)
- induced membrane (1)
- induction chemotherapy (1)
- inertial motion capture (1)
- infant (1)
- infants (1)
- infectious diseases (1)
- inferior frontal gyrus (1)
- inflammatory bowel disease (1)
- inflammatory cytokines (1)
- inflammatory markers (1)
- inhibitors (1)
- injury (1)
- innate and adaptive immune response (1)
- inner ear therapy (1)
- inositol signaling (1)
- insomnia (1)
- instructional interventions (1)
- insulin resistance (1)
- insulitis (1)
- integrated stress response (1)
- inter-individual variability (1)
- interaction partners (1)
- interactome (1)
- interferon type III (1)
- interleukin-6 (1)
- interleukins (1)
- intervertebral disc (IVD) (1)
- intrinsic drug resistance (1)
- invasion (1)
- invasive mold infection (1)
- inverse dynamics (1)
- investigational (1)
- inflammation (1)
- iron deficiency (1)
- iron overload versus deprivation (1)
- iron supplements (1)
- irradiation (1)
- ischaemia (1)
- isolation (1)
- joint bleeding (1)
- joint loading (1)
- joint moments (1)
- juvenile brain lesion (1)
- kaatsu training (1)
- kallikrein inhibitor (1)
- keratinized mucosa (1)
- ketogenic (1)
- ketone body (1)
- kidney formation (1)
- kidney function (1)
- kinase inhibitors (1)
- kinetic fingerprint (1)
- knee adduction moment (1)
- knee joint (1)
- knee noise (1)
- knee sound (1)
- knockout (1)
- kynureninase (1)
- kynurenine (1)
- lacosamide (1)
- lactate (1)
- lamotrigine (1)
- latent class analysis (1)
- left ventricular non-compaction (1)
- left ventricular trabeculation (1)
- leg alignment (1)
- lentiviral vector (1)
- leukocytes (1)
- leukopenia (1)
- levetiracetam (1)
- lichen extracts (1)
- light microscopy (1)
- limb girdle muscular dystrophy type 2B (LGMD2B) (1)
- lipid (1)
- lipid raft (1)
- lipidomic analysis (1)
- lipocalin-2 (1)
- lipoxin A4 (1)
- liquid PRF (1)
- liquid chromatography–mass spectrometry (1)
- liver fibrosis (1)
- liver transplantation (1)
- liver transplantation center (1)
- local inflammation (1)
- local-field potentials (1)
- locus coeruleus (1)
- long reads (1)
- long-term outcome (1)
- long-term potentiation (1)
- long-term prophylaxis (1)
- long-term success (1)
- long-term survival (1)
- longevity (1)
- longitudinal follow-up after epilepsy surgery (1)
- loss (1)
- low doses (1)
- low-density lipoprotein cholesterol (1)
- low-risk (1)
- lower extremity arterial disease (1)
- lumbago (1)
- lumbalgia (1)
- lumbar spinal canal stenosis (1)
- lumican (1)
- lung disease phenotype (1)
- lymphoma (1)
- lysosomes (1)
- mHealth (1)
- mRNA and protein expression (1)
- macrophage polarization (1)
- magentoencephalography (MEG) (1)
- magnetic resonance imaging (1)
- magnetic resonance imaging of the brain (1)
- maintenance (1)
- major adverse cardiovascular events (1)
- major depression (MD) (1)
- major depressive disorder (MDD) (1)
- mammary carcinomas (1)
- management (1)
- mandatory reporting (1)
- maternal tobacco smoke (1)
- mathematical modeling (1)
- matrikine (1)
- matrix metalloproteinases (1)
- mean diffusivity (1)
- measurement properties (1)
- mechanism of action (1)
- mechanistic oral absorption modeling (1)
- medical training (1)
- medication adherence rate (1)
- melanoma (1)
- membrane potential (1)
- membrane repair (1)
- memory (1)
- memory and learning tests (1)
- mental distress (1)
- mesenchymal stem cell (1)
- mesenchymal stromal/stem cells (1)
- meta-analysis (1)
- metabolic reprogramming (1)
- metabolic syndrome (1)
- metabolism (1)
- miR-142-3p (1)
- miR-181 (1)
- miR-6862-5p (1)
- mice (1)
- micro CT (1)
- microdialysis (1)
- microlesions (1)
- microsurgical treatment (1)
- mid-IR spectroscopy (1)
- migration and invasion (1)
- mini gastric bypass (1)
- minimal clinically important difference (1)
- minimal residual disease (1)
- mir-148a (1)
- mitochondrial antiviral signaling protein (MAVS) (1)
- mitochondrial dysfunction (1)
- mitochondrial metabolism (1)
- mitochondrial morphology (1)
- mitochondrial respiration (1)
- mixed lineage kinase domain-like (1)
- model psychosis (1)
- molecular adaptation (1)
- molecular biology (1)
- molecular dynamics (1)
- molecular switch (1)
- molecular tumor board (1)
- molecular typing (1)
- monoamine oxidase A (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- mononuclear cell (1)
- monotype abutment (1)
- monsoon (1)
- morphogenesis (1)
- morphological filtering (1)
- morphometry (1)
- mortality (1)
- mortality analysis (1)
- mortality risk (1)
- motivation (1)
- motor control exercise (1)
- mouse (1)
- mouse model (1)
- mouse models (1)
- movement pattern (1)
- movement profile (1)
- multi-network (1)
- multi-task learning (1)
- multimodal complex treatment (1)
- multimorbidity (1)
- multiple trauma (1)
- multitarget drugs (1)
- murine model (1)
- muscle (1)
- muscle disease (1)
- muscular dystrophy (1)
- musculoskeletal (1)
- musculoskeletal inflammation (1)
- musculoskeletal pain (1)
- musculoskeletal radiographs (1)
- mutational antigenic profiling (1)
- myocardial perfusion (1)
- myofascial (1)
- myofascial chains (1)
- myofascial force transmission (1)
- myoferlin (1)
- myotonia congenita (1)
- nanobodies (1)
- nanodiscs (1)
- narrative content analysis (1)
- narrative economics (1)
- narrative medicine (1)
- natriuretic peptide (1)
- natural cytotoxicity (1)
- natural killer cell (1)
- naturalistic sample (1)
- necrosis (1)
- neglect (1)
- negligencia (1)
- neonate (1)
- neonates (1)
- neonatology (1)
- neoplasms (1)
- nerve (1)
- nerve injury (1)
- networks (1)
- neurexin (1)
- neurogenesis (1)
- neurological impairment (1)
- neuronal maturation (1)
- neuropathic pain (1)
- neuropathy (1)
- neurophysiology (1)
- neuropsychology (1)
- neuroticism (1)
- neurovascular bundle preservation (1)
- neutralization (1)
- neutralizing antibodies (1)
- newborn (1)
- newborn screening (1)
- next-generation sequencing (1)
- nitroalkylation (1)
- niños (1)
- non-coding RNAs (1)
- non-malignant hematological diseases (1)
- noninterventional (1)
- noninvasive blood glucose analysis (1)
- nonspecific (1)
- non‐selective beta‐blocker (1)
- nuclear receptor (1)
- nucleotide analogue (1)
- nucleotide metabolism (1)
- nutrient endocytosis (1)
- observational study (1)
- occupational health (1)
- off-pump surgery (1)
- oncogenic signaling (1)
- oncological gastrectomy (1)
- oncological outcome (1)
- one anastomosis gastric bypass (1)
- online information processing (1)
- online reasoning patterns (1)
- online survey (1)
- operative (1)
- optical coherence tomography (1)
- orientation (1)
- orthopaedic patients (1)
- oscillations (1)
- osteoarthritis (1)
- osteogenic sarcoma cells (1)
- osteoimmunological changes (1)
- otoferlin (1)
- ouabain (1)
- outcomes (1)
- outside-in signaling (1)
- ovary (1)
- overweight (1)
- own-face perception (1)
- oxidised lipids (1)
- pacemaker implantation (1)
- pain research (1)
- pain screening (1)
- pancreatic ductal adenocarcinoma (1)
- pancreatic surgery (1)
- parkinson’s disease (1)
- passive immunization (1)
- passive smoke (1)
- patient centered care (1)
- patient preferences (1)
- patient questionnaire (1)
- patient triage (1)
- patient-reported outcome measure (1)
- patient’s decree (1)
- patient’s perspective (1)
- paxilline (1)
- peanut allergy (1)
- pediatric (1)
- pediatric epilepsy (1)
- pediatric eye screening (1)
- pediatrics (1)
- pelvic packing (1)
- pelvic ring fracture (1)
- peptide antibiotics (1)
- peptide transport (1)
- perceptual closure (1)
- performance assessment (1)
- performance tests (1)
- peri-implantitis (1)
- pericytes (1)
- periimplantitis (1)
- perineurium (1)
- periodontal disease progression (1)
- periodontal risk assessment (1)
- periodontal risk calculator (1)
- periodontal risk factors (1)
- perioperative outcome (1)
- perioperative period (1)
- peripheral arterial disease (1)
- peri‐implantitis (1)
- peri‐implantitis therapy (1)
- person-oriented approach (1)
- personalised therapy (1)
- pet rabbit (1)
- phage (1)
- phage display (1)
- phage lysis proteins (1)
- phage therapy (1)
- pharmacogenetics (1)
- pharmacokinetics/pharmacodynamics (PK/PD) (1)
- pharmacoresistance (1)
- phenotype/genotype relation (1)
- phenotypic spectrum (1)
- phosphate (1)
- phosphorus (1)
- photothermal detection (1)
- physical activity counseling (1)
- physical training (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- pigs (1)
- placenta (1)
- planimetric measurement (1)
- plasma (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- plasmid (1)
- plasticity (1)
- pneumocystis (1)
- point of care (1)
- polo-like kinase 1 (1)
- poly(A)-tail (1)
- polylactide (1)
- polyomavirus (1)
- polypharmacology (1)
- polysomnography (1)
- population dynamics (1)
- portosystemic shunt (1)
- positive organizational e-interventions (1)
- post-caesarean uterus (1)
- post-exercise hypotension (1)
- post-liver transplantation management (1)
- post-traumatic (1)
- posterior fossa tumor (1)
- postmonsoon (1)
- postoperative complications (1)
- postoperative delirium (1)
- posttransnational modification (1)
- posttraumatic inflammation (1)
- posttraumatic stress disorder (1)
- ppi1 (1)
- pre-school asthma (1)
- precision weighting (1)
- prediabetes (1)
- predictive coding (1)
- preschool health examination (1)
- primary biliary cirrhosis (1)
- primary sclerosing cholangitis (1)
- proanthocyanidin (1)
- process mining (1)
- prognostic marker (1)
- prognostic value (1)
- proinflammatory microenvironment (1)
- promotion index (1)
- prophylactic vaccine (1)
- prophylaxis (1)
- proprotein convertase subtilisin/kexin type 9 inhibition (1)
- prostate volume (1)
- protease inhibitor (1)
- protein quality control (1)
- protein turnover (1)
- proteoglycan (1)
- proximal tubule (1)
- pseudokinase (1)
- psoriatic arthritis (1)
- psychischer Stress (1)
- psycho-oncology (1)
- psychology (1)
- psychosocial adjustment (1)
- public health department (1)
- public mental health (1)
- pupillometry (1)
- qRT-PCR (1)
- qRT-PCR detection (1)
- quality (1)
- quality of care (1)
- quantitative MRT (1)
- quantitative proteomics (1)
- quantitative sensory testing (1)
- quantum cascade laser (QCL) (1)
- questionnaire (1)
- radiation oncology (1)
- radical prostatectomy (1)
- radioimmunotherapy (1)
- radiomic (1)
- radiosensitization (1)
- radiotherapy (1)
- radon therapy (1)
- range of motion (1)
- rare disease (1)
- rare diseases (1)
- rare variants (1)
- rat femur critical size defect (1)
- rct (1)
- re-osseointegration (1)
- re-transplantation (1)
- reaction (1)
- reaction time (1)
- readmission rates (1)
- receptor for advanced glycation end product (RAGE) (1)
- recombinant vesicular stomatitis virus‐Zaire ebolavirus (1)
- regioisomers (1)
- regulatory T cell (1)
- regulatory T cells (1)
- regulatory T helper cells (1)
- rehabilitation (1)
- relapsing fever (1)
- relaxometry (1)
- reliable change index (1)
- remodelling (1)
- renal cell cancer (1)
- renal transplantation (1)
- renal tubular cells (1)
- renal tubular epithelial cells (1)
- repeat biopsy (1)
- repeated (1)
- reperfusion injury (1)
- repetition suppression (RS) (1)
- repetitive firing (1)
- replicative fitness (1)
- repsonse process patterns (1)
- requirements analysis (1)
- resective surgery (1)
- resistance (1)
- resistance mutation (1)
- resolution (1)
- resolution of inflammation (1)
- resonance (1)
- resting EEG (1)
- reticulocyte haemoglobin (1)
- retinal (1)
- retinoid X receptor (1)
- rhabdomyosarcoma (1)
- rheumatoid arthritis (1)
- rhodopsin (1)
- ridge preservation (1)
- right heart catheter (1)
- risk factor (1)
- risk score (1)
- rotational thromboelastometry (1)
- sCD163 (1)
- sCD206 (1)
- safety (1)
- sarcoma (1)
- sarcopenia (1)
- scanner noise (1)
- scavenger receptor (1)
- sciatic nerve (1)
- second-hand smoke (1)
- seizures (1)
- selection (1)
- selective autophagy receptor (1)
- self‐expanding (1)
- sensorimotor (1)
- sensory coding (1)
- sensory neuropathy (1)
- serine protease (NS3-4A) (1)
- serology (1)
- serum (1)
- severe acute respiratory syndrome coronavirus (1)
- severe asthma (1)
- severe congenital neutropenia (1)
- severely injured (1)
- sex (1)
- shock filter (1)
- short linear motifs (SLiMs) (1)
- shrinkage (1)
- shunt (1)
- sialitis (1)
- sickle cell anemia (1)
- signaling (1)
- skeletal muscle (1)
- sleepiness (1)
- small molecule inhibitor (1)
- smoking in pregnancy (1)
- social determinants (1)
- social isolation (1)
- socioeconomic status (1)
- soft drinks (1)
- soluble MICA (1)
- sonography (1)
- sparse imaging (1)
- spatial learning (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- specific learning disorder (1)
- sphingosine 1-phoshate (1)
- sphingosine 1-phosphate antagonistst/inhibitors (1)
- sphingosine 1-phosphate metabolism (1)
- sphingosine 1-phosphate signaling (1)
- sphingosine kinase (1)
- sphingosine-1-phosphate (1)
- spiral ganglion cells (1)
- spirochetes (1)
- spirometry (1)
- spontaneous portosystemic shunt (1)
- sports (1)
- sports performance (1)
- spreading (1)
- squamous cell carcinoma (1)
- stabilization (1)
- standardization (1)
- standardized regression-based change norms (1)
- starvation (1)
- steady-state condition (1)
- stearic acid (1)
- steatosis (1)
- stem cell transplantation (1)
- stem cells (1)
- steroid control of aging (1)
- stiripentol (1)
- strength training (1)
- streptozotocin (1)
- stress response (1)
- stretching (1)
- stromal-derived factor 1 (1)
- structural biology (1)
- structure constraints (1)
- structure–activity relationships (1)
- substance abuse disorder (1)
- suicidality (1)
- suicide (1)
- supervision (1)
- supervisión (1)
- supplementary motor area (1)
- supportive periodontal therapy (1)
- suprapubic catheter (1)
- surfactant (1)
- surgical margin (1)
- surgical procedures (1)
- swallowing (1)
- sympathicus (1)
- symptoms (1)
- synaesthesia (1)
- synaptic plasticity (1)
- synaptic scaling (1)
- synergistic interaction (1)
- synovium (1)
- synuclein (1)
- systematic biopsy (1)
- systematic scoping review (1)
- tailored treatment schedule (1)
- talent development (1)
- talent identification (1)
- targeted biopsy (1)
- targeted therapy (1)
- targeting (1)
- tauopathies (1)
- tauopathy (1)
- tea (1)
- telemedicine (1)
- tension type headache (1)
- terapia cognitivo conductual enfocada en trauma (1)
- test protocol (1)
- testis (1)
- tetrahydrocannabinol (1)
- thalassemia (1)
- therapy monitoring (1)
- therapy resistance (1)
- thiazolidine and perhydrothiazine derivatives of aldophosphamide and I-aldophosphamide (1)
- third (1)
- three-dimensional analysis (1)
- three‐dimensional analysis (1)
- thrombopenia (1)
- thrombotic microangiopathy (1)
- thrombotic thrombocytopenic purpura (1)
- tick (1)
- time-lapse imaging (1)
- tissue slice co-cultures (1)
- tobacco control (1)
- tobacco products (1)
- toc64 (1)
- tooth (1)
- tooth autotransplantation (1)
- tooth loss (1)
- tooth transplantation (1)
- total hip replacement (1)
- tracking (1)
- traditional Chinese medicine (1)
- traffic accident (1)
- trafficking (1)
- training effects (1)
- transcatheter aortic valve replacement (TAVR) (1)
- transcatheter aortic valve replacement (TAVR), aortic valve stenosis (AS) (1)
- transcriptomics (1)
- transferrin (1)
- transforming growth factor-β (1)
- transfusion (1)
- transgenically augmented CAR NK cell (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- transjugular portosystemic intrahepatic (1)
- translational medical research (1)
- translational medicine (1)
- translational reseach (1)
- translatome (1)
- translocon (1)
- transmission routes (1)
- transportation (1)
- transrectal prostate biopsy (1)
- transurethral catheter (1)
- transverse axis (1)
- trauma (1)
- trauma registry (1)
- traumafocused cognitive behavioural therapy (1)
- traumatic brain injury (1)
- traumatic brain injury (TBI) (1)
- traumaticbraininjury(TBI) (1)
- treatment-related changes (1)
- trigeminal pain (1)
- trophoblast (1)
- tryptophan (1)
- tumor adhesion (1)
- tumor angiogenesis (1)
- tumor hypoxia (1)
- tumor infiltrating lymphocytes (1)
- tumor invasion (1)
- tumor migration (1)
- tumor pain (1)
- tumor perfusion (1)
- tumor stroma (1)
- tumor xenograft (1)
- tumor-associated macrophages (1)
- type 1 diabetes (1)
- type 2 diabetes (1)
- type-1-diabetes (1)
- tyrosinase inhibitor (1)
- tyrosine kinase inhibitor (1)
- tyrosine kinase inhibitors (1)
- tyrosine kinase inhibitors. (1)
- tyrosine kinase receptor signaling (1)
- ubiquitin (1)
- ubiquitin hydrolase (1)
- ubiquitin receptor (1)
- ultrasonic cleaning (1)
- ultrasound (1)
- unanticipated (1)
- unconventional T cell (1)
- unilateral hip osteoarthritis (1)
- unspecific low back pain (1)
- urethral stricture (1)
- urethroplasty (1)
- urinary tract development (1)
- uterine wall (1)
- vaccination (1)
- vacuuming (1)
- valproic acid (1)
- value frameworks (1)
- variability (1)
- variable silent delay (1)
- vascular endothelial growth factor receptor (1)
- vascular surgery (1)
- vector (1)
- venous occlusion (1)
- ventralis intermedius nucleus (1)
- venturesomeness (1)
- vertical transmission (1)
- vestibular schwannoma (1)
- vibroarthrographic (1)
- vigilance (1)
- vincristine (1)
- viral infection (1)
- viruses (1)
- vision (1)
- visual attention (1)
- visual priming (1)
- vitamin B deficiency (1)
- vitamin B12 (1)
- vitamin D (1)
- vitamin D deficiency (1)
- vitamin D metabolites (1)
- vitamin k antagonists (1)
- volatile sedation (1)
- von Willebrand diseases (1)
- waiting time (1)
- walking (1)
- weakly supervised learning (1)
- weight loss (1)
- wheezing (1)
- white matter hyperintensity (1)
- whole abdominal radiotherapy (1)
- whole genome sequencing (1)
- whole slide image (1)
- working memory (1)
- workplace health promotion (1)
- xenograft (1)
- yellow flags (1)
- youth football (1)
- zebrafish development (1)
- Öffentlichkeit (1)
- Übertragungswege (1)
- ΔNp63 (1)
- α-amylase inhibitor (1)
- α-particles (1)
- γ‐H2AX (1)
- fibrogenesis (1)
- fingolimod (1)
Institute
- Medizin (732)
- Biochemie, Chemie und Pharmazie (41)
- Biowissenschaften (22)
- Frankfurt Institute for Advanced Studies (FIAS) (21)
- Sportwissenschaften (21)
- MPI für Hirnforschung (14)
- Präsidium (14)
- Biochemie und Chemie (11)
- Psychologie und Sportwissenschaften (11)
- Ernst Strüngmann Institut (9)
Objectives: To assess tolerability and efficacy of lacosamide in adults with cerebrovascular epilepsy etiology (CVEE).
Materials and methods: Exploratory post hoc analyses of a double‐blind, initial monotherapy trial of lacosamide vs carbamazepine‐controlled release (carbamazepine‐CR) (SP0993; NCT01243177); a double‐blind conversion to lacosamide monotherapy trial (SP0902; NCT00520741); and an observational study of adjunctive lacosamide added to one antiepileptic drug (SP0973 VITOBA; NCT01098162). Patients with CVEE were identified based on epilepsy etiology recorded at baseline.
Results: In the initial monotherapy trial, 61 patients had CVEE (lacosamide: 27; carbamazepine‐CR: 34). 20 (74.1%) patients on lacosamide (27 [79.4%] on carbamazepine‐CR) reported treatment‐emergent adverse events (TEAEs), most commonly (≥10%) headache, dizziness, and fatigue (carbamazepine‐CR: headache, dizziness). A numerically higher proportion of patients on lacosamide than carbamazepine‐CR completed 6 months (22 [81.5%]; 20 [58.8%]) and 12 months (18 [66.7%]; 17 [50.0%]) treatment without seizure at last evaluated dose. In the conversion to monotherapy trial, 26/30 (86.7%) patients with CVEE reported TEAEs, most commonly (≥4 patients) dizziness, convulsion, fatigue, headache, somnolence, and cognitive disorder. During lacosamide monotherapy, 17 (56.7%) patients were 50% responders and six (20.0%) were seizure‐free. In the observational study, 36/83 (43.4%) patients with CVEE reported TEAEs, most commonly (≥5%) fatigue and dizziness. Effectiveness was assessed for 75 patients. During the last 3 months, 60 (80%) were 50% responders and 42 (56.0%) were seizure‐free.
Conclusions: These exploratory post hoc analyses suggested lacosamide was generally well tolerated and effective in patients with CVEE, with data from the initial monotherapy trial suggesting numerically better efficacy than carbamazepine‐CR.
Objective: To explore and describe exposure to suicidality in healthcare providers (HCP) working with oncological patients. Special emphasis was put on five central aspects from the HCPs perspective: Exposure, Confidence, Expertise, Distress, and Education.
Methods: A 48‐item online questionnaire was developed and distributed to HCPs working with cancer patients. Three hundred fifty‐four answered questionnaires were analyzed.
Results: Overall 83.3% of HCPs reported to have encountered at least one suicidal patient in the last year. Feeling confident in talking about suicidality was reported by 72.1% of HCPs, with 71.2% of nurses reporting feeling insecure compared with only 5.1% of psychotherapists. Similarly, 22.3% of HCPs felt overwhelmed when confronted with a patient who substantiated his suicidality during consultation. A lack of personal knowledge concerning suicidality in general and in oncological patients in particular, was reported by 39.6% and 49.8%, respectively. In total, 88.1% of HCPs reported feeling distressed when confronted with suicidality, while 81.1% of participants wanted further education regarding suicidality in cancer patients despite that 73.2% had already received some sort of psycho‐oncology education.
Conclusions: Despite the well‐documented fact of elevated suicide rates in cancer patients, there remain deficits in knowledge, which induce feelings of insecurity and helplessness in HCPs. There is a demand for further education concerning the treatment of suicidal cancer patients. Therefore, special curricula addressing this topic should be devised. A general debate about suicidality in cancer patients could help raise awareness of this problem and generate means of prevention.
Type 1 diabetes (T1D) is mainly precipitated by the destruction of insulin-producing β-cells in the pancreatic islets of Langerhans by autoaggressive T cells. The etiology of the disease is still not clear, but besides genetic predisposition the exposure to environmental triggers seems to play a major role. Virus infection of islets has been demonstrated in biopsies of T1D patients, but there is still no firm proof that such an infection indeed results in islet-specific autoimmunity. However, virus infection results in a local inflammation with expression of inflammatory factors, such as cytokines and chemokines that attract and activate immune cells, including potential autoreactive T cells. Many chemokines have been found to be elevated in the serum and expressed by islet cells of T1D patients. In mouse models, it has been demonstrated that β-cells express chemokines involved in the initial recruitment of immune cells to the islets. The bulk load of chemokines is however released by the infiltrating immune cells that also express multiple chemokine receptors. The result is a mutual attraction of antigen-presenting cells and effector immune cells in the local islet microenvironment. Although there is a considerable redundancy within the chemokine ligand-receptor network, a few chemokines, such as CXCL10, seem to play a key role in the T1D pathogenesis. Studies with neutralizing antibodies and investigations in chemokine-deficient mice demonstrated that interfering with certain chemokine ligand-receptor axes might also ameliorate human T1D. However, one important aspect of such a treatment is the time of administration. Blockade of the recruitment of immune cells to the site of autoimmune destruction might not be effective when the disease process is already ongoing. By that time, autoaggressive cells have already arrived in the islet microenvironment and a blockade of migration might even hold them in place leading to accelerated destruction. Thus, an anti-chemokine therapy makes most sense in situations where the cells have not yet migrated to the islets. Such situations include treatment of patients at risk already carrying islet-antigen autoantibodies but are not yet diabetic, islet transplantation recipients, and patients that have undergone a T cell reset as occurring after anti-CD3 antibody treatment.
Objective: Children with pre-school asthma suffer disproportionally more often from severe asthma exacerbations with emergency visits and hospital admissions compared to school children. Despite this high disease burden, there are only a few reports looking at this particular severe asthma cohort. Similarly, there is little real-life research on the distribution of asthma phenotypes and personalized treatment at discharge in this age group. Patients and Methods: Retrospective analysis of the electronic charts of all children aged 1–5 years with asthma hospitalizations (ICD J45) at the Frankfurt University between 2008 and 2017. An acute severe asthma exacerbation was defined as dyspnea, oxygen demand, and/or systemic steroid therapy. Age, gender, duration of hospitalization, asthma phenotype, treatment, and readmission rate were analyzed. Results: Of 572 patients, 205 met the definition of acute severe asthma. The phenotypic characterization showed 56.1% had allergic asthma, 15.2% eosinophilic asthma and 28.7% non-allergic asthma. Of these patients, 71.7% were discharged with inhaled corticosteroids (ICS) or ICS + long-acting-beta-agonists (LABA), 15.1% with leukotriene antagonists (LTRA) and 7.3% salbutamol on demand. The rate of emergency presentations (emergency department and readmission) within 12 months after discharge was high (n = 42; 20.5%). No phenotype tailored treatment was detectable. Neither the number of eosinophils (>300/μl) nor the treatment at discharge had an effect on emergency visits and readmission rate. Conclusion: Despite protective therapy with ICS, ICS + LABA, or LTRA, the readmission rate was high. Thus, current care and treatment strategies should be reevaluated continuously, in order to better control asthma in pre-school children and prevent hospitalization.
Photochemical internalization (PCI) is a technology to induce a localized, intracellular enhancement of therapeutics that are processed through endosomal pathways, including gemcitabine in malignant cells. In addition to a direct phototoxic and tumoricidal effect, PCI specifically disrupts endosomal membranes and, thereby, the compartmentalization of certain cytotoxic compounds to enhance a drug’s intended intracellular target reach within the tissue treated.
Non-resectable extrahepatic cholangiocarcinoma (eCCA) is a common primary tumor and gemcitabine/cisplatin chemotherapy is widely considered standard of care for it. PCI is well suited as an endoscopic intervention, and clinical observations in three subjects participating in a phase I/IIa dose escalation safety trial are described. The trial included patients with perihilar, non-resectable CCA suitable for standard-of-care chemotherapy. Per protocol, a single endoscopic PCI procedure with gemcitabine was conducted at the initiation of standard gemcitabine/cisplatin therapy. Sixteen patients enrolled in the initial dose escalation phase of the trial, which later was extended to explore the safety of a second PCI procedure during chemotherapy.
While limited to a case series, the various clinical observations described here serve to illustrate the effects of localized, perihilar tumor targeting in appropriate patients by any safe methodology, including PCI. As previously indicated by clinical data using other localized treatment modalities, adding a directed, tumor-targeting treatment to systemic therapy to ameliorate the progressively expanding extrahepatic tumor burden can have important effects on the overall outcome of systemic treatment in many patients who have incurable eCCA.
A novel, broad-acting peptide inhibitor of double-stranded DNA virus gene expression and replication
(2020)
Viral infections are a global disease burden with only a limited number of antiviral agents available. Due to newly emerging viral pathogens and increasing occurrence of drug resistance, there is a continuous need for additional therapeutic options, preferably with extended target range. In the present study, we describe a novel antiviral peptide with broad activity against several double-stranded DNA viruses. The 22-mer peptide TAT-I24 potently neutralized viruses such as herpes simplex viruses, adenovirus type 5, cytomegalovirus, vaccinia virus, and simian virus 40 in cell culture models, while being less active against RNA viruses. The peptide TAT-I24 therefore represents a novel and promising drug candidate for use against double-stranded DNA viruses.
Particulate autogenous tooth roots are used for alveolar bone augmentation surgery; however, dental plaque may provoke an inflammatory response that may counteract the desired graft consolidation process. Traditional mechanical cleaning of extracted teeth may be of support to lower a possible inflammatory response of the autograft. To test this assumption, extracted porcine teeth were left either uncleaned or underwent mechanical cleaning with a toothbrush and toothpaste before being fragmented and subjected to acid lysis, termed as unclean acid dentine lysate (ucADL) and clean acid dentine lysate (cADL), respectively. The inflammatory responses of murine macrophage RAW 264.7 cells being exposed to the respective acid dentine lysates were evaluated at the level of inflammatory gene expression and IL6 immunoassays. We report here that acid lysates obtained from uncleaned teeth provoked a robust increase in IL1β, IL6, and COX2 in RAW 264.7 cells. The mechanical removal of dental plaque significantly reduced the inflammatory response. Consistently, Limulus tests revealed that tooth cleaning lowers the presence of endotoxins in dentine lysates. To further prove the involvement of endotoxins, a toll-like receptor 4 (TLR4) inhibitor TAK242 was introduced. TAK242 abolished the inflammatory response provoked by acid lysates obtained from uncleaned teeth in RAW 264.7 cells. Moreover, nuclear translocation and phosphorylation of the TLR4 downstream NFκB-p65 were attenuated at the presence of cleaned versus uncleaned dentine lysates. Taken together, our data support the importance of dental plaque removal of teeth being extracted for alveolar bone augmentation surgery.
The Ebola virus (EBOV) can cause severe infections in humans, leading to a fatal outcome in a high percentage of cases. Neutralizing antibodies against the EBOV surface glycoprotein (GP) can prevent infections, demonstrating a straightforward way for an efficient vaccination strategy. Meanwhile, many different anti‐EBOV antibodies have been identified, whereas the exact binding epitopes are often unknown. Here, the analysis of serum samples from an EBOV vaccine trial with the recombinant vesicular stomatitis virus‐Zaire ebolavirus (rVSV‐ZEBOV) and an Ebola virus disease survivor, using high‐density peptide arrays, is presented. In this proof‐of‐principle study, distinct IgG and IgM antibodies binding to different epitopes of EBOV GP is detected: By mapping the whole GP as overlapping peptide fragments, new epitopes and confirmed epitopes from the literature are found. Furthermore, the highly selective binding epitope of a neutralizing monoclonal anti‐EBOV GP antibody could be validated. This shows that peptide arrays can be a valuable tool to study the humoral immune response to vaccines in patients and to support Ebola vaccine development.
Hepatocellular carcinoma (HCC) is highly resistant to anticancer therapy and novel therapeutic strategies are needed. Chronotherapy may become a promising approach because it may improve the efficacy of antimitotic radiation and chemotherapy by considering timing of treatment. To date little is known about time‐of‐day dependent changes of proliferation and DNA damage in HCC. Using transgenic c‐myc/transforming growth factor (TGFα) mice as HCC animal model, we immunohistochemically demonstrated Ki67 as marker for proliferation and γ‐H2AX as marker for DNA damage in HCC and surrounding healthy liver (HL). Core clock genes (Per1, Per2, Cry1, Cry2, Bmal 1, Rev‐erbα and Clock) were examined by qPCR. Data were obtained from samples collected ex vivo at four different time points and from organotypic slice cultures (OSC). Significant differences were found between HCC and HL. In HCC, the number of Ki67 immunoreactive cells showed two peaks (ex vivo: ZT06 middle of day and ZT18 middle of night; OSC: CT04 and CT16). In ex vivo samples, the number of γ‐H2AX positive cells in HCC peaked at ZT18 (middle of the night), while in OSC their number remained high during subjective day and night. In both HCC and HL, clock gene expression showed a time‐of‐day dependent expression ex vivo but no changes in OSC. The expression of Per2 and Cry1 was significantly lower in HCC than in HL. Our data support the concept of chronotherapy of HCC. OSC may become useful to test novel cancer therapies.
Background: To volumetrically assess the bone microstructure following vertical alveolar ridge augmentation using differently conditioned autogenous tooth roots (TR) and second‐stage implant placement.
Materials and methods: The upper premolars were bilaterally extracted in n = 4 beagle dogs and randomly assigned to either autoclavation (TR‐A) or no additional treatment (TR‐C). Subsequently, TR were used as block grafts for vertical alveolar ridge augmentation in both lower quadrants. At 12 weeks, titanium implants were inserted and left to heal 3 weeks. Microcomputed tomography was used to quantify bone volume per tissue volume (BV/TV), trabecular thickness (Tb.Th), and trabecular spacing (Tb.Sp) at vestibular (v) and oral (o) aspects along the implant and in the augmented upper half of the implant, respectively.
Results: Median BV/TV [TR‐C: 51.33% (v) and 70.42% (o) vs TR‐A: 44.05% (v) and 64.46% (o)], Tb.th [TR‐C: 0.22 mm (v) and 0.27 mm (o) vs TR‐A: 0.23 mm (v) and 0.29 mm (o)] and Tb.Sp [TR‐C: 0.26 mm (v) and 0.13 mm (o) vs TR‐A: 0.29 μm (v) and 0.15 mm (o)] values were comparable in both groups.
Conclusion: Both TR‐C and TR‐A grafts were associated with a comparable bone microstructure within the grafted area.
Sphingosine‐1‐phosphate lyase 1 (S1P lyase or SGPL1) is an essential sphingosine‐1‐phosphate‐degrading enzyme. Its manipulation favors onset and progression of colorectal cancer and others in vivo. Thus, SGPL1 is an important modulator of cancer initiation. However, in established cancer, the impact of retrospective SGPL1 modulation is elusive. Herein, we analyzed how SGPL1 siRNA affects malignancy of the human colorectal cancer cells DLD‐1 and found that in parallel to the reduction of SGPL1 expression levels, migration, invasion, and differentiation status changed. Diminished SGPL1 expression was accompanied with reduced cell migration and cell invasion in scratch assays and transwell assays, whereas metabolic activity and proliferation was not altered. Decreased migration was attended by increased cell–cell‐adhesion through upregulation of E‐cadherin and formation of cadherin‐actin complexes. Spreading cell islets showed lower vimentin abundance in border cells. Furthermore, SGPL1 siRNA treatment induced expression of epithelial cell differentiation markers, such as intestinal alkaline phosphatase and cytokeratin 20. Hence, interference with SGPL1 expression augmented a partial redifferentiation of colorectal cancer cells toward normal colon epithelial cells. Our investigation showed that SGPL1 siRNA influenced tumorigenic activity of established colorectal cancer cells. We therefore suggest SGPL1 as a target for lowering malignant potential of already existing cancer.
Hypersensitivity reactions to non‐steroidal anti‐inflammatory drugs (NSAIDs) – a retrospective study
(2020)
Background: The aim of this study was to verify the validity of clinical history and oral provocation challenges of patients with NSAID hypersensitivity and to identify safe alternatives. The COX‐2 inhibitor etoricoxib, in particular, was studied.
Patients and methods: In all, 104 patients with confirmed diagnoses of NSAID hypersensitivity treated at the Department of Dermatology, Frankfurt University Hospital, Germany between 2004 and 2012 were retrospectively studied.
Results: The medical history and hypersensitivity symptoms during oral provocation testing (OPT) largely coincided and were mostly mild to moderate. Acetylsalicylic acid (ASA) was the most frequent trigger both anamnestically (27.9 %) and during OPT (47.8 %). Etoricoxib caused the fewest reactions during OPT (4.2 %). Acetaminophen led to reactions in only 6.7 % of the cases studied although it was named more often in clinical histories (14 %).
Conclusions: OPT should be the aim whenever possible as most symptoms are mild to moderate. To distinguish between selective and cross‐hypersensitivity reactions, ASA should be part of the test protocol. Furthermore, the findings of this study indicate that etoricoxib and acetaminophen are safe treatment alternatives in case of NSAID hypersensitivity. However, these drugs should not be administered without prior OPT in an inpatient setting, as severe symptoms can occur.
Background: The present study aimed to assess the three‐dimensional changes following soft tissue augmentation using free gingival grafts (FGG) at implant sites over a 3‐month follow‐up period.
Methods: This study included 12 patients exhibiting deficient keratinized tissue (KT) width (i.e., <2 mm) at the vestibular aspect of 19 implants who underwent soft tissue augmentation using FGG at second stage surgery following implant placement. Twelve implants were considered for the statistical analysis (n = 12). The region of interest (ROI) was intraorally scanned before surgery (S0), immediately post‐surgery (S1), 30 (S2) and 90 (S3) days after augmentation. Digital scanned files were used for quantification of FGG surface area (SA) and converted to standard tessellation language (STL) format for superimposition and evaluation of thickness changes between the corresponding time points. FGG shrinkage (%) in terms of SA and thickness was calculated between the assessed time points.
Results: Mean FGG SA amounted to 91 (95% CI: 63 to 119), 76.2 (95% CI: 45 to 106), and 61.3 (95% CI: 41 to 81) mm2 at S1, S2, and S3, respectively. Mean FGG SA shrinkage rate was 16.3% (95% CI: 3 to 29) from S1 to S2 and 33% (95% CI: 19 to 46) from S1 to S3. Mean thickness gain from baseline (S0) to S1, S2, and S3 was 1.31 (95% CI: 1.2 to 1.4), 0.82 (95% CI: 0.5 to 1.12), and 0.37 (0.21 to 0.5) mm, respectively. FGG thickness shrinkage was of 38% (95% CI: 17.6 to 58) from S1 to S2 and 71.8% (95% CI: 60 to 84) from S1 to S3. Dimensional changes from S1 to S3 were statistically significant, P <0.017. Soft tissue healing was uneventful in all patients.
Conclusions: The present three‐dimensional assessment suggests that FGG undergo significant dimensional changes in SA and thickness over a 3‐month healing period.
Purpose: Surgery of KOOS IV vestibular schwannoma remains challenging regarding the balance of extent of tumor resection (EoR) and functional outcome. Our aim was to evaluate the outcome of surgical resection and define a cut-off value for safe resection with low risk for tumor regrowth of KOOS IV vestibular schwannoma.
Methods: All patients presenting at the authors’ institution between 2000 and 2019 with surgically treated KOOS IV vestibular schwannoma were included. Outcome measures included EoR, facial/hearing nerve function, surgical complications and progression of residual tumor during the median follow-up period of 28 months.
Results: In 58 patients, mean tumor volume was 17.1 ± 9.2 cm3, and mean EoR of 81.6 ± 16.8% could be achieved. Fifty-one patients were available for the follow-up analysis. Growth of residual tumor was observed in 11 patients (21.6%) followed by adjuvant treatment with stereotactic radiosurgery or repeat surgery in 15 patients (29.4%). Overall serviceable hearing preservation was achieved in 38 patients (74.5%) and good facial outcome at discharge was observed in 66.7% of patients, significantly increasing to 82.4% at follow-up. Independent predictors for residual tumor growth was EoR ≤ 87% (OR11.1) with a higher EoR being associated with a very low number of residual tumor progression amounting to 7.1% at follow-up (p=0.008).
Conclusions: Subtotal tumor resection is a good therapeutic concept in patients with KOOS IV vestibular schwannoma resulting in a high rate of good hearing and facial nerve function and a very low rate of subsequent tumor progression. The goal of surgery should be to achieve more than 87% of tumor resection to keep residual tumor progression low.
Respiratory chain signalling is essential for adaptive remodelling following cardiac ischaemia
(2020)
Cardiac ischaemia‐reperfusion (I/R) injury has been attributed to stress signals arising from an impaired mitochondrial electron transport chain (ETC), which include redox imbalance, metabolic stalling and excessive production of reactive oxygen species (ROS). The alternative oxidase (AOX) is a respiratory enzyme, absent in mammals, that accepts electrons from a reduced quinone pool to reduce oxygen to water, thereby restoring electron flux when impaired and, in the process, blunting ROS production. Hence, AOX represents a natural rescue mechanism from respiratory stress. This study aimed to determine how respiratory restoration through xenotopically expressed AOX affects the re‐perfused post‐ischaemic mouse heart. As expected, AOX supports ETC function and attenuates the ROS load in post‐anoxic heart mitochondria. However, post‐ischaemic cardiac remodelling over 3 and 9 weeks was not improved. AOX blunted transcript levels of factors known to be up‐regulated upon I/R such as the atrial natriuretic peptide (Anp) whilst expression of pro‐fibrotic and pro‐apoptotic transcripts were increased. Ex vivo analysis revealed contractile failure at nine but not 3 weeks after ischaemia whilst label‐free quantitative proteomics identified an increase in proteins promoting adverse extracellular matrix remodelling. Together, this indicates an essential role for ETC‐derived signals during cardiac adaptive remodelling and identified ROS as a possible effector.
Aims: Preventing hospitalization by detecting early evidence of heart failure (HF) decompensation in an outpatient setting can improve patient's quality of life and reduce costs of care. The purpose of this study was to assess the value of cardiac acoustic biomarkers (CABs), a combination of cardiohaemic vibrations synchronized with ECG signals, and heart rate (HR) for detecting HF decompensation during first 3 months after hospital discharge for HF.
Methods and results: Patients with an ejection fraction ≤35% (HFrEF) and hospitalized for decompensated HF were enrolled in a prospective observational study. All subjects wore a wearable cardioverter‐defibrillator (ZOLL LifeVest®, Pittsburgh, PA, USA) that is capable of recording CABs and HR. The primary endpoint of the study was the first HF event, defined as HF readmission or HF emergency room visit. From June 2017 through August 2019, 671 patients with HFrEF were enrolled. Eighty‐one patients (12.1%) had a total of 112 HF events. The algorithm detected HF events with a median of 32 days (interquartile range = 11‐45) in advance of the first HF event. The algorithm had a sensitivity of 69%, specificity of 60%, positive predictive value of 19%, and a negative predictive value of 94%. Of note, the baseline (first 7 days post‐enrolment) algorithm using CABs and HR was superior to New York Heart Association classification in detecting patients more likely to have HF decompensation (sensitivity and specificity of 61% and 68% vs. 46% and 55%, respectively).
Conclusions: This prospective international registry showed that an algorithm incorporating CABs and HR data detected HF events 30 days in advance of the event in patients with HFrEF during first 3 months after hospital discharge. Therefore, integrating CAB technology into clinical practice may prevent HF rehospitalizations.
Central cholinergic function and metabolic changes in streptozotocin‐induced rat brain injury
(2020)
As glucose hypometabolism in the brain is an early sign of Alzheimer´s dementia (AD), the diabetogenic drug streptozotocin (STZ) has been used to induce Alzheimer‐like pathology in rat brain by intracereboventricular injection (icv‐STZ). However, many details of the pathological mechanism of STZ in this AD model remain unclear. Here, we report metabolic and cholinergic effects of icv‐STZ using microdialysis in freely moving animals. We found that icv‐STZ at a dose of 3 mg/kg (2 × 1.5 mg/kg) causes overt toxicity reflected in body weight loss. Three weeks after STZ administration, histological examination revealed a high number of glial fibrillary acidic protein reactive cells in the hippocampus, accompanied by Fluoro‐Jade C‐positive cells in the CA1 region. Glucose and lactate levels in microdialysates were unchanged, but mitochondrial respiration measured ex vivo was reduced by 9%–15%. High‐affinity choline uptake, choline acetyltransferase, and acetylcholine esterase (AChE) activities in the hippocampus were reduced by 16%, 28%, and 30%, respectively. Importantly, extracellular acetylcholine (ACh) levels in the hippocampus were unchanged and responded to behavioral and pharmacological challenges. In comparison, extracellular ACh levels and cholinergic parameters in the striatum were unchanged or slightly increased. We conclude that the icv‐STZ model poorly reflects central cholinergic dysfunction, an important characteristic of dementia. The icv‐STZ model may be more aptly described as an animal model of hippocampal gliosis.
The digital and information age has fundamentally transformed the way in which students learn and the study material they have at their disposal, especially in higher education. Students need to possess a number of higher-order cognitive and metacognitive skills, including effective information processing and critical reasoning to be able to navigate the Internet and use online sources, even those found outside of academically curated domains and in the depths of the Internet, and to solve (domain-specific) problems. Linking qualitative and quantitative research and connecting the humanities to empirical educational science studies, this article investigates the role of narratives and their impact on university students’ information seeking and their critical online reasoning (COR). This study focuses on the link between students’ online navigation skills, information seeking behavior and critical reasoning with regard to the specific domains: economics and medicine. For the empirical analysis in this article, we draw on a study that assesses the COR skills of undergraduate students of economics and medicine at two German universities. To measure COR skills, we used five tasks from the computer-based assessment “Critical Online Reasoning Assessment” (CORA), which assesses students’ skills in critically evaluating online sources and reasoning using evidence on contentious issues. The conceptual framework of this study is based on an existing methodology – narrative economics and medicine – and discusses its instructional potential and how it can be used to develop a new tool of “wise interventions” to enhance students’ COR in higher education. Based on qualitative content analyses of the students’ written responses, i.e., short essays, three distinct patterns of information seeking behavior among students have been identified. These three patterns – “Unambiguous Fact-Checking,” “Perspective-Taking Without Fact-Checking,” and “Web Credibility-Evaluating” – differ substantially in their potential connection to underlying narratives of information used by students to solve the CORA tasks. This analysis suggests that training university students in narrative analysis can strongly contribute to enhancing their critical online reasoning.
In der vorliegenden Untersuchung wurde das bovine, Hydroxylapatit-basierte, Knochenersatzmaterial Hypro-Oss® zunächst ex vivo überprüft, anschließend subkutan in den interskapulären Bereich von 12 weiblichen Wistar-Ratten (Testgruppe) eingebracht; bei 12 weiteren Tieren erfolgte eine Sham-Operation ohne Einbringung von Biomaterial (Kontrollgruppe). Anschließend wurde die Gewebereaktion über 30 Tage beobachtet und die Explantate jeweils nach Tag 3, 15 und 30 histologisch und histomorphometrisch untersucht.
Die histologische Analyse zeigte innerhalb des Beobachtungszeitraums von 30 Tagen eine störungsfreie Eingliederung der Hypro-Oss®-Granula in das umliegende Gewebe. Bereits 3 Tage nach Einbringung des Biomaterials waren mononukleäre Zellen erkennbar, die bis Tag 30 weiter zunahmen. Ab diesem Zeitpunkt zeigten sich auch TRAP-positive, CD-68-negative Multinukleäre Zellen, die das Ergebnis einer Fusion von Makrophagen sind und eine Fremdkörperreaktion indizierten. Nach 30 Tagen zeigten sich die Granula histologisch stabil integriert ohne Anzeichen einer immunologischen Abstoßungsreaktion.
Die CD-68-Expression der aufgefundenen Makrophagen und mehrkernigen Riesenzellen bildete ein Kriterium zur Unterscheidung der MNGCs von Osteoklasten, die ebenfalls mehrkernig sind, aber dieses Cluster of Differentiation nicht tragen. Dies charakterisiert die vorgefundenen MNGCs als Fremdkörper-Riesenzellen, da sie ebenso wie die pathologischen Riesenzellen vom Typ Langerhans CD-68 exprimieren.
Dieses Bild bestätigte sich für die Hypro-Oss®-Gruppe in der histomorphometrischen Betrachtung über eine kontinuierliche Zunahme von überwiegend CD-68-positiven Makrophagen bis zum Tag 30, während sie für die Kontrollgruppe über die gesamte Zeit rückläufig waren. Die Multinukleären Zellen erreichten dagegen bereits an Tag 15 ihren Höhepunkt, während in der Kontrollgruppe über den gesamten Beobachtungszeitraum erwartungsgemäß keine MNGCs gefunden wurden.
Der hoch signifikante Anstieg der MNGC-Zahl der Testgruppe bis Tag 15 korreliert positiv mit den Vaskularisationsdaten, was darauf hindeutet, dass die Multinukleären Zellen durch die Einbringung des Biomaterials induziert wurden und über die Sekretion des Signalmoleküls VEGF einen wesentlichen Faktor für die Blutgefäßbildung bilden.
Eine Auffälligkeit hat sich jedoch in Bezug auf das Alleinstellungsmerkmal von Hypro-Oss® gezeigt, welches bei der Aufreinigung nicht erhitzt wird. Diverse Studien haben einen Zusammenhang der Höhe der Sintertemperatur mit der Bildung von MNGCs nachgewiesen, wonach für Hypro-Oss® eine geringe Induzierung von MNGCs zu erwarten gewesen wäre als für vergleichbare, höher erhitzte bovine Knochenersatzmaterialien. Dagegen zeigten die Vaskularisationsdaten unserer Untersuchung für Hypro-Oss® im Vergleich zu 2 anderen bovinen Knochenersatzmaterialien (Bio-Oss® und BEGO OSS®) jedoch signifikant höhere Werte für die Blutgefäßbildung als dies aus der Korrelation von Sintertemperatur mit der Anzahl Multinukleärer Riesenzellen zu erwarten gewesen wäre.
Aufgrund der relativ kurzen Dauer der Beobachtung lassen sich keine belastbaren Ergebnisse in Bezug auf den zu erwartenden Materialabbau und die ossäre Integration von Hypro-Oss® feststellen, welche einer längerfristigen Analyse bedürften als es in dieser Untersuchung möglich war. Es gibt aber klinische Erfahrungsberichte23 hinsichtlich Handling, Heilungsverlauf und Materialintegration von Hypro-Oss® bei Sinusbodenelevation und Guided Bone Regeneration, die auch in der Langfristbetrachtung positive Ergebnisse zeigten. Offen bleibt, ob nicht eine physiologische Wundheilung nur mittels Makrophagen einer pathologischen Wundheilung unter Mitwirkung Multinukleärer Riesenzellen überlegen ist: zumindest robustere Knochenersatzmaterialien wie z.B. das hier untersuchte Hypro-Oss® scheinen dabei weniger sensibel auf Multinukleäre Riesenzellen zu reagieren.
Acute lymphoblastic leukemia (ALL), a neoplastic disorder of blood cells of the lymphoid lineage, is the most frequent childhood cancer. In spite of increasing survival rates, the outcome for adults, infants or relapsed patients is still less favorable, highlighting the need for novel treatment options. Reactive oxygen species (ROS) are important signaling molecules that are involved in a variety of cellular pathways. As high ROS levels lead to oxidative stress and irreversible oxidation of cellular macromolecules, the production and elimination of ROS is tightly controlled. Therefore, cells express several antioxidant molecules and enzymes, including glutathione, catalase and the thioredoxin (Trx) system, to balance ROS levels. As cancer cells were found to have increased ROS levels that could contribute to tumor progression and metastasis, they rely strongly on these antioxidant systems to prevent oxidative damage, making cancer cells especially vulnerable to ROS-inducing treatments. ROS and oxidative stress have been shown to induce programmed cell death via different pathways, however the exact mechanisms that couples oxidative signaling and cell death is not completely understood.
As a disturbance of the cellular redox homeostasis was reported during leukemia development and progression, we wanted to determine the potential of Trx inhibitors for ALL therapy. Additionally, we aimed to further understand the role of ROS and subsequent protein oxidation in the induction and execution of programmed cell death.
First, we demonstrated that the Trx1 inhibitor PX-12 induced cell death in three ALL cell lines. Further analysis of the events leading to PX-12-induced cell death in FADD-deficient (FD) Jurkat cells revealed an increase in ROS levels and oxidation-mediated dimer formation of peroxiredoxin 3 (PRDX3). Interestingly cell death was inhibited by the thiol-containing antioxidant N-acetylcysteine (NAC), but not by non-thiol-containing ROS scavengers. PX-12 treatment further induced cleavage of caspase-9 and -3 and activation of the pro-apoptotic BCL-2 protein BAK, leading us to the conclusion that mitochondria-dependent apoptosis was induced. Interestingly, we could demonstrate an important role for the BH3-only protein NOXA in the mediation of PX-12-induced apoptosis as knock-down of NOXA prevented cell death induction and BAK activation. Our findings give novel insights into the mechanism of PX-12-induced cell death in ALL cell lines and underscores the potential of PX-12 for the treatment of ALL.
To further understand the processes leading to cell death upon inhibition of the Trx system, we analyzed global protein oxidation in Jurkat FD cells upon treatment with the Trx reductase inhibitor Auranofin. In line with previous results, Auranofin induced intrinsic apoptosis that was dependent on BAK and accompanied by increased ROS levels. Using a BIAM Switch Assay followed by mass spectrometry, we demonstrated that Auranofin treatment induced oxidation of over 200 proteins. We identified several proteins whose oxidation upon Auranofin treatment was expected, like Trx1, Trx2 and several peroxiredoxins. Additionally, we verified oxidation of APAF1-interacting protein (APIP) and protein arginine N-methyltransferase (PRMT1) that are both implicated in the regulation of apoptosis. With this analysis we were able to demonstrate that Auranofin treatment leads to changes in global protein oxidation. Whether oxidation of the determined proteins changes their functionality and contributes to apoptosis induction remains to be elucidated.
As we identified BAK as an important player in PX-12- and Auranofin-induced cell death in the previous parts of this study, we wanted to further understand its involvement in ROS-mediated cell death. First analyses in wild-type (WT) and BAK-/- murine embryonic fibroblasts (MEFs) revealed that BAK was essential for Auranofin-induced cell death and that this cell death was caspase-independent in MEFs. Interestingly, BAK oxidation was induced upon treatment with Auranofin, but not upon stimulation with the apoptosis-inducing compound Etoposide. Expression of mutated BAK, with either one or both oxidation-sensitive cysteines mutated to oxidation-insensitive serines, revealed that mutating already one cysteine protected cells from Auranofin , but not Etoposide-induced cell death. Of note, mutation of the BAK BH3 domain rescued MEFs from both, Auranofin- and Etoposide-mediated cell death. The presence of cysteine residues also altered BAK interactions as observed by a mass spectrometric analysis of Auranofin-treated MEFs expressing either WT or cysteine-less BAK. We identified interactions of WT BAK with proteins involved in mitochondrial fission and vesicle transport upon Auranofin treatment. Of note, interaction with proteins involved in apoptosis, like BAX or BCL-XL, was not changed between WT and cysteine-less BAK. Our results demonstrate a critical role for BAK oxidation in Auranofin-induced cell death. Furthermore, we identified novel oxidation-dependent BAK interaction partners.
To conclude, this study highlights the potential of ROS-inducing treatments for ALL therapy and provides novel insights into the redox regulation of programmed cell death.
Aufgrund der starken Heterogenität und Komplexität der akuten myeloischen Leukämie ist diese bis heute nicht zufriedenstellend zu behandeln. Die bestmögliche Therapie wird mittlerweile zunehmend auf die Erkrankung des Einzelnen angepasst. Vermehrt gewinnen Tyrosinkinase-Inhibitoren in der Therapie an Bedeutung. Diese Inhibitoren hemmen Proteine auf zellulärer Ebene.
Bei etwa 30% der AML-Patienten lassen sich Mutationen des FLT3-Gens nachweisen. Das Gen kodiert für die fms like tyrosine kinase 3, eine Rezeptor-Tyrosinkinase an der Zelloberfläche von unreifen Blutzellen des Knochenmarks. Durch Mutationen des FLT3 Gens erhalten diese Zellen einen Proliferationsvorteil gegenüber den physiologischen Blutzellen.
Am häufigsten kommt es zu in frame-Insertionen des FLT3-Gens, vor allem im Bereich der juxtamembranen Domäne: sogenannte interne Tandemduplikationen (ITD). Weiterhin kommen zu einem geringeren Teil Punktmutationen einzelner Codons, zum Beispiel im Bereich des activation loops oder im Bereich des gatekeepers vor. Durch das Auftreten der Punktmutationen, die entweder bereits zum Zeitpunkt der Diagnose vorliegen oder erst während einer Therapie mit einem Tyrosinkinase-Inhibitor entstehen können, verändert sich das Bindungsverhalten vieler solcher gegen FLT3 gerichteten Inhibitoren. Durch Letzteres kann ein mögliches Therapieversagen beispielsweise während der Behandlung mit AC220 (Quizartinib) erklärt werden (Smith et al.).
In der vorliegenden Dissertationsschrift sind Unterschiede der Signalwege zwischen FLT3-ITD und FLT3-ITD mit der zusätzlichen gatekeeper-Punktmutation F691L herausgearbeitet. Dafür wurden die beiden FLT3-Mutationen in den Vektor pMy-IRES-GFP eingebracht und retroviral in Ba/F3-Zellen transduziert. Nach Überprüfung der Expression von FLT3 ITD und dem Wachstumsverhalten unter Zugabe von AC220 (Quizartinib), wurden verschiedene Signalkaskaden von FLT3 mittels Western Blot untersucht. Hierbei zeigten sich sowohl Unterschiede für die Expression von phosphoryliertem ERK als auch von phosphoryliertem STAT5.
Durch verschieden starke Expressionen der FLT3130kDa- und FLT3160kDA-Varianten wurde eine unterschiedliche Lokalisation von FLT3-ITD in Zellen mit und ohne die Mutation F691L postuliert. Allerdings ließ sich diese experimentell mittels Immunfluoreszenz nicht belegen, da die Methode für die verwendeten Suspensionszellen nicht ausreichend geeignet war.
In den durchgeführten Versuchen zum Wachstumsverhalten der Zellen bei der Verwendung von Kinaseinhibitoren konnte bei der Verwendung des SYK-Inhibitors R406 eine dosisabhängige Proliferationshemmung der FLT3-ITD-mutierten Ba/F3- und 32D-Zellen beobachtet werden. Die Hemmung von FLT3 durch R406 wurde in der Literatur bereits beschrieben (Braselmann et al.).
Die abschließenden Experimente der Massenspektrometrie mit SILAC Markierung lassen mit der Detektion von mehreren hundert signifikant regulierten phosphorylierten Proteinen in den beiden FLT3-ITD-exprimierenden Populationen auf die Aktivierung unterschiedlicher Signalwege schließen. Durch das Vergleichen einzelner Teilexperimente ergaben sich Proteine, deren Phosphorylierung mehrfach in die gleiche Richtung reguliert war. Für Zellen, die zusätzlich zur ITD-Mutation die Mutation F691L besaßen, konnten insgesamt sieben hoch-regulierte, phosphorylierte Proteine ermittelt werden, bei denen ein zellulärer Effekt durch die Phosphorylierung der entsprechenden Aminosäurereste in der Literatur beschrieben ist.
Das im Western Blot nachgewiesene, in Zellen mit der Mutation F691L stärker phosphorylierte STAT5 ist aller Voraussicht nach Ursache der nachgewiesenen verstärkten Phosphorylierung von RPS6 im Experiment der globalen Phosphorylierung. Die PIM-Kinasen als Substrate einer STAT5-induzierten Transkription phosphorylieren RPS6 an Serin 235. Dies führt seinerseits zu einer verstärkten Translation von mRNA weiterer Gene. Die genauen Zusammenhänge der hier ermittelten Unterschiede müssen jedoch weiter untersucht werden.
In Zukunft könnte zudem die Untersuchung der beiden Proteine SHP 1 oder HSP90 weitere Aufschlüsse über die unterschiedlichen Signalwege geben. Für beide Proteine wurden Phosphorylierungen detektiert, die in den untersuchten Zellen mit FLT3-ITD bzw. der zusätzlichen Punktmutation F691L unterschiedlich reguliert sind.
Hintergrund. Die Achtung der individuellen Autonomie ist eines von vier medizinethischen Prinzipien, das im Kontext von Medizin und Forschung insbesondere in Bezug auf die informierte Einwilligung einer Person thematisiert wird. Menschen mit Demenz können aufgrund innerer oder äußerer Faktoren in ihrer Einwilligungsfähigkeit beeinträchtigt sein, was zu einer Einschränkung ihres Rechts auf Selbstbestimmung führen kann. Im diesbezüglichen Spannungsfeld zwischen Fürsorge und Autonomie soll Entscheidungsassistenz zur Ermöglichung selbstbestimmter Entscheidungen beitragen.
Zielrichtung der Arbeit. Ziel der vorliegenden Dissertation ist die Definition, Implementierung und Evaluation von Entscheidungsassistenzmaßnahmen für Menschen mit Demenz, um deren Autonomie in Entscheidungsprozessen zu unterstützen. Drei Teilprojekte umfassen die Ermittlung des internationalen Forschungsstands zu Entscheidungsassistenz bei Demenz, die Definition und Pilotierung von Unterstützungstools in der Praxis und die Analyse des individuellen Erlebens der vereinfachten Aufklärungsgespräche durch Menschen mit Demenz.
Methode. Im ersten Teilprojekt wurde eine am PRISMA-Standard orientierte systematische Literaturrecherche in Medline und PsycINFO durchgeführt. Die extrahierten relevanten Informationen wurden inhaltlich systematisiert. Aufbauend auf diesen Ergebnissen wurden im zweiten Teilprojekt konkrete Unterstützungstools definiert und in reale Aufklärungsgespräche (Lumbalpunktion) implementiert. Die Tools wurden in der Pilotierung in der Praxis sowie in einem iterativen Diskussionsprozess mit Experten weiterentwickelt. Im dritten Teilprojekt wurde das individuelle Erleben der Teilnehmer der vereinfachten Aufklärungsgespräche mittels problemzentrierter Interviews untersucht und die Daten einer qualitativen Inhaltsanalyse unterzogen.
Ergebnisse. Die Datenbankrecherche ergab initial 2348 Treffer. Nach Screenings der Titel, Abstracts und Volltexte konnten 11 Artikel eingeschlossen werden. Vier der eingeschlossenen Studien sind Interventionsstudien, die übrigen sieben qualitative Interviewstudien. Die identifizierten Unterstützungsmaßnahmen wurden zunächst den beiden Kategorien Interventionen und Strategien und anschließend unter Zuhilfenahme des Konzepts des Contextual Consents fünf komplexitätssteigernden Dimensionen einer Entscheidungssituation zugeordnet (individuelle, soziale, medizinische, informationelle und Folgendimension). Darauf aufbauend wurden im zweiten Teilprojekt acht Entscheidungsassistenzmaßnahmen abgeleitet: (1) Gesprächsstruktur, (2) Elaborierte klare Sprache, (3) Ambiente / Raumgestaltung, (4) Stichwortlisten, (5) Prioritätenkarten, (6) Visualisierung, (7) Vereinfachte schriftliche Einverständniserklärung sowie (8) Personenzentrierte Haltung des Entscheidungsassistenten (1-7: Tools, 8: Grundeinstellung). Die Tools zielen überwiegend auf eine Komplexitätsreduktion in der informationellen Dimension unter Berücksichtigung der fähigkeitsbezogenen und der bedürfnisbezogenen individuellen Dimension ab. Durch Anpassungen der Informationsdarbietung oder der kommunikativen Interaktion im Gespräch dienen sie mehrheitlich der Förderung des (Informations-) Verständnisses. Die Analyse der qualitativen Daten im dritten Teilprojekt zeigt, dass die Erfahrung der vereinfachten Aufklärungsgespräche durch drei übergreifende Themen gekennzeichnet ist. Die Kategorie Formalität versus Informationsgewinn illustriert die individuelle Bedeutung des Aufklärungsgesprächs für die Teilnehmer und deren Bewertung des Prozesses der informierten Einwilligung. Die Kategorie Wahrnehmung der Unterstützung skizziert die Bewertungen der angewandten Unterstützungstools durch die Teilnehmer. Die Kategorie Der Wahrheit ins Auge sehen müssen stellt dar, dass die erlebte Situation des vereinfachten Aufklärungsgesprächs wesentlich durch die Verdachtsdiagnose Demenz bestimmt ist, die im Rahmen aller Aufklärungsgespräche besprochen wurde.
Fazit. Bislang gibt es wenig empirische Forschung zu Entscheidungsassistenz für Menschen mit Demenz und Unterstützungsmaßnahmen werden überwiegend unsystematisch entwickelt und angewendet. Die Wirksamkeit einzelner Unterstützungsmaßnahmen kann aufgrund fehlender Interventionsstudien selten beurteilt werden. Unterstützungsmaßnahmen zielen überwiegend auf eine Komplexitätsreduktion in der Informationsdarbietung und im kommunikativen Interaktionsprozess ab, wobei sie kognitive Beeinträchtigungen und Interaktions-/ Entscheidungsbedürfnisse von Menschen mit Demenz berücksichtigen. Die definierten Tools können als erste konkret handhabbare Werkzeuge verstanden werden, die das strukturierte Leisten von Entscheidungsassistenz für Menschen mit Demenz erleichtern sollen. Sie sind übertragbar auf verschiedene Entscheidungssituationen. Eine Bewertung der Wirksamkeit der definierten Tools sollte in weiteren Entscheidungssituationen und mit größeren Stichproben weiteruntersucht werden. Die Ergebnisse der Evaluation liefern jedoch erste Hinweise darauf, dass einige Teilnehmer sich von einzelnen Tools unterstützt gefühlt haben und die anvisierte Komplexitätsreduktion in der informationellen Dimension in einigen Fällen erfolgreich war. Eine wesentliche Komplexitätssteigerung in der untersuchten Entscheidungssituation entstand durch die negative Emotionen auslösende Vermittlung einer potentiellen Demenzdiagnose (Folgendimension). Dieses Ergebnis impliziert, dass die definierte „verständnisfördernde Toolbox“ um Unterstützungsmaßnahmen zur emotionalen Entlastung von Menschen mit Demenz erweitert werden muss, da davon ausgegangen werden kann, dass vielfältige Entscheidungssituationen für Menschen mit Demenz emotional hoch belastend sind.
Hintergrund
Obwohl Feedback ein wichtiges und gut untersuchtes Element der medizinischen Ausbildung darstellt, wird es trotz eines großen Bedarfs der Studierenden sowohl im Unterricht als auch in Prüfungssituationen nur selten angewendet. Die Frankfurter Medizinstudierenden beklagen besonders, dass sie zu ihren Objective Structured Clinical Examinations (OSCEs) als Abschlussprüfung im Fach Chirurgie bisher kein detailliertes Feedback erhalten. Auch die Prüfenden beklagen häufig, dass sie die Studierenden weder für herausragende Leistungen loben noch über auftretende Fehler informieren können.
Ziel dieser Arbeit ist deshalb die Erstellung und Implementierung eines strukturierten schriftlichen Feedbacks in eine bestehende OSCE-Prüfung im Fach Chirurgie, das an den Bedürfnissen sowohl der Studierenden als auch der Prüfenden orientiert ist.
Material und Methoden
Das Studiendesign war prospektiv. Im ersten Schritt wurde eine Befragung erfahrener OSCE-Prüfender durchgeführt, um zu erheben, welches Feedback sie gerne an Studierende weitergeben würden. Basierend hierauf wurde ein erster Feedbackbogen erstellt. Dieser umfasste neben vorformulierten Aussagen auch die Möglichkeit Freitextkommentare zu geben und wurde von den Prüfenden für jeden Studierenden in der Wechselzeit zwischen den OSCE-Stationen ausgefüllt. Die Feedbackbögen wurden anschließend eingescannt und per E- Mail an die Studierenden geschickt. Im Anschluss hieran erfolgte eine webbasierte Befragung der Studierenden und der OSCE-Prüfenden, sowie eine tiefergehende Befragung der Studierenden in Form von Fokusgruppen- Interviews.
Basierend auf den Ergebnissen der Umfragen und der Fokusgruppen wurden die Feedbackbögen nochmals grundlegend überarbeitet und im folgenden OSCE erneut angewendet. Die Zufriedenheit der Prüfenden und Studierenden wurde analog zur ersten Befragung erhoben.
Ergebnisse
Insgesamt nahmen 351 Studierende und 51 Prüfende in beiden OSCEs an der Studie teil. In der abschließenden Online-Evaluation gaben 87,5% der Studierenden und 91,6% der Prüfenden an, dass sie zustimmen oder eher zustimmen, dass das schriftliche Feedback in zukünftigen OSCE-Prüfungen weiterhin angewendet werden soll. Mehr als 50% der Studierenden gaben jedoch an, dass das Feedback noch nicht konkret genug sei.
Mehr als ein Viertel der Prüfenden gab an, dass das Ausfüllen der Feedbackbögen zeitlich herausfordernd sei. In allen Fokusgruppen wurde das schriftliche Feedback durch die Studierenden befürwortet.
Schlussfolgerung
Die Implementierung eines strukturierten schriftlichen Feedbacks in einen OSCE ist problemlos möglich. Das schriftliche Feedback wird sowohl von den Prüfenden als auch von den Studierenden als nützlich empfunden.
Inflammation is a highly regulated biological response of the immune system that is triggered by assaulting pathogens or endogenous alarmins. It is now well established that some soluble extracellular matrix constituents, such as small leucine-rich proteoglycans (SLRPs), can act as danger signals and trigger aseptic inflammation by interacting with innate immune receptors. SLRP inflammatory signaling cascade goes far beyond its canonical function. By choosing specific innate immune receptors, coreceptors, and adaptor molecules, SLRPs promote a switch between pro- and anti-inflammatory signaling, thereby determining disease resolution or chronification. Moreover, by orchestrating signaling through various receptors, SLRPs fine-tune inflammation and, despite their structural homology, regulate inflammatory processes in a molecule-specific manner. Hence, the overarching theme of this review is to highlight the molecular and functional specificity of biglycan-, decorin-, lumican-, and fibromodulin-mediated signaling in inflammatory and autoimmune diseases.
The transcription factor ∆Np63 is a master regulator of epithelial cell identity and essential for the survival of squamous cell carcinoma (SCC) of lung, head and neck, oesophagus, cervix and skin. Here, we report that the deubiquitylase USP28 stabilizes ∆Np63 and maintains elevated ∆NP63 levels in SCC by counteracting its proteasome‐mediated degradation. Impaired USP28 activity, either genetically or pharmacologically, abrogates the transcriptional identity and suppresses growth and survival of human SCC cells. CRISPR/Cas9‐engineered in vivo mouse models establish that endogenous USP28 is strictly required for both induction and maintenance of lung SCC. Our data strongly suggest that targeting ∆Np63 abundance via inhibition of USP28 is a promising strategy for the treatment of SCC tumours.
Sphingosine‐1‐phosphate (S1P) regulates pathophysiological processes, including liver regeneration, vascular tone control, and immune response. In patients with liver cirrhosis, acute deterioration of liver function is associated with high mortality rates. The present study investigated whether serum S1P concentrations are associated with disease severity in patients with chronic liver disease from compensated cirrhosis (CC), acute decompensation (AD), or acute‐on‐chronic liver failure (ACLF). From August 2013 to October 2017, patients who were admitted to the University Hospital Frankfurt with CC, AD, or ACLF were enrolled in our cirrhosis cohort study. Tandem mass spectrometry was performed on serum samples of 127 patients to assess S1P concentration. Our study comprised 19 patients with CC, 55 with AD, and 51 with ACLF, aged 29 to 76 years. We observed a significant decrease of S1P according to advanced liver injury from CC and AD up to ACLF (P < 0.001). S1P levels further decreased with progression to ACLF grade 3 (P < 0.05), and S1P highly inversely correlated with the Model for End‐Stage Liver Disease score (r = −0.508; P < 0.001). In multivariate analysis, S1P remained an independent predictor of 7‐day mortality with high diagnostic accuracy (area under the curve, 0.874; P < 0.001). Conclusion: In patients with chronic liver disease, serum S1P levels dramatically decreased with advanced stages of liver disease and were predictive of early mortality. Because S1P is a potent regulator of endothelial integrity and immune response, low S1P levels may significantly influence progressive multiorgan failure. Our data justify further elucidation of the diagnostic and therapeutic role of S1P in ACLF.
Analyse der Genauigkeit des neurochirurgischen Operationsroboters Robotic Surgery Assistant (ROSA)
(2020)
In der vorliegenden Arbeit sollte untersucht werden, ob der Roboter ROSA bei der Durchführung von intrakraniellen Biopsien oder Elektrodenimplantationen eine Alternative zur klassischen, rahmenbasierten Stereotaxie darstellt. Dazu sollte die mechanische und die Anwendungsgenauigkeit des Systems ermittelt werden. Zur Bestimmung der mechanischen Genauigkeit wurde eine experimentelle Phantomstudie durchgeführt. Hier wurden durch den Roboter wiederholt zehn Trajektorien an einem Stereotaxiephantom angefahren. Der Abstand der robotischen Nadel zum Zielpunkt im Phantom wurde anhand von Röntgenbildern bestimmt. Die Wiederholung des Versuchsaufbaus unter Variation der Planungsbildgebung erlaubte den Vergleich verschiedener Schichtdicken sowie zwischen low-dose und normal-dose Verfahren. Die Anwendungsgenauigkeit sollte durch die Analyse operativer Ergebnisse der ROSA erfasst werden. Dazu wurde anhand von postoperativen Bildern die Genauigkeit anhand des Abstands zwischen geplanter und tatsächlicher Lage von Stereoelektroenzephalographie-Elektroden ermittelt. Es wurden verschiedene Referenzierungstechniken, die der Orientierung des Roboters dienen und bei denen eine präoperative Planungsbildgebung (CT oder MRT) mit einem Abbild des OP-Gebietes (durch Oberflächenerkennung oder durch einen Stereotaxierahmen) referenziert wird, verglichen, nämlich CT-Laser; CT-Leksell-Rahmen und MRT-Laser. Die Ergebnisse wurden einer statistischen Analyse unterzogen. Dabei zeigte sich, dass der ROSA-Roboter eine sehr hohe mechanische Genauigkeit im Submillimeterbereich erreicht. Genauigkeitseinbußen bei einer größeren Schichtdicke der zur Planung verwendeten Computertomographie sind messbar, aber gering. Ein signifikanter Einfluss bei der Verwendung eines low-dose-Protokolls konnte nicht festgestellt werden. Dennoch zeigte sich, dass der entscheidende Teil der Ungenauigkeiten in der klinischen Anwendung entsteht und dabei insbesondere durch die Referenzierungstechnik bestimmt wird. Referenzierungen, die auf einer Computertomographie basierten, erwiesen sich als zufriedenstellend genau und als konkurrenzfähig zur konventionellen Methode. Der Unterschied zwischen dem rahmenbasierten und dem auf Oberflächenerkennung basierenden Verfahren war dabei so gering, dass letzteres sich angesichts seiner Vorteile in der Anwendung als besonders günstiges Verfahren hervortut. Im Gegensatz dazu stand das MRT-Laser-Verfahren, welches bei relativ hohen Abweichungen nur eingeschränkt anwendbar scheint und sich damit eher für Anwendungsbereiche mit geringeren Genauigkeitsanforderungen eignet, wie bspw. Biopsien. Weiterhin kann der Verlauf der Trajektorie an den höheren Sicherheitsabstand angepassten werden. Bei der Einordnung der ermittelten Genauigkeiten ist zu beachten, dass es viele weitere, von der Referenzierungs- und Bildgebungsmethode unabhängige Einflussfaktoren gibt. In dieser Arbeit war der Einfluss der erfassten externen Paramter zwar limitiert, bei anderen Autoren zeigte sich jedoch ein signifikanter Effekt. Dennoch deckt sich die Gesamtgenauigkeit mit den Ergebnissen anderer Arbeiten.
In Zusammenschau der Ergebnisse weist die vom ROSA-Assistenzsystem assistierte Stereotaxie eine verbesserte Prozessqualität auf, unter anderem durch die erhebliche Zeitersparnis, ggf. der Wegfall des Transports des narkotisierten Patienten, die Adaptionsmöglichkeiten der Prozessteilschritte an den Patienten, sowie eine hohe Nutzerfreundlichkeit. Entscheidend ist jedoch, dass es sich um ein sehr sicheres Verfahren handelt: Durch die hohe Genauigkeit wird das Operationsrisiko minimiert, gleichzeitig erlauben Laser-gestützte Registrierungsverfahren eine Reduktion der Strahlenexposition. Zur Konsolidierung der in dieser Arbeit gewonnenen Erkenntnisse sind weitere klinische Daten notwendig.
Astrozyten erfüllen verschiedene Funktionen im Zentralnervensystem, welche sich in die Bereiche Entwicklung, Durchblutung, Metabolismus, Strukturerhalt und Gliotransmission unterteilen lassen. Astrozyten sind an der synaptischen Informationsverarbeitung beteiligt und wirken an zahlreichen höheren Hirnfunktionen mit. Durch Regulation der synaptischen Transmission und Plastizität sind Astrozyten am Lernverhalten und Erinnerungsvermögen, sowie an der Verhaltensmodulation und Verarbeitung emotionaler Reize involviert. Im Zuge dieser zahlreichen Funktionen können Astrozyten auf externe Stimuli mit der gezielten Freisetzung von Gliotransmittern reagieren.
In kultivierten Astrozyten konnte Keil143 das TGN, bestehend aus Zisternen und Vesikeln, darstellen und mit anti-Rab6 identifizieren. Rab6 mit seinen Subtypen A und B gehört der Superfamilie der monomeren Ras-GTPasen an, die den intrazellulären Membran- und Vesikelverkehr regulieren. Rab6 spielt in HeLa-Zellen beim Transport vesikulärer Organellen vom TGN zur Zellmembran eine wichtige Rolle. Assoziationsanalysen von Rab6A mit vesikulären Glutamattransportern, Serinracemase und Markern der regulierten Exozytose in kultivierten Astrozyten143 deuten darauf hin, dass dieses Rab6A-Organellsystem die ultrastrukturelle Grundlage für die Freisetzung von Gliotransmittern wie D-Serin und Glutamat bildet.
Zur Untersuchung, ob Rab6A tatsächlich ein System der Glia-Neuron-Kommunikation im Gehirn darstellt, war es zunächst unabdingbar das Vorkommen von Rab6A in situ zu untersuchen. Die durchgeführten immunzytochemischen Färbungen an Hirnschnitten der Maus zeigen das gleichmäßige und ubiquitäre Vorkommen von Rab6A in allen untersuchten Hirnregionen. Durch verblindet durchgeführte Kolokalisationsanalysen von Rab6A mit den etablierten astrozytären Markern Glutaminsynthetase (GS), Glial fibrillary acidic protein (GFAP), Aldh1L1 und Sox9 konnte eine Lokalisation von Rab6A in allen Astrozyten gezeigt werden. Weitere Analysen schließen die Lokalisation von Rab6A in Mikroglia (Iba1), NG2-Zellen (NG2) und Oligodendrozyten (CNPase) aus. Die Astrozyten unterscheiden sich in Größe und subzellulärem Verteilungsmuster der Rab6A+ Strukturen, wonach eine Kategorisierung in vier Typen vorgenommen wurde. Anhand der Einteilung kann vermutet werden, dass größere Rab6A+ TGN-Zisternen bis weit in die Zellperipherie transportiert werden und kleine Rab6A+ Vesikel erst dort ausknospen und der Exozytose zugeführt werden. Zur Frage der möglichen astrozytären Subpopulationen konnte gezeigt werden, dass alle untersuchten Astrozyten GS+, Aldh1L1+, Sox9+ und Rab6A+ sind, jedoch nicht GFAP+.
Um die prinzipielle Übertragbarkeit der gewonnenen Befunde auf den Menschen zu überprüfen, wurde reseziertes Cortex-Gewebe von drei Patienten mit unterschiedlicher pathologischer Genese untersucht. Rab6A ist im massiven Ausmaß in humanen Astrozyten lokalisiert, was nahelegt, dass die zuvor an der Maus gewonnenen Ergebnisse auf den Menschen übertragbar sind.
Die mögliche funktionelle Bedeutung von astrozytärem Rab6A im Gehirn wurde an HFS-Schnitten untersucht. Die Untersuchung zeigt einen signifikanten Anstieg der Rab6A+ Intensität in der gesamten Molekularschicht der Fascia dentata der stimulierten im Vergleich zur unstimulierten Seite. Da die HFS ein etabliertes LTP-Modell darstellt, könnte es infolge dieser zu einer strukturellen, intrazellulären Veränderung der Astrozyten mit erhöhter Freisetzung von D-Serin oder Glutamat aus Rab6A+ Vesikeln kommen, was das Lernverhalten beeinflussen könnte. Die dargestellten Ergebnisse legen eine Auswirkung der HFS auf Rab6A nahe.
Zur Bestätigung der immunzytochemischen Untersuchungen wurde die mRNA-Expression von Rab6A in Astrozyten bereits publizierter Transkriptomanalysen untersucht. Die in den Publikationen verwendeten Genom-Chips treffen allenfalls indirekt eine Aussage zu Rab6A, da Rab6 allgemein und nur Rab6B spezifisch untersucht wurde, jedoch keine spezifische Rab6A Sonde erwähnt wird.
Zusammenfassend kann Rab6A als spezifisches und selektiv in Astrozyten vorkommendes Protein dargestellt und als neuer astrozytärer Marker etabliert werden, der auch Astrozyten des humanen Gewebes markiert. Durch die gewonnenen Befunde kann in nachfolgenden Studien die mögliche Bedeutung von Rab6A in neuropathologischen und neurophysiologischen Prozessen untersucht werden.
Different experimental multiple trauma models induce comparable inflammation and organ injury
(2020)
Multiple injuries appear to be a decisive factor for experimental polytrauma. Therefore, our aim was to compare the inflammatory response and organ damage of five different monotrauma with three multiple trauma models. For this, mice were randomly assigned to 10 groups: Healthy control (Ctrl), Sham, hemorrhagic shock (HS), thoracic trauma (TxT), osteotomy with external fixation (Fx), bilateral soft tissue trauma (bsTT) or laparotomy (Lap); polytrauma I (PT I, TxT + HS + Fx), PT II (TxT + HS + Fx + Lap) and one multi-trauma group (MT, TxT + HS + bsTT + Lap). The inflammatory response and organ damage were quantified at 6 h by analyses of IL-6, IL-1β, IL-10, CXCL1, SAA1, HMGB1 and organ injury. Systemic IL-6 increased in all mono and multiple trauma groups, while CXCL1 increased only in HS, PT I, PT II and MT vs. control. Local inflammatory response was most prominent in HS, PT I, PT II and MT in the liver. Infiltration of inflammatory cells into lung and liver was significant in all multiple trauma groups vs. controls. Hepatic and pulmonary injury was prominent in HS, PT I, PT II and MT groups. These experimental multiple trauma models closely mimic the early post-traumatic inflammatory response in human. Though, the choice of read-out parameters is very important for therapeutic immune modulatory approaches.
Introduction: From the beginning of the corona pandemic until August 19, 2020, more than 21,989,366 cases have been reported worldwide – 228,495 in Germany alone, including 12,648 children aged 0–14. In many countries, the proportion of infected children in the total population is comparatively low; in addition, children often have no or milder symptoms and are less likely to transmit the pathogen to adults than the other way round. Based on the registration data in Frankfurt am Main, Germany, the symptoms of children in comparison with adults and the likely routes of transmission are presented below.
Materials and methods: The documentation of the mandatory reports includes personal data (name, date of birth, gender, place of residence), disease characteristics (date of report, date of onset of the disease, symptoms), possible contact persons (family, others) and i.a. possible activity or care in children’s community facilities. All reports were viewed, especially with regard to likely transmission routes.
Results: From March 1 to July 31, 2020, 1,977 infected people were reported, including 138 children between the ages of 0 and 14 years. Children had fewer and milder symptoms than adults. None of the children experienced severe respiratory symptoms or the need for ventilation. 62% of the children had no symptoms at all (19% adults), 5% of the children were hospitalized (24% adults), and none of the children died (3.8% adults).
After excluding a cluster of 34 children from refugee accommodations and 14 children from a parish, 78% of the remaining 90 children had been infected by an adult within the family, and only 4% were likely to have a reverse transmission route. In 5.5% of cases, transmission in a community facility was likely.
Discussion: The results of the registration data from Frankfurt am Main, Germany confirm the results published in other countries: Children are less likely to become infected, and if infected, their symptoms are less severe than in adults, and they are apparently not the main drivers of virus transmission. Therefore, scientific medical associations strongly recommend reopening schools.
Background: Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and is often a time-consuming procedure, which could result in missing out on potentially eligible patients. Pre-selection of those patients using a registry could facilitate the process of eligibility testing and increase the number of identified patients. One aim with the PRAEGNANT registry (NCT02338167) is to identify patients for therapies based on clinical and molecular data. Here, we report eligibility testing for the SHERBOC trial using the German PRAEGNANT registry.
Methods:Heregulin (HRG) has been reported to identify patients with better responses to therapy with the anti-HER3 monoclonal antibody seribantumab (MM-121). The SHERBOC trial investigated adding seribantumab (MM-121) to standard therapy in patients with advanced HER2-negative, hormone receptor–positive (HR-positive) breast cancer and HRG overexpression. The PRAEGNANT registry was used for identification and tumor testing, helping to link potential HRG positive patients to the trial. Patients enrolled in PRAEGNANT have invasive and metastatic or locally advanced, inoperable breast cancer. Patients eligible for SHERBOC were identified by using the registry. Study aims were to describe the HRG positivity rate, screening procedures, and patient characteristics associated with inclusion and exclusion criteria.
Results: Among 2769 unselected advanced breast cancer patients, 650 were HER2-negative, HR-positive and currently receiving first- or second-line treatment, thus potentially eligible for SHERBOC at the end of current treatment; 125 patients also met further clinical eligibility criteria (e.g. menopausal status, ECOG). In the first/second treatment lines, patients selected for SHERBOC based on further eligibility criteria had a more favorable prognosis than those not selected. HRG status was tested in 38 patients, 14 of whom (36.8%) proved to be HRG-positive.
Conclusion: Using a real-world breast cancer registry allowed identification of potentially eligible patients for SHERBOC focusing on patients with HER3 overexpressing, HR-positive, HER2-negative metastatic breast cancer. This approach may provide insights into differences between patients eligible or non-eligible for clinical trials.
Trial registration: Clinicaltrials, NCT02338167, Registered 14 January 2015 - retrospectively registered.
Background: Meta-analysis of observational studies concluded that soft drinks may increase the risk of depression, while high consumption of coffee and tea may reduce the risk. Objectives were to explore the associations between the consumption of soft drinks, coffee or tea and: (1) a history of major depressive disorder (MDD) and (2) the severity of depressive symptoms clusters (mood, cognitive and somatic/vegetative symptoms). Methods: Cross-sectional and longitudinal analysis based on baseline and 12-month-follow-up data collected from four countries participating in the European MooDFOOD prevention trial. In total, 941 overweight adults with subsyndromal depressive symptoms aged 18 to 75 years were analyzed. History of MDD, depressive symptoms and beverages intake were assessed. Results: Sugar-sweetened soft drinks were positively related to MDD history rates whereas soft drinks with non-nutritive sweeteners were inversely related for the high vs. low categories of intake. Longitudinal analysis showed no significant associations between beverages and mood, cognitive and somatic/vegetative clusters. Conclusion: Our findings point toward a relationship between soft drinks and past MDD diagnoses depending on how they are sweetened while we found no association with coffee and tea. No significant effects were found between any studied beverages and the depressive symptoms clusters in a sample of overweight adults.
Glia, the helper cells of the brain, are essential in maintaining neural resilience across time and varying challenges: By reacting to changes in neuronal health glia carefully balance repair or disposal of injured neurons. Malfunction of these interactions is implicated in many neurodegenerative diseases. We present a reductionist model that mimics repair-or-dispose decisions to generate a hypothesis for the cause of disease onset. The model assumes four tissue states: healthy and challenged tissue, primed tissue at risk of acute damage propagation, and chronic neurodegeneration. We discuss analogies to progression stages observed in the most common neurodegenerative conditions and to experimental observations of cellular signaling pathways of glia-neuron crosstalk. The model suggests that the onset of neurodegeneration can result as a compromise between two conflicting goals: short-term resilience to stressors versus long-term prevention of tissue damage.
The role of radiation therapy in the treatment of (colo)-rectal cancer has changed dramatically over the past decades. Introduced with the aim of reducing the high rates of local recurrences after conventional surgery, major developments in imaging, surgical technique, systemic therapy and radiation delivery have now created a much more complex environment leading to a more personalized approach. Functional aspects including reduction of acute or late treatment-related side effects, sphincter or even organ-preservation and the unsolved problem of still high distant failure rates have become more important while local recurrence rates can be kept low in the vast majority of patients. This review summarizes the actual role of radiation therapy in different subgroups of patients with rectal cancer, including the current standard approach in different subgroups as well as recent developments focusing on neoadjuvant treatment intensification and/or non-operative treatment approaches aiming at organ-preservation.
The novel coronavirus infection (COVID-19) is caused by the new coronavirus SARS-CoV-2 and is characterized by an exaggerated inflammatory response that can lead to severe manifestations such as adult respiratory syndrome, sepsis, coagulopathy, and death in a proportion of patients. Among other factors and direct viral effects, the increase in the vasoconstrictor angiotensin II, the decrease in the vasodilator angiotensin, and the sepsis-induced release of cytokines can trigger a coagulopathy in COVID-19. A coagulopathy has been reported in up to 50% of patients with severe COVID-19 manifestations. An increase in d-dimer is the most significant change in coagulation parameters in severe COVID-19 patients, and progressively increasing values can be used as a prognostic parameter indicating a worse outcome. Limited data suggest a high incidence of deep vein thrombosis and pulmonary embolism in up to 40% of patients, despite the use of a standard dose of low-molecular-weight heparin (LMWH) in most cases. In addition, pulmonary microvascular thrombosis has been reported and may play a role in progressive lung failure. Prophylactic LMWH has been recommended by the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology (ASH), but the best effective dosage is uncertain. Adapted to the individual risk of thrombosis and the d-dimer value, higher doses can be considered, especially since bleeding events in COVID-19 are rare. Besides the anticoagulant effect of LMWH, nonanticoagulant properties such as the reduction in interleukin 6 release have been shown to improve the complex picture of coagulopathy in patients with COVID-19.
Signaling pathways, depending on the second messenger molecule cAMP, modulate hippocampal cell signaling via influencing transcription factors like cAMP-regulated element-binding protein (CREB) or early growth response 1 EGR1/Krox24/zif268/ZENK (EGR1). Here, we investigated two reporter cell lines derived from an immortalized hippocampal neuronal cell line stably expressing a CRE- or EGR1-luciferase reporter gene (HT22CREluc and HT22EGR1luc, respectively). The cells were subjected to phosphodiesterase inhibitors and other cAMP-modulating agents to investigate dose- and time-dependent phosphodiesterase (PDE)-mediated fine-tuning of cAMP-dependent transcriptional signaling. The non-isoform-specific cyclic nucleotide phosphodiesterase (PDE) inhibitor isobutyl-methyl-xanthine (IBMX), as well as selective inhibitors of PDE3 (milrinone) and PDE4 (rolipram), were tested for their ability to elevate CRE- and EGR1-luciferase activity. Pharmacological parameters like onset of activity, maximum activity, and offset of activity were determined. In summary, phosphodiesterase inhibition appeared similarly potent in comparison to adenylate cyclase stimulation or direct activation of protein kinase A (PKA) via specific cAMP agonists and was at least partly mediated by PKA as shown by the selective PKA inhibitor <i>Rp</i>-8-Br-cAMPS. Moreover, transcriptional activation by PDE inhibition was also influenced by organic anion-exchanger action and interacted with fibroblast growth factor (FGF) receptor-mediated pathways.
Comprehensive analysis of tumour sub-volumes for radiomic risk modelling in locally advanced HNSCC
(2020)
Simple Summary: Radiomic risk models are usually based on imaging features, which are extracted from the entire gross tumour volume (GTV entire ). This approach does not explicitly consider the complex biological structure of the tumours. Therefore, in this retrospective study, we investigated the prognostic value of radiomic analyses based on different tumour sub-volumes using computed tomography imaging of patients with locally advanced head and neck squamous cell carcinoma who were treated with primary radio-chemotherapy. The GTV entire was cropped by different margins to define the rim and corresponding core sub-volumes of the tumour. Furthermore, the best performing tumour rim sub-volume was extended into surrounding tissue with different margins. As a result, the models based on the 5 mm tumour rim and on the 3 mm extended rim sub-volume showed an improved performance compared to models based on the corresponding tumour core. This indicates that the consideration of tumour sub-volumes may help to improve radiomic risk models.
Abstract: Imaging features for radiomic analyses are commonly calculated from the entire gross tumour volume (GTVentire). However, tumours are biologically complex and the consideration of different tumour regions in radiomic models may lead to an improved outcome prediction. Therefore, we investigated the prognostic value of radiomic analyses based on different tumour sub-volumes using computed tomography imaging of patients with locally advanced head and neck squamous cell carcinoma. The GTVentire was cropped by different margins to define the rim and the corresponding core sub-volumes of the tumour. Subsequently, the best performing tumour rim sub-volume was extended into surrounding tissue with different margins. Radiomic risk models were developed and validated using a retrospective cohort consisting of 291 patients in one of the six Partner Sites of the German Cancer Consortium Radiation Oncology Group treated between 2005 and 2013. The validation concordance index (C-index) averaged over all applied learning algorithms and feature selection methods using the GTVentire achieved a moderate prognostic performance for loco-regional tumour control (C-index: 0.61 ± 0.04 (mean ± std)). The models based on the 5 mm tumour rim and on the 3 mm extended rim sub-volume showed higher median performances (C-index: 0.65 ± 0.02 and 0.64 ± 0.05, respectively), while models based on the corresponding tumour core volumes performed less (C-index: 0.59 ± 0.01). The difference in C-index between the 5 mm tumour rim and the corresponding core volume showed a statistical trend (p = 0.10). After additional prospective validation, the consideration of tumour sub-volumes may be a promising way to improve prognostic radiomic risk models.
Simple Summary: Therapeutic antibodies are an integral part of treatment regimens for metastasized colorectal cancer. In KRAS wildtype tumors both bevacizumab and cetuximab are active. While bevacizumab has previously been shown to induce tumor hypoxia, we here report that EGFR inhibition by cetuximab protects colon cancer cells from hypoxia-induced cell death. This effect appears to be responsible for the inferior efficacy of a treatment sequence of bevacizumab followed by cetuximab versus an inverse sequence that we observed in a colorectal cancer mouse model. It also offers a mechanistic explanation for effects observed in clinical trials such as underadditive or even detrimental effects when combining bevacizumab and cetuximab (CAIRO2 trial) and the superior efficacy of first line cetuximab (FIRE-3 trial) under chemotherapy backbones in colorectal cancer.
Abstract: Monoclonal antibodies like cetuximab, targeting the epidermal growth factor receptor (EGFR), and bevacizumab, targeting the vascular endothelial growth factor (VEGF), are an integral part of treatment regimens for metastasized colorectal cancer. However, inhibition of the EGFR has been shown to protect human glioma cells from cell death under hypoxic conditions. In colon carcinoma cells, the consequences of EGFR blockade in hypoxia (e.g., induced by bevacizumab) have not been evaluated yet. LIM1215 and SW948 colon carcinoma and LNT-229 glioblastoma cells were treated with cetuximab, PD153035, and erlotinib and analyzed for cell density and viability. The sequential administration of either cetuximab followed by bevacizumab (CET->BEV) or bevacizumab followed by cetuximab (BEV->CET) was investigated in a LIM1215 (KRAS wildtype) and SW948 (KRAS mutant) xenograft mouse model. In vitro, cetuximab protected from hypoxia. In the LIM1215 model, a survival benefit with cetuximab and bevacizumab monotherapy was observed, but only the sequence CET->BEV showed an additional benefit. This effect was confirmed in the SW948 model. Our observations support the hypothesis that bevacizumab modulates the tumor microenvironment (e.g., by inducing hypoxia) where cetuximab could trigger protective effects when administered later on. The sequence CET->BEV therefore seems to be superior as possible mutual adverse effects are bypassed.
Background: Hyperhomocysteinemia is considered a possible contributor to the complex pathology of Alzheimer’s disease (AD). For years, researchers in this field have discussed the apparent detrimental effects of the endogenous amino acid homocysteine in the brain. In this study, the roles of hyperhomocysteinemia driven by vitamin B deficiency, as well as potentially beneficial dietary interventions, were investigated in the novel AppNL-G-F knock-in mouse model for AD, simulating an early stage of the disease. Methods: Urine and serum samples were analyzed using a validated LC-MS/MS method and the impact of different experimental diets on cognitive performance was studied in a comprehensive behavioral test battery. Finally, we analyzed brain samples immunohistochemically in order to assess amyloid-β (Aβ) plaque deposition. Results: Behavioral testing data indicated subtle cognitive deficits in AppNL-G-F compared to C57BL/6J wild type mice. Elevation of homocysteine and homocysteic acid, as well as counteracting dietary interventions, mostly did not result in significant effects on learning and memory performance, nor in a modified Aβ plaque deposition in 35-week-old AppNL-G-F mice. Conclusion: Despite prominent Aβ plaque deposition, the AppNL-G-F model merely displays a very mild AD-like phenotype at the investigated age. Older AppNL-G-F mice should be tested in order to further investigate potential effects of hyperhomocysteinemia and dietary interventions.
Pathogenic variants in PRRT2, encoding the proline-rich transmembrane protein 2, have been associated with an evolving spectrum of paroxysmal neurologic disorders. Based on a cohort of children with PRRT2-related infantile epilepsy, this study aimed at delineating the broad clinical spectrum of PRRT2-associated phenotypes in these children and their relatives. Only a few recent larger cohort studies are on record and findings from single reports were not confirmed so far. We collected detailed genetic and phenotypic data of 40 previously unreported patients from 36 families. All patients had benign infantile epilepsy and harbored pathogenic variants in PRRT2 (core cohort). Clinical data of 62 family members were included, comprising a cohort of 102 individuals (extended cohort) with PRRT2-associated neurological disease. Additional phenotypes in the cohort of patients with benign sporadic and familial infantile epilepsy consist of movement disorders with paroxysmal kinesigenic dyskinesia in six patients, infantile-onset movement disorders in 2 of 40 individuals, and episodic ataxia after mild head trauma in one girl with bi-allelic variants in PRRT2. The same girl displayed a focal cortical dysplasia upon brain imaging. Familial hemiplegic migraine and migraine with aura were reported in nine families. A single individual developed epilepsy with continuous spikes and waves during sleep. In addition to known variants, we report the novel variant c.843G>T, p.(Trp281Cys) that co-segregated with benign infantile epilepsy and migraine in one family. Our study highlights the variability of clinical presentations of patients harboring pathogenic PRRT2 variants and expands the associated phenotypic spectrum.
Iron deprivation activates mitophagy and extends lifespan in nematodes. In patients suffering from Parkinson’s disease (PD), PINK1-PRKN mutations via deficient mitophagy trigger iron accumulation and reduce lifespan. To evaluate molecular effects of iron chelator drugs as a potential PD therapy, we assessed fibroblasts by global proteome profiles and targeted transcript analyses. In mouse cells, iron shortage decreased protein abundance for iron-binding nucleotide metabolism enzymes (prominently XDH and ferritin homolog RRM2). It also decreased the expression of factors with a role for nucleotide surveillance, which associate with iron-sulfur-clusters (ISC), and are important for growth and survival. This widespread effect included prominently Nthl1-Ppat-Bdh2, but also mitochondrial Glrx5-Nfu1-Bola1, cytosolic Aco1-Abce1-Tyw5, and nuclear Dna2-Elp3-Pold1-Prim2. Incidentally, upregulated Pink1-Prkn levels explained mitophagy induction, the downregulated expression of Slc25a28 suggested it to function in iron export. The impact of PINK1 mutations in mouse and patient cells was pronounced only after iron overload, causing hyperreactive expression of ribosomal surveillance factor Abce1 and of ferritin, despite ferritin translation being repressed by IRP1. This misregulation might be explained by the deficiency of the ISC-biogenesis factor GLRX5. Our systematic survey suggests mitochondrial ISC-biogenesis and post-transcriptional iron regulation to be important in the decision, whether organisms undergo PD pathogenesis or healthy aging.
Mobile genetic elements (MGEs), especially multidrug-resistance plasmids, are major vehicles for the dissemination of antimicrobial resistance determinants. Herein, we analyse the MGEs in three extensively drug-resistant (XDR) Klebsiella pneumoniae isolates from Germany. Whole genome sequencing (WGS) is performed using Illumina and MinION platforms followed by core-genome multi-locus sequence typing (MLST). The plasmid content is analysed by conjugation, S1-pulsed-field gel electrophoresis (S1-PFGE) and Southern blot experiments. The K. pneumoniae isolates belong to the international high-risk clone ST147 and form a cluster of closely related isolates. They harbour the blaOXA-181 carbapenemase on a ColKP3 plasmid, and 12 antibiotic resistance determinants on an multidrug-resistant (MDR) IncR plasmid with a recombinogenic nature and encoding a large number of insertion elements. The IncR plasmids within the three isolates share a high degree of homology, but present also genetic variations, such as inversion or deletion of genetic regions in close proximity to MGEs. In addition, six plasmids not harbouring any antibiotic resistance determinants are present in each isolate. Our study indicates that genetic variations can be observed within a cluster of closely related isolates, due to the dynamic nature of MGEs. The mobilome of the K. pneumoniae isolates combined with the emergence of the XDR ST147 high-risk clone have the potential to become a major challenge for global healthcare.
The two main phytocannabinoids—delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)—have been extensively studied, and it has been shown that THC can induce transient psychosis. At the same time, CBD appears to have no psychotomimetic potential. On the contrary, emerging evidence for CBD's antipsychotic properties suggests that it may attenuate effects induced by THC. Thus, we investigated and compared the effects of THC and CBD administration on emotion, cognition, and attention as well as the impact of CBD pre-treatment on THC effects in healthy volunteers. We performed a placebo-controlled, double-blind, experimental trial (GEI-TCP II; ClinicalTrials.gov identifier: NCT02487381) with 60 healthy volunteers randomly allocated to four parallel intervention groups, receiving either placebo, 800 mg CBD, 20 mg THC, or both cannabinoids. Subjects underwent neuropsychological tests assessing working memory (Letter Number Sequencing test), cognitive processing speed (Digit Symbol Coding task), attention (d2 Test of Attention), and emotional state (adjective mood rating scale [EWL]). Administration of CBD alone did not influence the emotional state, cognitive performance, and attention. At the same time, THC affected two of six emotional categories—more precisely, the performance-related activity and extraversion—, reduced the cognitive processing speed and impaired the performance on the d2 Test of Attention. Interestingly, pre-treatment with CBD did not attenuate the effects induced by THC. These findings show that the acute intake of CBD itself has no effect per se in healthy volunteers and that a single dose of CBD prior to THC administration was insufficient to mitigate the detrimental impact of THC in the given setting. This is in support of a complex interaction between CBD and THC whose effects are not counterbalanced by CBD under all circumstances.
Pain is the most frequent cause triggering patients to visit a physician. The worldwide incidence of chronic pain is in the range of 20% of adults, and chronic pain conditions are frequently associated with several comorbidities and a drastic decrease in patients’ quality of life. Although several approved analgesics are available, such therapy is often not satisfying due to insufficient efficacy and/or severe side effects. Therefore, novel strategies for the development of safe and highly efficacious pain killers are urgently needed. To reach this goal, it is necessary to clarify the causes and signal transduction cascades underlying the onset and progression of the different types of chronic pain. The papers in this Special Issue cover a wide variety of mechanisms involved in different pain types such as inflammatory, neuropathic or cancer pain. Therefore, the results summarized here might contribute to a better understanding of the mechanisms in chronic pain and thereby to the development of novel therapeutic strategies for pain patients.
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S) protein by cellular proteases. Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations. An analysis of proteomics and translatome data indicated that SARS-CoV-2 replication is associated with a downregulation of host cell protease inhibitors. Hence, aprotinin may compensate for downregulated host cell proteases during later virus replication cycles. Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air–liquid interface cultures) and against four virus isolates. In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity. An approved aprotinin aerosol may have potential for the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a severe, systemic disease.
Simple Summary: Pseudoprogression detection in glioblastoma patients remains a challenging task. Although pseudoprogression has only a moderate prevalence of 10–30% following first-line treatment of glioblastoma patients, it bears critical implications for affected patients. Non-invasive techniques, such as amino acid PET imaging using the tracer O-(2-[18F]-fluoroethyl)-L-tyrosine (FET), expose features that have been shown to provide useful information to distinguish tumor progression from pseudoprogression. The usefulness of FET-PET in IDH-wildtype glioblastoma exclusively, however, has not been investigated so far. Recently, machine learning (ML) algorithms have been shown to offer great potential particularly when multiparametric data is available. In this preliminary study, a Linear Discriminant Analysis-based ML algorithm was deployed in a cohort of newly diagnosed IDH-wildtype glioblastoma patients (n = 44) and demonstrated a significantly better diagnostic performance than conventional ROC analysis. This preliminary study is the first to assess the performance of ML in FET-PET for diagnosing pseudoprogression exclusively in IDH-wildtype glioblastoma and demonstrates its potential.
Abstract: Pseudoprogression (PSP) detection in glioblastoma remains challenging and has important clinical implications. We investigated the potential of machine learning (ML) in improving the performance of PET using O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) for differentiation of tumor progression from PSP in IDH-wildtype glioblastoma. We retrospectively evaluated the PET data of patients with newly diagnosed IDH-wildtype glioblastoma following chemoradiation. Contrast-enhanced MRI suspected PSP/TP and all patients underwent subsequently an additional dynamic FET-PET scan. The modified Response Assessment in Neuro-Oncology (RANO) criteria served to diagnose PSP. We trained a Linear Discriminant Analysis (LDA)-based classifier using FET-PET derived features on a hold-out validation set. The results of the ML model were compared with a conventional FET-PET analysis using the receiver-operating-characteristic (ROC) curve. Of the 44 patients included in this preliminary study, 14 patients were diagnosed with PSP. The mean (TBRmean) and maximum tumor-to-brain ratios (TBRmax) were significantly higher in the TP group as compared to the PSP group (p = 0.014 and p = 0.033, respectively). The area under the ROC curve (AUC) for TBRmax and TBRmean was 0.68 and 0.74, respectively. Using the LDA-based algorithm, the AUC (0.93) was significantly higher than the AUC for TBRmax. This preliminary study shows that in IDH-wildtype glioblastoma, ML-based PSP detection leads to better diagnostic performance.
Background: Due to the difficulties in the definite diagnosis, data on brain imaging in pediatric patients with central nervous system (CNS)-invasive mold infection (IMD) are scarce. Our aim was to describe brain imaging abnormalities seen in immunocompromised children with CNS-IMD, and to analyze retrospectively whether specific imaging findings and sequences have a prognostic value. Methods: In a retrospective study of 19 pediatric patients with proven or probable CNS-IMD, magnetic resonance imaging (MRI)-findings were described and analyzed. The results were correlated with outcome, namely death, severe sequelae, or no neurological sequelae. Results: 11 children and 8 adolescents (11/8 with proven/probable CNS-IMD) were included. Seven of the patients died and 12/19 children survived (63%): seven without major neurological sequelae and five with major neurological sequelae. Multifocal ring enhancement and diffusion restriction were the most common brain MRI changes. Diffusion restriction was mostly seen at the core of the lesion. No patient with disease limited to one lobe died. Perivascular microbleeding seen on susceptibility weighted imaging (SWI) and/or gradient-echo/T2* images, as well as infarction, were associated with poor prognosis. Conclusions: The presence of infarction was related to poor outcome. As early microbleeding seems to be associated with poor prognosis, we suggest including SWI in routine diagnostic evaluation of immunocompromised children with suspected CNS-IMD.
Functional circuit training (FCT) has been demonstrated to acutely enhance cognitive performance (CP). However, the moderators of this observation are unknown. This study aimed to elucidate the role of exercise intensity. According to an a priori sample size calculation, n = 24 healthy participants (26 ± 3 years, 13 females), in randomized order, performed a single 15-min bout of FCT with low (20–39% of the heart rate reserve/HRR), moderate (40–59% HRR) or high intensity (maximal effort). Immediately pre- and post-workout, CP was measured by use of the Digit Span test, Stroop test and Trail Making test. Non-parametric data analyses did not reveal significant differences between conditions (p > 0.05) although parameter-free 95% confidence intervals showed pre-post improvements in some outcomes at moderate and high intensity only. The effort level does not seem to be a major effect modifier regarding short-term increases in CP following HCT in young active adults.
Perceptual-cognitive function and unplanned athletic movement task performance: a systematic review
(2020)
The performance of choice-reaction tasks during athletic movement has been demonstrated to evoke unfavorable biomechanics in the lower limb. However, the mechanism of this observation is unknown. We conducted a systematic review examining the association between (1) the biomechanical and functional safety of unplanned sports-related movements (e.g., jumps/runs with a spontaneously indicated landing leg/cutting direction) and (2) markers of perceptual–cognitive function (PCF). A literature search in three databases (PubMed, ScienceDirect and Google Scholar) identified five relevant articles. The study quality, rated by means of a modified Downs and Black checklist, was moderate to high (average: 13/16 points). Four of five papers, in at least one parameter, found either an association of PCF with task safety or significantly reduced task safety in low vs. high PCF performers. However, as (a) the outcomes, populations and statistical methods of the included trials were highly heterogeneous and (b) only two out of five studies had an adequate control condition (pre-planned movement task), the evidence was classified as conflicting. In summary, PCF may represent a factor affecting injury risk and performance during unplanned sports-related movements, but future research strengthening the evidence for this association is warranted.
Baseline presence of NAFLD predicts weight loss after gastric bypass surgery for morbid obesity
(2020)
Background. Bariatric surgery is a widely used treatment for morbid obesity. Prediction of postoperative weight loss currently relies on prediction models, which mostly overestimate patients’ weight loss. Data about the influence of Non-alcoholic fatty liver disease (NAFLD) on early postoperative weight loss are scarce. Methods. This prospective, single-center cohort study included 143 patients receiving laparoscopic gastric bypass surgery (One Anastomosis-Mini Gastric Bypass (OAGB-MGB) or Roux-en-Y Gastric Bypass (RYGB)). Liver biopsies were acquired at surgery. NAFLD activity score (NAS) assigned patients to “No NAFLD”, “NAFL” or “NASH”. Follow up data were collected at 3, 6 and 12 months. Results. In total, 49.7% of patients had NASH, while 41.3% had NAFL. Compared with the No NAFLD group, NAFL and NASH showed higher body-mass-index (BMI) at follow-up (6 months: 31.0 kg/m2 vs. 36.8 kg/m2 and 36.1 kg/m2, 12 months: 27.0 kg/m2 vs. 34.4 and 32.8 kg/m2) and lower percentage of total body weight loss (%TBWL): (6 months: 27.1% vs. 23.3% and 24.4%; 12 months: 38.5% vs. 30.1 and 32.6%). Linear regression of NAS points significantly predicts percentage of excessive weight loss (%EWL) after 6 months (Cologne-weight-loss-prediction-score). Conclusions. Histopathological presence of NAFLD might lead to inferior postoperative weight reduction after gastric bypass surgery. The mechanisms underlying this observation should be further studied.
Simple Summary: Targeted therapies are of growing interest to physicians in cancer treatment. These drugs target specific genes and proteins involved in the growth and survival of cancer cells. Brain tumor therapy is complicated by the fact that not all drugs can penetrate the blood brain barrier and reach their target. We explored the non-invasive method, Magnetic Resonance Spectroscopy, for monitoring drug penetration and its effects in live animals bearing brain tumors. We were able to show the presence of the investigated drug in mouse brains and its on-target activity.
Abstract: Background: BAY1436032 is a fluorine-containing inhibitor of the R132X-mutant isocitrate dehydrogenase (mIDH1). It inhibits the mIDH1-mediated production of 2-hydroxyglutarate (2-HG) in glioma cells. We investigated brain penetration of BAY1436032 and its effects using 1H/19F-Magnetic Resonance Spectroscopy (MRS). Methods: 19F-Nuclear Magnetic Resonance (NMR) Spectroscopy was conducted on serum samples from patients treated with BAY1436032 (NCT02746081 trial) in order to analyze 19F spectroscopic signal patterns and concentration-time dynamics of protein-bound inhibitor to facilitate their identification in vivo MRS experiments. Hereafter, 30 mice were implanted with three glioma cell lines (LNT-229, LNT-229 IDH1-R132H, GL261). Mice bearing the IDH-mutated glioma cells received 5 days of treatment with BAY1436032 between baseline and follow-up 1H/19F-MRS scan. All other animals underwent a single scan after BAY1436032 administration. Mouse brains were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS). Results: Evaluation of 1H-MRS data showed a decrease in 2-HG/total creatinine (tCr) ratios from the baseline to post-treatment scans in the mIDH1 murine model. Whole brain concentration of BAY1436032, as determined by 19F-MRS, was similar to total brain tissue concentration determined by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS), with a signal loss due to protein binding. Intratumoral drug concentration, as determined by LC-MS/MS, was not statistically different in models with or without R132X-mutant IDH1 expression. Conclusions: Non-invasive monitoring of mIDH1 inhibition by BAY1436032 in mIDH1 gliomas is feasible.
Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma
(2020)
Pancreatic ductal adenocarcinoma (PDAC) is resistant to virtually all chemo‐ and targeted therapeutic approaches. Epigenetic regulators represent a novel class of drug targets. Among them, BET and HDAC proteins are central regulators of chromatin structure and transcription, and preclinical evidence suggests effectiveness of combined BET and HDAC inhibition in PDAC. Here, we describe that TW9, a newly generated adduct of the BET inhibitor (+)‐JQ1 and class I HDAC inhibitor CI994, is a potent dual inhibitor simultaneously targeting BET and HDAC proteins. TW9 has a similar affinity to BRD4 bromodomains as (+)‐JQ1 and shares a conserved binding mode, but is significantly more active in inhibiting HDAC1 compared to the parental HDAC inhibitor CI994. TW9 was more potent in inhibiting tumor cell proliferation compared to (+)‐JQ1, CI994 alone or combined treatment of both inhibitors. Sequential administration of gemcitabine and TW9 showed additional synergistic antitumor effects. Microarray analysis revealed that dysregulation of a FOSL1‐directed transcriptional program contributed to the antitumor effects of TW9. Our results demonstrate the potential of a dual chromatin‐targeting strategy in the treatment of PDAC and provide a rationale for further development of multitarget inhibitors.
High glucosylceramides and low anandamide contribute to sensory loss and pain in Parkinson's disease
(2020)
Background: Parkinson's disease (PD) causes chronic pain in two‐thirds of patients, in part originating from sensory neuropathies. The aim of the present study was to describe the phenotype of PD‐associated sensory neuropathy and to evaluate its associations with lipid allostasis, the latter motivated by recent genetic studies associating mutations of glucocerebrosidase with PD onset and severity. Glucocerebrosidase catalyzes the metabolism of glucosylceramides.
Methods: We used quantitative sensory tests, pain ratings, and questionnaires and analyzed plasma levels of multiple bioactive lipid species using targeted lipidomic analyses. The study comprised 2 sets of patients and healthy controls: the first 128 Israeli PD patients and 224 young German healthy controls for exploration, the second 50/50 German PD patients and matched healthy controls for deeper analyses.
Results: The data showed a 70% prevalence of PD pain and sensory neuropathies with a predominant phenotype of thermal sensory loss plus mechanical hypersensitivity. Multivariate analyses of lipids revealed major differences between PD patients and healthy controls, mainly originating from glucosylceramides and endocannabinoids. Glucosylceramides were increased, whereas anandamide and lysophosphatidic acid 20:4 were reduced, stronger in patients with ongoing pain and with a linear relationship with pain intensity and sensory losses, particularly for glucosylceramide 18:1 and glucosylceramide 24:1.
Conclusions: Our data suggest that PD‐associated sensory neuropathies and PD pain are in part caused by accumulations of glucosylceramides, raising the intriguing possibility of reducing PD pain and sensory loss by glucocerebrosidase substituting or refolding approaches. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Background & Aims: Phosphodiesterase‐5 inhibitors (PDE‐5‐I) are used for treatment of erectile dysfunction (ED), which is common in patients with cirrhosis. They may improve portal hypertension (PH), but contradictory data on efficacy and side‐effects have been reported. Non‐selective beta blockers (NSBB) reduce portal pressure, but might aggravate ED. Thus, we evaluated the combination of PDE‐5‐I with NSBB and its impact on PH and ED in experimental cirrhosis.
Methods: ED was assessed in cirrhotic patients (n = 86) using standardized questionnaire. Experimental cirrhosis was induced by bile‐duct‐ligation or carbon‐tetrachloride intoxication in rats. Corpus cavernosum pressure – a surrogate of ED ‐, as well as systemic and portal haemodynamics, were measured in vivo and in situ after acute administration of udenafil alone or in combination with propranolol. mRNA and protein levels of PDE‐5 signalling were analysed using PCR and western Blot.
Results: ED in humans was related to severity of liver disease and to NSBB treatment. PDE‐5 was mainly expressed in hepatic stellate cells and upregulated in human and experimental cirrhosis. Propranolol reduced corpus cavernosum pressure in cirrhotic rats and it was restored by udenafil. Even though udenafil treatment improved PH, it led to a reduction of mean arterial pressure. The combination of udenafil and propranolol reduced portal pressure and hepatic resistance without systemic side‐effects.
Conclusions: ED is common with advanced cirrhosis and concomitant NSBB treatment. The combination of PDE‐5‐I and NSBB improves ED and PH in experimental cirrhosis.
EEG microstate periodicity explained by rotating phase patterns of resting-state alpha oscillations
(2020)
Spatio-temporal patterns in electroencephalography (EEG) can be described by microstate analysis, a discrete approximation of the continuous electric field patterns produced by the cerebral cortex. Resting-state EEG microstates are largely determined by alpha frequencies (8-12 Hz) and we recently demonstrated that microstates occur periodically with twice the alpha frequency.
To understand the origin of microstate periodicity, we analyzed the analytic amplitude and the analytic phase of resting-state alpha oscillations independently. In continuous EEG data we found rotating phase patterns organized around a small number of phase singularities which varied in number and location. The spatial rotation of phase patterns occurred with the underlying alpha frequency. Phase rotors coincided with periodic microstate motifs involving the four canonical microstate maps. The analytic amplitude showed no oscillatory behaviour and was almost static across time intervals of 1-2 alpha cycles, resulting in the global pattern of a standing wave.
In n=23 healthy adults, time-lagged mutual information analysis of microstate sequences derived from amplitude and phase signals of awake eyes-closed EEG records showed that only the phase component contributed to the periodicity of microstate sequences. Phase sequences showed mutual information peaks at multiples of 50 ms and the group average had a main peak at 100 ms (10 Hz), whereas amplitude sequences had a slow and monotonous information decay. This result was confirmed by an independent approach combining temporal principal component analysis (tPCA) and autocorrelation analysis.
We reproduced our observations in a generic model of EEG oscillations composed of coupled non-linear oscillators (Stuart-Landau model). Phase-amplitude dynamics similar to experimental EEG occurred when the oscillators underwent a supercritical Hopf bifurcation, a common feature of many computational models of the alpha rhythm.
These findings explain our previous description of periodic microstate recurrence and its relation to the time scale of alpha oscillations. Moreover, our results corroborate the predictions of computational models and connect experimentally observed EEG patterns to properties of critical oscillator networks.
Background: To assess the influence of ridge preservation procedures on the healing of extraction sockets under antiresorptive therapy.
Material and Methods: A total of 10 Dutch Belted rabbits were randomly allocated to either the intravenous administration of amino‐bisphosphonate (zoledronic acid) (Za) (n = 5) or a negative control group (no Za [nZa]) (n = 5). At 6 months, the mandibular and maxillary molars were extracted and the four experimental sites randomly allocated to the following subgroups: (a) socket grafting using a collagen‐coated natural bone mineral (BOC) + primary wound closure, (b) coronectomy (CO), or (c) spontaneous healing + primary wound closure (SP). Za medication was continued for another 4 months. Histomorphometrical analyses considered, for example, crestal hard tissue closure of the extraction site (C) and mineralized tissue (MT) formation.
Results: Za‐SP was associated with an incomplete median C (31.76% vs 100% in nZa‐SP) and signs of bone arrosion along the confines of the socket. BOC had no major effects on increases in C and MT values in the Za group. CO commonly resulted in an encapsulation and partial replacement resorption of residual roots by MT without any histological signs of osteonecrosis.
Conclusions: (a) Za‐SP was commonly associated with a compromised socket healing and signs of osteonecrosis, (b) BOC had no major effect on socket healing in the Za group, and (c) CO at noninfected teeth might be a feasible measure for the prevention of a Za‐related osteonecrosis of the jaw.
Aim: To assess volumetric tissue changes at peri‐implantitis sites following combined surgical therapy of peri‐implantitis over a 6‐month follow‐up period.
Materials and Methods: Twenty patients (n = 28 implants) diagnosed with peri‐implantitis underwent access flap surgery, implantoplasty at supracrestally or bucally exposed implant surfaces and augmentation at intra‐bony components using a natural bone mineral and application of a native collagen membrane during clinical routine treatments. The peri‐implant region of interest (ROI) was intra‐orally scanned pre‐operatively (S0), and after 1 (S1) and 6 (S2) months following surgical therapy. Digital files were converted to standard tessellation language (STL) format for superimposition and assessment of peri‐implant volumetric variations between time points. The change in thickness was assessed at a standardized ROI, subdivided into three equidistant sections (i.e. marginal, medial and apical). Peri‐implant soft tissue contour area (STCA) (mm2) and its corresponding contraction rates (%) were also assessed.
Results: Peri‐implant tissues revealed a mean thickness change (loss) of −0.11 and −0.28 mm at 1 and 6 months. S0 to S1 volumetric variations pointed to a thickness change of −0.46, 0.08 and 0.4 mm at marginal, medial and apical regions, respectively. S0 to S2 analysis exhibited corresponding thickness changes of −0.61, −0.25 and −0.09 mm, respectively. The thickness differences between the areas were statistically significant at both time periods. The mean peri‐implant STCA totalled to 189.2, 175 and 158.9 mm2 at S0, S1 and S2, showing a significant STCA contraction rate of 7.9% from S0 to S1 and of 18.5% from S0 to S2. Linear regression analysis revealed a significant association between the pre‐operative width of keratinized mucosa (KM) and STCA contraction rate.
Conclusions: The peri‐implant mucosa undergoes considerable volumetric changes after combined surgical therapy. However, tissue contraction appears to be influenced by the width of KM.
Aim: To evaluate the level of agreement between the periodontal risk assessment (PRA) and the periodontal risk calculator (PRC).
Materials and methods: Periodontal risk was retrospectively assessed among 50 patients using PRA and PRC. Both methods were modified. PRA by assessing probing pocket depths and bleeding on probing at four (PRA4) and six (PRA6) sites per tooth, PRC by permanently marking or unmarking the dichotomously selectable factors “irregular recall,” “oral hygiene in need of improvement” and “completed scaling and root planing” for PRC. Agreement between PRA and PRCred (summarized risk categories) was determined using weighted kappa.
Results: Fifty patients enrolled in periodontal maintenance (48% female, age: 63.8 ± 11.2 years) participated. PRA4 and PRA6 matched in 32 (64%) patients (κ‐coefficient = 0.48, p < .001). There was 100% agreement between both PRC versions. There was minimal agreement of PRA6 and PRCred (66%, 28% one different category, 6% two different categories; κ‐coefficient = 0.34; p = .001). PRA4 and PRCred did not match (60% agreement, 34% one different category, 6% two different categories; κ‐coefficient = 0.23; p = .13). For the SPT diagnosis of severe periodontitis, PRA6 and PRCred agreed weakly (κ‐coefficient = 0.44; p = .004).
Conclusion: PRA and PRC showed a minimal agreement. Specific disease severity may result in improved agreement.
Die vorliegende Arbeit liefert ein Versatzstück zu grundlagentheoretischen Überlegungen im Themenfeld Gesundheit. Dabei wird der Fokus insbesondere auf wissenschaftstheoretische, -soziologische und sozialpsychologische Reflektionen der gesundheitsbezogenen Diskurslandschaft im wissenschaftlichen Bereich gelegt. Diese werden nach gesellschaftsdiagnostischen Anteilen der Arbeit in reflektierter Art und Weise in einen diskursiven Vorschlag überführt, der wiederum für Gesundheit im universitären Setting wegweisend sein kann.
Acute clinical deterioration of a patient with chronic liver disease remains a decisive time point both in terms of medical management and prognosis. This condition, also known as acute decompensation (AD), is an important event determining a crossroad in the trajectory of patients. A significant number of patients with AD may develop hepatic or extrahepatic organ failure, or both, which defines the syndrome acute-on-chronic liver failure (ACLF), and ACLF is associated with a high morbidity and short-term mortality. ACLF may occur at any phase during chronic liver disease and is pathogenetically defined by systemic inflammation and immune metabolic dysfunction. When organ failures develop in the presence of cirrhosis, especially extrahepatic organ failures, liver transplantation (LT) may be the only curative treatment. This review outlines the evidence supporting LT in ACLF patients, highlighting the role of timing, bridging to LT, and possible indicators of futility. Importantly, prospective studies on ACLF and transplantation are urgently needed.
DNA methylation was shown previously to be a crucial mechanism responsible for transcriptional deregulation in the pathogenesis of classical Hodgkin lymphoma (cHL). To identify epigenetically inactivated miRNAs in cHL, we have analyzed the set of miRNAs downregulated in cHL cell lines using bisulfite pyrosequencing. We focused on miRNAs with promoter regions located within or <1000 bp from a CpG island. Most promising candidate miRNAs were further studied in primary Hodgkin and Reed-Sternberg (HRS) cells obtained by laser capture microdissection. Last, to evaluate the function of identified miRNAs, we performed a luciferase reporter assay to confirm miRNA: mRNA interactions and therefore established cHL cell lines with stable overexpression of selected miRNAs for proliferation tests. We found a significant reverse correlation between DNA methylation and expression levels of mir-339-3p, mir-148a-3p, mir-148a-5p and mir-193a-5 demonstrating epigenetic regulation of these miRNAs in cHL cell lines. Moreover, we demonstrated direct interaction between miR-148a-3p and IL15 and HOMER1 transcripts as well as between mir-148a-5p and SUB1 and SERPINH1 transcripts. Furthermore, mir-148a overexpression resulted in reduced cell proliferation in the KM-H2 cell line. In summary, we report that mir-148a is a novel tumor suppressor inactivated in cHL and that epigenetic silencing of miRNAs is a common phenomenon in cHL.
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serological assays are urgently needed for rapid diagnosis, contact tracing, and for epidemiological studies. So far, there is limited data on how commercially available tests perform with real patient samples, and if positive tested samples show neutralizing abilities. Focusing on IgG antibodies, we demonstrate the performance of two enzyme‐linked immunosorbent assay (ELISA) assays (Euroimmun SARS‐CoV‐2 IgG and Vircell COVID‐19 ELISA IgG) in comparison to one lateral flow assay (FaStep COVID‐19 IgG/IgM Rapid Test Device) and two in‐house developed assays (immunofluorescence assay [IFA] and plaque reduction neutralization test [PRNT]). We tested follow up serum/plasma samples of individuals polymerase chain reaction‐diagnosed with COVID‐19. Most of the SARS‐CoV‐2 samples were from individuals with moderate to the severe clinical course, who required an in‐patient hospital stay. For all examined assays, the sensitivity ranged from 58.8 to 76.5% for the early phase of infection (days 5‐9) and from 93.8% to 100% for the later period (days 10‐18).
The deep fascia enveloping the skeletal muscle has been shown to contribute to the mechanics of the locomotor system. However, less is known about the role of the superficial fascia (SF). This study aimed to describe the potential interaction between the Hamstring muscles and the SF. Local movement of the dorsal thigh's soft tissue was imposed making use of myofascial force transmission effects across the knee joint: In eleven healthy individuals (26.8 ± 4.3 years, six males), an isokinetic dynamometer moved the ankle into maximal passive dorsal extension (knee extended). Due to the morphological continuity between the gastrocnemius and the Hamstrings, stretching the calf led to soft tissue displacements in the dorsal thigh. Ultrasound recordings were made to dynamically visualize (a) the semimembranosus muscle and (b) the superficial fascia. Differences in and associations between horizontal movement amplitudes of the two structures, quantified via cross‐correlation analyses, were calculated by means of the Mann–Whitney U test and Kendal's tau test, respectively. Mean horizontal movement was significantly higher in the muscle (5.70 mm) than in the SF (0.72 mm, p < 0.001, r = 0.82). However, a strong correlation between the tissue displacements in both locations was detected (p < 0.001, r = 0.91). Direct mechanical relationship may exist between the SF and the skeletal muscle. Deep pathologies or altered muscle stiffness could thus have long‐term consequences for rather superficial structures and vice versa.
TNFR1 is a crucial regulator of NF‐ĸB‐mediated proinflammatory cell survival responses and programmed cell death (PCD). Deregulation of TNFα‐ and TNFR1‐controlled NF‐ĸB signaling underlies major diseases, like cancer, inflammation, and autoimmune diseases. Therefore, although being routinely used, antagonists of TNFα might also affect TNFR2‐mediated processes, so that alternative approaches to directly antagonize TNFR1 are beneficial. Here, we apply quantitative single‐molecule localization microscopy (SMLM) of TNFR1 in physiologic cellular settings to validate and characterize TNFR1 inhibitory substances, exemplified by the recently described TNFR1 antagonist zafirlukast. Treatment of TNFR1‐mEos2 reconstituted TNFR1/2 knockout mouse embryonic fibroblasts (MEFs) with zafirlukast inhibited both ligand‐independent preligand assembly domain (PLAD)‐mediated TNFR1 dimerization as well as TNFα‐induced TNFR1 oligomerization. In addition, zafirlukast‐mediated inhibition of TNFR1 clustering was accompanied by deregulation of acute and prolonged NF‐ĸB signaling in reconstituted TNFR1‐mEos2 MEFs and human cervical carcinoma cells. These findings reveal the necessity of PLAD‐mediated, ligand‐independent TNFR1 dimerization for NF‐ĸB activation, highlight the PLAD as central regulator of TNFα‐induced TNFR1 oligomerization, and demonstrate that TNFR1‐mEos2 MEFs can be used to investigate TNFR1‐antagonizing compounds employing single‐molecule quantification and functional NF‐ĸB assays at physiologic conditions.
Background: Recent advances in 3D printing technology have enabled the emergence of new educational and clinical tools for medical professionals. This study provides an exemplary description of the fabrication of 3D‐printed individualised patient models and assesses their educational value compared to cadaveric models in oral and maxillofacial surgery.
Methods: A single‐stage, controlled cohort study was conducted within the context of a curricular course. A patient's CT scan was segmented into a stereolithographic model and then printed using a fused filament 3D printer. These individualised patient models were implemented and compared against cadaveric models in a curricular oral surgery hands‐on course. Students evaluated both models using a validated questionnaire. Additionally, a cost analysis for both models was carried out. P‐values were calculated using the Mann‐Whitney U test.
Results: Thirty‐eight fourth‐year dental students participated in the study. Overall, significant differences between the two models were found in the student assessment. Whilst the cadaveric models achieved better results in the haptic feedback of the soft tissue, the 3D‐printed individualised patient models were regarded significantly more realistic with regard to the anatomical correctness, the degree of freedom of movement and the operative simulation. At 3.46 € (compared to 6.51 €), the 3D‐printed patient individualised models were exceptionally cost‐efficient.
Conclusions: 3D‐printed patient individualised models presented a realistic alternative to cadaveric models in the undergraduate training of operational skills in oral and maxillofacial surgery. Whilst the 3D‐printed individualised patient models received positive feedback from students, some aspects of the model leave room for improvement.
Background: The INTERCEPT™ Blood System for Red Blood Cells (RBCs) utilizes amustaline (S‐303) and glutathione (GSH) to inactivate pathogens and leukocytes in transfused RBCs. Treatment‐emergent low titer non‐hemolytic antibodies to amustaline/GSH RBC were detected in clinical trials using a prior version of the process. The amustaline/GSH process was re‐formulated to decrease S‐303 RBC adduct formation.
Study Design and Methods: A standard three‐cell antibody screening panel was modified to include reagent red cells (RRC) with high (S‐303H) or low (S‐303L) S‐303 adduct density as assessed by flow cytometry, representative of the original and current amustaline/GSH treatment processes, respectively. General hospital and RBC transfusion‐dependent patients never exposed, and clinical trial subjects exposed to amustaline/GSH RBC were screened for antibodies to amustaline/GSH RBC using a standardized agglutination assay.
Results: Twelve (0.1%) of 10,721 general hospital and 5 (0.5%) of 998 repeatedly‐transfused patients not previously exposed to amustaline/GSH RBCs expressed natural, low titer (2‐32) IgM and/or IgG (non‐IgG1 or IgG3 isotype) antibodies with acridine (a structural element of amustaline) (n = 14) or non‐acridine (n = 3) specificity. 11 of 17 sera reacted with S‐303L panel RRCs. In clinical studies 81 thalassemia and 25 cardiac surgery patients were transfused with a total of 1085 amustaline/GSH RBCs and no natural or treatment‐emergent S‐303 antibodies were detected.
Conclusion: Standardized RRC screening panels are sensitive for the detection of natural and acquired S‐303‐specific antibodies. Natural low titer antibodies to amustaline/GSH RBC are present in 0.15% of naïve patients. The clinical relevance of these antibodies appears minimal but is under further investigation.
Perioperative management for patients with von Willebrand disease: Defining the optimal approach
(2020)
von Willebrand disease (VWD) is the most common inherited bleeding disorder characterised by a quantitative or qualitative deficiency in von Willebrand factor (VWF). During invasive surgical procedures, patients with VWD require additional treatment to maintain haemostasis; however, due to the complexity of VWD, there is a lack of consensus on the optimal management. In the perioperative period, patients are usually treated with VWF and factor FVIII (FVIII)‐containing concentrates to provide an immediate haemostatic response to prevent excessive bleeding during both elective and emergency surgery. With the introduction of recombinant VWF (rVWF), there is a need for guidance on the use of the various VWF products in the perioperative period for all types of patients and surgeries. This review provides an overview of the current evidence for the surgical management of patients with VWD and, summarises the optimal treatment approach during the perioperative period, and highlights key unanswered questions and the research needed to address the evidence gaps.
Objective: To analyze the effect of adverse preoperative patient and tumor characteristics on perioperative outcomes of open (ORP) and robot-assisted radical prostatectomy (RARP).
Material and Methods: We retrospectively analyzed 656 patients who underwent ORP or RARP according to intraoperative blood loss (BL), operation time (OR time), neurovascular bundle preservation (NVBP) and positive surgical margins (PSM). Univariable and multivariable logistic regression models were used to identify risk factors for impaired perioperative outcomes.
Results: Of all included 619 patients, median age was 66 years. BMI (<25 vs. 25-30 vs. ≥30) had no influence on blood loss. Prostate size >40cc recorded increased BL compared to prostate size ≤ 40cc in patients undergoing ORP (800 vs. 1200 ml, p < 0.001), but not in patients undergoing RARP (300 vs. 300 ml, p = 0.2). Similarly, longer OR time was observed for ORP in prostates >40cc, but not for RARP. Overweight (BMI 25-30) and obese ORP patients (BMI ≥30) showed longer OR time compared to normal weight (BMI <25). Only obese patients, who underwent RARP showed longer OR time compared to normal weight. NVBP was less frequent in obese patients, who underwent ORP, relative to normal weight (25.8% vs. 14.0%, p < 0.01). BMI did not affect NVPB at RARP. No differences in PSM were recorded according to prostate volume or BMI in ORP or RARP. In multivariable analyses, patient characteristics such as prostate volume and BMI was an independent predictor for prolonged OR time. Moreover, tumor characteristics (stage and grade) predicted worse perioperative outcome.
Conclusion: Patients with larger prostates and obese patients undergoing ORP are at risk of higher BL, OR time or non-nervesparing procedure. Conversely, in patients undergoing RARP only obesity is associated with increased OR time. Patients with larger prostates or increased BMI might benefit most from RARP compared to ORP.
The hidden burden of severe asthma: from patient perspective to new opportunities for clinicians
(2020)
Severe asthma is an important topic in respiratory diseases, due to its high impact on morbidity and mortality as well as on health-care resources. The many challenges that still exist in the management of the most difficult-to-treat forms of the disease, and the acknowledgement of the existence of unexplored areas in the pathophysiological mechanisms and the therapeutic targets represent an opportunity to gather experts in the field with the immediate goals to summarize current understanding about the natural history of severe asthma and to identify gaps in knowledge and research opportunities, with the aim to contribute to improved medical care and health outcomes. This article is a consensus document from the “International Course on Severe Asthma” that took place in Palermo, Italy, on May 10–11, 2019. Emerging topics in severe asthma were addressed and discussed among experts, with special focus on patient’s needs and research opportunities, with the aim to highlight the unanswered questions in the diagnostic process and therapeutic approach.
Objective To evaluate the success of initiation of adjunctive brivaracetam in patients who required a change in antiepileptic drug (AED) regimen and substituted at least one AED with brivaracetam. Methods In this retrospective noninterventional study conducted in specialized epilepsy centers across Germany, patients initiated adjunctive brivaracetam between February 15, 2016, and August 31, 2016, as part of an intended change in AED regimen. The primary effectiveness variable was the proportion of patients who continued on brivaracetam after 3 months, and withdrew at least one AED either before or within 6 months after brivaracetam initiation. Results Five hundred and six patients had at least one brivaracetam dose and were included in the safety set (SS). Four hundred and seventy patients started to reduce the dose of one AED before/after brivaracetam initiation, had at least one concomitant AED at brivaracetam initiation, and were included in the full analysis set (FAS) for effectiveness analyses. At baseline, patients had a median of seven lifetime AEDs and a median of 3.8 seizures/28 days. In the SS, 85.2% of patients withdrew one AED before/after initiation of brivaracetam, most commonly levetiracetam (49.4%). 46.2% of patients substituted another AED with brivaracetam within 24 hours (fast withdrawal). The proportions of patients (FAS) who continued on brivaracetam after 3 and 6 months and withdrew one AED were 75.5% and 46.6%, respectively. After 6 months, 32.1% of patients were 50% responders; 13.0% were seizure‐free. In the SS, 34.6% of patients reported treatment‐emergent adverse events (TEAEs); 21.9% had TEAEs that were assessed by the treating physician as drug‐related. Incidences of behavioral AEs before (3‐month baseline) and after brivaracetam initiation in patients who withdrew levetiracetam were 19.2% and 8.0%, respectively (5.0% and 7.7% in patients who withdrew other AEDs). Significance Brivaracetam was effective and well‐tolerated in patients who required a change in AED drug regimen and initiated adjunctive brivaracetam in German clinical practice.
Postoperative complications after pancreatic surgery are still a significant problem in clinical practice. The aim of this study was to characterize and compare the microbiomes of different body compartments (bile duct, duodenal mucosa, pancreatic tumor lesion, postoperative drainage fluid, and stool samples; preoperative and postoperative) in patients undergoing pancreatic surgery for suspected pancreatic cancer, and their association with relevant clinical factors (stent placement, pancreatic fistula, and gland texture). For this, solid (duodenal mucosa, pancreatic tumor tissue, stool) and liquid (bile, drainage fluid) biopsy samples of 10 patients were analyzed using 16s rRNA gene next-generation sequencing. Our analysis revealed: (i) a distinct microbiome in the different compartments, (ii) markedly higher abundance of Enterococcus in patients undergoing preoperative stent placement in the common bile duct, (iii) significant differences in the beta diversity between patients who developed a postoperative pancreatic fistula (POPF B/C), (iv) patients with POPF B/C were more likely to have bacteria belonging to the genus Enterococcus, and (v) differences in microbiome composition with regard to the pancreatic gland texture. The structure of the microbiome is distinctive in different compartments, and can be associated with the development of a postoperative pancreatic fistula.
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
(2020)
Background: Head and neck squamous cell cancer (HNSCC) frequently causes severe symptoms that may be reduced, when the tumor is successfully treated. The SOCCER trial studied the association of treatment response with patient reported tumor symptom burden in first line treatment of recurrent and/or metastatic HNSCC.
Methods: In this prospective, multi-center, non-interventional trial patients were treated either with platinum-based chemotherapy and cetuximab or radiotherapy and cetuximab. Tumor symptom burden was assessed every four weeks with a questionnaire containing ten visual analogue scales (VAS, range 0–100), which were summarized to the overall VAS score.
Results: Fourhundred seventy patients were registered in 97 German centers. A total of 315 patients with at least the baseline and one subsequent questionnaire were available for analysis. Changes in the VAS score were rated as absolute differences from baseline. Negative values indicate improvement of symptoms. The overall VAS score improved significantly at the first post-baseline assessment in responders (− 2.13 vs. non-responders + 1.15, p = 0.048), and even more for the best post-baseline assessment (− 7.82 vs. non-responders − 1.97, p = 0.0005). The VAS for pain (− 16.37 vs. non-responders − 8.89, p = 0.001) and swallowing of solid food (− 16.67 vs. non-responders − 5.06, p = 0.002) improved significantly more in responders (best post-baseline assessment). In the multivariable Cox regression analysis, worse overall VAS scores were associated with worse overall survival (hazard ratio for death 1.12 per 10 points increment on the overall VAS scale, 95% CI 1.05–1.20, p = 0.0009).
Conclusion: In unselected patients beyond randomized controlled trials, treatment response lowers tumor symptom burden in recurrent and/or metastatic HNSCC.
Trial registration: ClinicalTrials.gov, NCT00122460. Registered 22 Juli 2005,
Der Plexus tympanicus ist ein komplex aufgebautes Nervengeflecht in der Mukosa des Mittelohrs. Aus anatomischen Studien ist bekannt, dass zuführende und wegführende Verbindungen unterschiedlichen Hirnnerven und sympathischen Bahnen angehören. Insbesondere werden parasympathische und sympathische Innervationssysteme beschrieben und damit stellt der Plexus tympanicus einen Plexus des vegetativen Nervensystems dar.
Bisher fehlen detaillierte Analysen über die Chemoarchitektur dieses Plexus. In der vorliegenden Studie soll das Vorhandensein unterschiedlicher Neurotransmitter und -peptide untersucht werden, um Vorstellungen über die Funktion dieses komplexen Geflechts zu entwickeln.
Es wurden immuncytochemische Färbungen an sechs Parallelserien von Kryostatschnitten durchgeführt. Dabei wurden Primärantikörper benutzt, die gegen Cholinacetyltransferase (ChAT), Dopamin-β-Hydroxylase (DBH), Substanz P (SP), Vasoaktives intestinales Peptid (VIP) und Neuropeptid Y (NPY) gerichtet waren. Dadurch konnten sympathische Nervenfasern durch den Nachweis von DBH als Leitenzym für die Noradrenalinsynthese analysiert werden; parasympathische Strukturen konnten durch Anti-ChAT-AK, das Leitenzym für die Acetylcholinsynthese, differenziert werden.
Alle genannten Neurotransmitter und -peptide konnten in den Mittelohrschnitten nachgewiesen werden. Dabei wurden sie in folgenden Lokalisationen gefunden: VIP wurde vor allem in perikapillären Boutons und Gefäßwänden im gesamten Ohrbereich sowie basal im Drüsenbereich des Meatus acusticus externus nachgewiesen. In der Mittelohrschleimhaut war VIP weit verbreitet und gerade im Bereich des Promotoriums waren einzelne Zellen intensiv angefärbt, die Zeichen sekretorischer Aktivität trugen. SP wurde vor allem in netzartigen um Gefäße gelagerten Fasern und in beaded Nervenfasern in der Mittelohrschleimhaut gefunden. Auch im Bereich der Drüsen, vor allem an Talgdrüsen des äußeren Gehörgangs, wurde SP nachgewiesen. NPY-IR zeigte sich in Geflechten um große Gefäße, an motorischen Endplatten der benachbarten Muskulatur, in der Mittelohrschleimhaut, in Nervenstämmen, Ganglien des Mittelohrbereichs und weniger dicht an Drüsen. ChAT-ir Strukturen sind direkt auf dem Knochen aufliegend in der Mittelohrschleimhaut, gefäßbegleitend an motorischen Endplatten und basal an Drüsenzellen vorhanden. ChAT-ir Nervenzellperikaryen wurden in großer Zahl in Ganglien gefunden, außerdem waren die Nerven allgemein leicht positiv. DBH-ir Strukturen wurden zwischen den Drüsen, in den Gefäßwänden der Arterien im Mittelohrbereich und in Nervenstämmen nachgewiesen. Einige DBH-ir Nervenzellperikaryen befanden sich in den Ganglien innerhalb des Mittelohrbereichs und der zuführenden Hirnnerven. Auch in der Mittelohrschleimhaut wurden Perikaryen, teilweise ganglienartig organisiert, gefunden. In verschiedenen Strukturen im Innenohrbereich konnten alle Neurotransmitter und -peptide in unterschiedlich starker Tingierung nachgewiesen werden.
Anhand des Verteilungsmuster lassen sich Kolokalisationen der Neuropeptide mit noradrenergen und cholinergen Neuronen vermuten, die bereits in anderen Studien für verschiedene Komponenten des vegetativen Nervensystems beschrieben wurden. Anhand der vorliegenden Analysen wurden Lokalisationsübereinstimmungen von ChAT und VIP, ChAT und SP und DBH und NPY gefunden.
Diese Studie soll als Grundlage für weitere Untersuchungen dienen. Insbesondere für das Verständnis von Funktionen und Pathologien des Nervengeflechts bedarf es weiterer Forschung. Die vorliegende Arbeit weist eindeutig nach, dass der Plexus tympanicus ein integratives System darstellt, das im Gegensatz zu früheren Vorstellungen einer reinen Durchgangsorganisation alle Voraussetzungen für ein Kontrollsystem erfüllt.
The influence of delayed auditory feedback on action evaluation and execution of real-life action-induced sounds apart from language and music is still poorly understood. Here, we examined how a temporal delay impacted the behavioral evaluation and neural representation of hurdling and tap-dancing actions in a functional magnetic resonance imaging (fMRI) experiment, postulating that effects of delay diverge between the two, as we create action-induced sounds intentionally in tap dancing, but incidentally in hurdling. Based on previous findings, we expected that conditions differ regarding the engagement of the supplementary motor area (SMA), posterior superior temporal gyrus (pSTG), and primary auditory cortex (A1). Participants were videotaped during a 9-week training of hurdling and tap dancing; in the fMRI scanner, they were presented with point-light videos of their own training videos, including the original or the slightly delayed sound, and had to evaluate how well they performed on each single trial. For the undelayed conditions, we replicated A1 attenuation and enhanced pSTG and SMA engagement for tap dancing (intentionally generated sounds) vs. hurdling (incidentally generated sounds). Delayed auditory feedback did not negatively influence behavioral rating scores in general. Blood-oxygen-level-dependent (BOLD) response transiently increased and then adapted to repeated presentation of point-light videos with delayed sound in pSTG. This region also showed a significantly stronger correlation with the SMA under delayed feedback. Notably, SMA activation increased more for delayed feedback in the tap-dancing condition, covarying with higher rating scores. Findings suggest that action evaluation is more strongly based on top–down predictions from SMA when sounds of intentional action are distorted.
Der Nationale Aktionsplan für Menschen mit Seltenen Erkrankungen (SE) enthält 52 konkrete Maßnahmen, u. a. in den Handlungsfeldern Versorgung, Forschung, Diagnose und Informationsmanagement. Mit dem Ziel, langfristig die Qualität und Interoperabilität von nationalen Registern zu erhöhen, sieht Maßnahmenvorschlag 28 die Etablierung einer Strategiegruppe „Register für Seltene Erkrankungen“ vor. Diese Strategiegruppe hat 2016 ihre Arbeit aufgenommen. Sie berichtet hier über Entwicklungen auf nationaler und internationaler Ebene, um Empfehlungen für nationale Initiativen daraus abzuleiten.
Zusätzlich werden die Konsentierung und Implementierung sowie mit der Zeit ggf. die Anpassung eines Minimaldatensatzes zur Verwendung in Registern für Seltene Erkrankungen erläutert. Zusätzlich werden die verwendeten Datenelemente bzw. -schemata in einem sog. Metadata Repository abgebildet. Dieses Positionspapier wurde durch die Strategiegruppe sowie weitere Autoren erarbeitet und innerhalb der Gruppe konsentiert. Es wird als Konzeptpapier zum Aufbau und Betrieb von Registern der Strategiegruppe „Register“ veröffentlicht.
Therapy resistance in leukemia may be due to cancer cell-intrinsic and/or -extrinsic mechanisms. Mutations within BCR-ABL1, the oncogene giving rise to chronic myeloid leukemia (CML), lead to resistance to tyrosine kinase inhibitors (TKI), and some are associated with clinically more aggressive disease and worse outcome. Using the retroviral transduction/transplantation model of CML and human cell lines we faithfully recapitulate accelerated disease course in TKI resistance. We show in various models, that murine and human imatinib-resistant leukemia cells positive for the oncogene BCR-ABL1T315I differ from BCR-ABL1 native (BCR-ABL1) cells with regards to niche location and specific niche interactions. We implicate a pathway via integrin β3, integrin-linked kinase (ILK) and its role in deposition of the extracellular matrix (ECM) protein fibronectin as causative of these differences. We demonstrate a trend towards a reduced BCR-ABL1T315I+ tumor burden and significantly prolonged survival of mice with BCR-ABL1T315I+ CML treated with fibronectin or an ILK inhibitor in xenogeneic and syngeneic murine transplantation models, respectively. These data suggest that interactions with ECM proteins via the integrin β3/ILK-mediated signaling pathway in BCR-ABL1T315I+ cells differentially and specifically influence leukemia progression. Niche targeting via modulation of the ECM may be a feasible therapeutic approach to consider in this setting.
Natural killer (NK) cells are a noteworthy lymphocyte subset in cancer adoptive cell therapy. NK cells initiate innate immune responses against infections and malignancies with natural cytotoxicity, which is independent of foreign antigen recognition. Based on these substantive features, genetically modifying NK cells is among the prime goals in immunotherapy but is currently difficult to achieve. Recently, we reported a fully human CAR19 construct (huCAR19) with remarkable function in gene-modified T-cells. Here, we show efficient and stable gene delivery of huCAR19 to primary human NK cells using lentiviral vectors with transduction efficiencies comparable to those achieved with NK cell lines. These huCAR19 NK cells display specific and potent cytotoxic activity against target cells. To improve homing of NK cells to the bone marrow, we augmented huCAR19 NK cells with the human CXCR4 gene, resulting in transgenically augmented CAR NK cells (TRACKs). Compared to conventional CAR NK cells, TRACKs exhibit enhanced migration capacity in response to recombinant SDF-1 or bone marrow stromal cells while retaining functional and cytolytic activity against target cells. Based on these promising findings, TRACKs may become a novel candidate for immunotherapeutic strategies in clinical applications.
Introduction: Prophylaxis with factor VIII (FVIII) concentrates in children with haemophilia A (HA) is current standard of care. The benefit of prophylactic treatment for adult HA patients is not commonly accepted.
Aim: To investigate the benefit of prophylaxis over on‐demand treatment in adult and elderly patients with severe or non‐severe HA in a real‐life setting.
Methods: Data from 163 patients comprising 1202 patient‐years were evaluated for 7.5 (±5.3) years. The effects on the annual bleeding rate (ABR, including spontaneous and traumatic bleeds) of treatment with a plasma‐derived FVIII concentrate, the patient's age and disease severity were investigated. The effect of changing the treatment from on demand to continuous prophylaxis on the patients’ ABRs was further analysed.
Results: Prophylaxis had the greatest effect on the ABRs of patients of any age with severe or non‐severe HA. The difference in ABR of all patients treated on demand (median 31.4; interquartile range (IQR) 27.6; N = 83) compared with those treated prophylactically (median 1.3; IQR 3.6; N = 122) was statistically significant (P < .05), even for patients with non‐severe HA (median 8.4; IQR 15.5; N = 11) vs median 1.5; IQR 4.2 (N = 17), P < .05). Patients, aged up to 88 years, switching from on demand to continuous prophylaxis showed the lowest median ABR (1.1; N = 51) after their regimen change.
Conclusion: Any (even low‐frequency) prophylaxis results in lower ABR than on‐demand treatment. Patients switching to prophylaxis benefitted the most, irrespective of age or HA severity. Prophylactic treatment—even tertiary—is the regimen of choice for patients of any age, including elderly patients, with severe or non‐severe HA.
Osteonecrosis (ON) is an acquired debilitating skeletal disorder, which is caused by a multitude of traumatic and non-traumatic etiological factors. Vascular damage, mechanical stress and increased intraosseous pressure have been discussed as contributors to ON. The optimal treatment of ON remains to be determined, since the current gold standard, core decompression, is insufficiently effective. Specific properties of mesenchymal stromal cells (MSCs) provide the rationale for their assessment in advanced stages of ON: Osteoinductive potential has been demonstrated and MSC preparations of suitable quality for use as medicinal products have been developed. Here we review the scant information on the use of allogeneic or autologous MSCs in advanced ON as well as potentially supportive data from pre-clinical studies with autologous bone marrow mononuclear cells (auto BM-MNCs), which have been studied quite extensively and the presumed therapeutic effect of which was attributed to the rare MSCs contained in these cell products. Outcomes in clinical trials with MSCs and auto-BM-MNCs remain preliminary and non-definitive, at best promising, with respect to their pharmacological effect. Clearly, though, the application of any of these cell therapies was technically feasible and safe in that it was associated with low complication rates. The heterogeneity of cell type and source, study protocols, cell manufacturing, cell properties, cell doses and surgical techniques might contribute to inconsistent results.
In Eurotransplant kidney allocation system (ETKAS), candidates can be considered unlimitedly for repeated re‐transplantation. Data on outcome and benefit are indeterminate. We performed a retrospective 15‐year patient and graft outcome data analysis from 1464 recipients of a third or fourth or higher sequential deceased donor renal transplantation (DDRT) from 42 transplant centers. Repeated re‐DDRT recipients were younger (mean 43.0 vs. 50.2 years) compared to first DDRT recipients. They received grafts with more favorable HLA matches (89.0% vs. 84.5%) but thereby no statistically significant improvement of patient and graft outcome was found as comparatively demonstrated in 1st DDRT. In the multivariate modeling accounting for confounding factors, mortality and graft loss after 3rd and ≥4th DDRT (P < 0.001 each) and death with functioning graft (DwFG) after 3rd DDRT (P = 0.001) were higher as compared to 1st DDRT. The incidence of primary nonfunction (PNF) was also significantly higher in re‐DDRT (12.7%) than in 1st DDRT (7.1%; P < 0.001). Facing organ shortage, increasing waiting time, and considerable mortality on dialysis, we question the current policy of repeated re‐DDRT. The data from this survey propose better HLA matching in first DDRT and second DDRT and careful selection of candidates, especially for ≥4th DDRT.
Confinement measures during the COVID-19 pandemic have caused substantial reductions in global physical activity (PA) levels. In view of the manifold health benefits of PA, the development of interventions counteracting this trend is paramount. Our survey with 15,261 participants (38 ± 15 years, 58.5% females) examined preferences towards digital home exercise programs in 14 countries affected by COVID-19. More than two-thirds of the sample (68.4%, n = 10,433) indicated being interested in home exercise, and most participants were willing to work out at least three times per week (89.3%, n = 9328). Binary logistic regression revealed that female sex, working part-time, younger age, and being registered in a gym were associated with willingness to exercise. Flexibility (71.1%, n = 7377), resistance (68.6%, n = 7116), and endurance training (62.4%, n = 6478) were the most preferred types of exercise. Our results may guide health providers in developing individually tailored PA interventions during the current and future pandemics.
Prior studies indicate the protective role of Ultraviolet-B (UVB) radiation in human health, mediated by vitamin D synthesis. In this observational study, we empirically outline a negative association of UVB radiation as measured by ultraviolet index (UVI) with the number of COVID-19 deaths. We apply a fixed-effect log-linear regression model to a panel dataset of 152 countries over 108 days (n = 6524). We use the cumulative number of COVID-19 deaths and case-fatality rate (CFR) as the main dependent variables and isolate the UVI effect from potential confounding factors. After controlling for time-constant and time-varying factors, we find that a permanent unit increase in UVI is associated with a 1.2 percentage points decline in daily growth rates of cumulative COVID-19 deaths [p < 0.01] and a 1.0 percentage points decline in the CFR daily growth rate [p < 0.05]. These results represent a significant percentage reduction in terms of daily growth rates of cumulative COVID-19 deaths (− 12%) and CFR (− 38%). We find a significant negative association between UVI and COVID-19 deaths, indicating evidence of the protective role of UVB in mitigating COVID-19 deaths. If confirmed via clinical studies, then the possibility of mitigating COVID-19 deaths via sensible sunlight exposure or vitamin D intervention would be very attractive.
Risk stratification for bipolar disorder using polygenic risk scores among young high-risk adults
(2020)
Objective: Identifying high-risk groups with an increased genetic liability for bipolar disorder (BD) will provide insights into the etiology of BD and contribute to early detection of BD. We used the BD polygenic risk score (PRS) derived from BD genome-wide association studies (GWAS) to explore how such genetic risk manifests in young, high-risk adults. We postulated that BD-PRS would be associated with risk factors for BD.
Methods: A final sample of 185 young, high-risk German adults (aged 18–35 years) were grouped into three risk groups and compared to a healthy control group (n = 1,100). The risk groups comprised 117 cases with attention deficit hyperactivity disorder (ADHD), 45 with major depressive disorder (MDD), and 23 help-seeking adults with early recognition symptoms [ER: positive family history for BD, (sub)threshold affective symptomatology and/or mood swings, sleeping disorder]. BD-PRS was computed for each participant. Logistic regression models (controlling for sex, age, and the first five ancestry principal components) were used to assess associations of BD-PRS and the high-risk phenotypes.
Results: We observed an association between BD-PRS and combined risk group status (OR = 1.48, p < 0.001), ADHD diagnosis (OR = 1.32, p = 0.009), MDD diagnosis (OR = 1.96, p < 0.001), and ER group status (OR = 1.7, p = 0.025; not significant after correction for multiple testing) compared to healthy controls.
Conclusions: In the present study, increased genetic risk for BD was a significant predictor for MDD and ADHD status, but not for ER. These findings support an underlying shared risk for both MDD and BD as well as ADHD and BD. Improving our understanding of the underlying genetic architecture of these phenotypes may aid in early identification and risk stratification.
Background & Aims: Acute‐on‐chronic liver failure (ACLF) is characterized by high short‐term mortality and systemic inflammation (SI). Recently, different cardiodynamic states were shown to independently predict outcomes in cirrhosis. The relationship between cardiodynamic states, SI, and portal hypertension and their impact on ACLF development remains unclear. The aim of this study was therefore to evaluate the interplay of cardiodynamic state and SI on fatal ACLF development in cirrhosis.
Results: At inclusion, hemodynamic measures including cardiac index (CI) and hepatic venous pressure gradient of 208 patients were measured. Patients were followed prospectively for fatal ACLF development (primary endpoint). SI was assessed by proinflammatory markers such as interleukins (ILs) 6 and 8 and soluble IL‐33 receptor (sIL‐33R). Patients were divided according to CI (<3.2; 3.2‐4.2; >4.2 L/min/m2) in hypo‐ (n = 84), normo‐ (n = 69) and hyperdynamic group (n = 55). After a median follow‐up of 3 years, the highest risk of fatal ACLF was seen in hyperdynamic (35%) and hypodynamic patients (25%) compared with normodynamic (14%) (P = .011). Hyperdynamic patients showed the highest rate of SI. The detectable level of IL‐6 was an independent predictor of fatal ACLF development.
Conclusions: Cirrhotic patients with hyperdynamic and hypodynamic circulation have a higher risk of fatal ACLF. Therefore, the cardiodynamic state is strongly associated with SI, which is an independent predictor of development of fatal ACLF.
In dieser Studie haben wir die Modulation von Arachidonsäure (AA)-Stoffwechselwegen während einer Wurminfektionen mit dem Fadenwurm Heligmosomoides polygyrus bakeri (Hpb) als angeborene regulatorische Strategie zur Modulation der Typ-2-Entzündung untersucht. Wir zeigten, dass Hpb in frühen Stadien der Infektion (Tag 7) die Produktion von regulatorischen Prostaglandinen (PGE2 und 6-keto PGF1-α, ein Abbauprodukt von PGI2) und COX-Metaboliten (12-HHT und TXB2) fördert, jedoch die Sekretion von entzündungsfördernden Mediatoren PGD2 und LTs (LTB4, cysLTs) unterdrückt. Die Hpb-gesteuerte Regulierung des AA-Stoffwechsels könnte eine Strategie zur Immunsuppression/ Immunevasion dieses Parasiten darstellen, die darauf abzielt, die vom Wirt ausgelösten Immunantworten des Typs-2 zu unterbinden und sowohl die Infiltration und Rekrutierung von Granulozyten als auch die Schleimproduktion zu begrenzen und auf diese Weise das Abtöten bzw. Ausscheiden der Larven zu verhindern.
Als Schwerpunkt der Arbeit, konnten wir ebenso zeigen, dass ein Larvenextrakt aus Heligmosomoides polygyrus bakeri (HpbE) den AA Stoffwechsel in myeloiden Zellen wie Makrophagen und Granulozyten moduliert, indem die Synthese von 5-LOX in Richtung COX-Metaboliten verschoben wird. Die Behandlung von murinen und humanen Makrophagen mit HpbE induzierte die Synthese von regulatorischen Prostaglandinen (PGE2) und Prostaglandinen, die an der Wundheilung und Blutgerinnung beteiligt sind (12-HHT, TXB2), wohingegen die Produktion von entzündungsfördernden Lipidmediatoren (LTs, PGD2) unterdrückt wurde. Weiter induzierte HpbE in humanen und murinen Makrophagen die Synthese der Typ-2 hemmenden Mediatoren IL-10 und IL-1β und modulierte die Produktion von Zytokinen, die an der Regulierung von M2-Polarisierung und der Typ-2-Entzündung (IL-12, IL-28, IL-27 und TNF-α) in humanen Makrophagen beteiligt sind. Ähnlich zu der HpbE-vermittelten Eicosanoid-Umprogrammierung in Makrophagen, veränderte HpbE den AA-Stoffwechsel humaner Granulozyten und zeigt eine Verschiebung von LOX- in Richtung COX-Metabolismus. Außerdem kann HpbE direkt auf humane Granulozyten wirken und die Chemotaxis von Granulozyten effizienter hemmen als zur Asthmabehandlung verwendete Standardarzneimittel, indem es die Expression von LT synthetisierenden Enzymen (LTA4H und LTC4S) verringert und die Expression von chemotaktischen Rezeptoren (CCR3 und CRTH2) herunterreguliert.
Darüber hinaus, konnten wir die Mechanismen identifizieren, die der HpbE-gesteuerten Eicosanoid-Umprogrammierung in Makrophagen zugrunde liegen. Hpb Produkte induzierten die Aktivierung von p38 MAPK, welche COX und die Transkriptionsfaktoren HIF-1α und NFκβ aktiviert und die Produktion von Prostaglandinen (PGE2 and TXB2) sowie der Typ-2 unterdrückenden Zytokine IL-10 and IL-1β fördert. Der der Induktion des COX-Signalwegs zugrunde liegende Upstream-Mechanismus umfasste mehrere PPRs (TLR2, Dectin-1/2). Diese Rezeptoren waren allerdings nicht an der HpbE-gesteuerten Induktion von IL-10 beteiligt. Die Mechanismen der Modulation des 5-LOX-Signalweges muss noch in zukünftigen Studien weiter erforscht werden.
Das therapeutische Potential von HpbE oder HpbE-behandelten Makrophagen wurde in einem Maus Model mit HDM-induzierter allergischer Atemwegsentzündung in vivo gezeigt. Eine intranasale Behandlung mit HpbE vor HDM-Sensibilisierung und -Provokation führte zu einer Umprogrammierung des AA-Stoffwechsels und verhinderte die Allergie-induzierte Eosinophilie, Zellinfiltration, Atemwegsentzündung und Schleimproduktion. Die Modulation der Typ-2-Entzündung durch HpbE wurde vor allem durch COX-2-Metabolite vermittelt, die von HpbE-stimulierten Makrophagen freigesetzt wurden. Dies zeigte sich insbesondere darin, dass der Transfer von HpbE-stimulierten Wildtyp- aber nicht COX-2-defizienten Makrophagen vor Provokation die Granulozyten Rekrutierung und Typ-2-Entzündung während der HDM-induzierten Allergie in vivo abschwächte.
Mittels eines Maus Models für die allergische Atemwegsentzündung in unterschiedlichen Altersstufen (Neugeboren, Jungtier und Erwachsen) zeigte dieses Forschungsprojekt, dass das Alter der Sensibilisierung eine Schlüsselrolle bei der Produktion von LTs, der Expression von LT-Synthese Enzymen sowie von Faktoren, die zu strukturellen Veränderungen in den Atemwegen führen, spielt. Hier haben wir auch festgestellt, dass der Mechanismus hinter der LT-Produktion und dem Atemwegs-Remodeling im Epithel von ausgewachsenen sensibilisierten Mäusen die Aktivierung der Faktoren sPLA2X, TGM2 und Wnt5a beinhaltet.
Des Weiteren zeigte unsere Studie, dass eine Wechselwirkung zwischen entzündetem Atemwegsepithel und Alveolar-ähnlichen Makrophagen die Synthese von LTs fördern kann. Der vorgeschlagene Mechanismus startet mit der Sekretion von Wnt5a durch das entzündete Atemwegsepithel, welches die Expression von TGM2 in Makrophagen aktiviert und die Produktion von entzündungsfördernden LTs induziert, wodurch die Rolle der Makrophagen in entzündeten Atemwegen bei Erwachsenen weiter unterstützt wird. Die Relevanz der entdeckten Kaskade konnte auch in Geweben von Patienten mit chronischer Rhinosinusitis und Nasenpolypen (CRSwNP) bestätigt werden. Hohe Konzentrationen von LT Enzymen (5-LO, LTC4S LTA4H), sPLA2-X, TGM2 und Wnt5a wurden in humanen Nasenpolyp Geweben beobachtet, und hohe Konzentrationen von CysLTs wurden in Nasenpolyp Sekreten dieser Patienten gemessen. Dies lässt vermuten, dass die Expression von Atemwegs Remodeling-Faktoren, LT-Synthese Enzymen und die LT Synthese steroidresistent sind. Daher könnte diese entzündliche Kaskade ein alternatives therapeutisches Ziel für die Behandlung von Asthma darstellen, speziell bei Patienten mit steroidresistenten Formen von Atemwegsentzündungen.
Basierend auf den möglichen therapeutischen Anwendungen von HpbE haben wir begonnen, an der Charakterisierung der im HpbE vorhandenen immunmodulatorischen Wirkstoffe zu arbeiten. Glutamatdehydrogenase (GDH) und Ferritin wurden als potenzielle immunmodulatorische Komponenten von HpbE identifiziert. Es ist jedoch weitere Arbeit erforderlich, um diese in HpbE vorhandenen Proteine rekombinant herzustellen und den Wirkungsmechanismus im Bezug auf die Typ-2-Entzündung weiter aufzuklären.
Background: Blunt chest (thoracic) trauma (TxT) and haemorrhagic shock with subsequent resuscitation (H/R) induce strong systemic and local inflammatory response, which is closely associated with apoptotic cell loss and subsequently impaired organ function. The underlying mechanisms are not completely understood, therefore, the treatment of patients suffering from TxT+H/R is challenging. In our recent studies, we have demonstrated local anti-inflammatory effects of ethyl pyruvate (EtP) in lung and liver after TxT+H/R. Here, the therapeutic potential of a reperfusion regime with EtP on the early post-traumatic systemic inflammatory response and apoptotic changes after TxT followed by H/R were investigated.
Methods: Female Lewis rats underwent TxT followed by haemorrhagic shock (60 min). Resuscitation was performed with own blood transfusion and either lactated Ringers solution (LR) or LR supplemented with EtP (50 mg/kg). Sham group underwent the surgical procedures. After 2 h blood as well as lung and liver tissues were obtained for analyses. Systemic activation of neutrophils (expression of CD11b and CD62L), leukocyte phagocytosis, apoptosis (caspase-3/7 activation), pyroptosis (caspase-1 activation) and NF-κB p65 activity were assessed. p < 0.05 was considered significant.
Results: TxT+H/R-induced systemic activation of neutrophils (increased CD11b and reduced CD62L expression) was significantly reduced by EtP. Trauma-induced delayed neutrophil apoptosis was further reduced by EtP reperfusion but remained unaltered in monocytes. Reperfusion with EtP significantly increased the phagocytizing capacity of granulocytes. Trauma-induced inflammasome activation, which was observed in monocytes and not in neutrophils, was significantly reduced by EtP in both cell entities. NF-κB p65 activation, which was increased in neutrophils and monocytes was significantly decreased in monocytes.
Conclusion: TxT+H/R-induced systemic activation of both neutrophils and monocytes concomitant with increased systemic inflammation was reduced by a reperfusion with EtP and was associated with a down-regulation of NF-κB p65 activation.
Background: Lung disease phenotype varies widely even in the F508del (homozygous) genotype. Leukocyte-driven inflammation is important for pulmonary disease pathogenesis in cystic fibrosis (CF). Blood cytokines correlate negatively with pulmonary function in F508del homozygous patients, and gap junction proteins (GJA) might be related to the influx of blood cells into the lung and influence disease course. We aimed to assess the relationship between GJA1/GJA4 genotypes and the clinical disease phenotype. Methods: One-hundred-and-sixteen homozygous F508del patients (mean age 27 years, m/f 66/50) were recruited from the CF centers of Bonn, Frankfurt, and Amsterdam. Sequence analysis was performed for GJA1 and GJA4. The clinical disease course was assessed over 3 years using pulmonary function tests, body mass index, Pseudomonas aeruginosa colonization, diabetes mellitus, survival to end-stage lung disease, blood and sputum inflammatory markers. Results: Sequence analysis revealed one clinically relevant single nucleotide polymorphism. In this GJA4 variant (rs41266431), homozygous G variant carriers (n = 84/116; 72.4%) had poorer pulmonary function (FVC% pred: mean 78/86, p < 0.040) and survival to end-stage lung disease was lower (p < 0.029). The frequency of P. aeruginosa colonization was not influenced by the genotype, but in those chronically colonized, those with the G/G genotype had reduced pulmonary function (FVC% pred: mean 67/80, p < 0.049). Serum interleukin-8 (median: 12.4/6.7 pg/ml, p < 0.052) and sputum leukocytes (2305/437.5 pg/ml, p < 0.025) were higher for the G/G genotype. Conclusions: In carriers of the A allele (27.6%) the GJA4 variant is associated with significantly better protection against end-stage lung disease and superior pulmonary function test results in F508del homozygous patients. This SNP has the potential of a modifier gene for phenotyping severity of CF lung disease, in addition to the CFTR genotype.
Clinical Trial Registration: The study was registered with ClinicalTrials.gov, number NCT04242420, retrospectively on January 24th, 2020.
The sphingolipid sphingosine‐1‐phosphate (S1P) fulfills distinct functions in immune cell biology via binding to five G protein‐coupled receptors. The immune cell‐specific sphingosine‐1‐phosphate receptor 4 (S1pr4) was connected to the generation of IL‐17‐producing T cells through regulation of cytokine production in innate immune cells. Therefore, we explored whether S1pr4 affected imiquimod‐induced murine psoriasis via regulation of IL‐17 production. We did not observe altered IL‐17 production, although psoriasis severity was reduced in S1pr4‐deficient mice. Instead, ablation of S1pr4 attenuated the production of CCL2, IL‐6, and CXCL1 and subsequently reduced the number of infiltrating monocytes and granulocytes. A connection between S1pr4, CCL2, and Mϕ infiltration was also observed in Zymosan‐A induced peritonitis. Boyden chamber migration assays functionally linked reduced CCL2 production in murine skin and attenuated monocyte migration when S1pr4 was lacking. Mechanistically, S1pr4 signaling synergized with TLR signaling in resident Mϕs to produce CCL2, likely via the NF‐κB pathway. We propose that S1pr4 activation enhances TLR response of resident Mϕs to increase CCL2 production, which attracts further Mϕs. Thus, S1pr4 may be a target to reduce perpetuating inflammatory responses.
Aim: Pharmacoresistance is a major burden in epilepsy treatment. We aimed to identify genetic biomarkers in response to specific antiepileptic drugs (AEDs) in genetic generalized epilepsies (GGE). Materials & methods: We conducted a genome-wide association study (GWAS) of 3.3 million autosomal SNPs in 893 European subjects with GGE – responsive or nonresponsive to lamotrigine, levetiracetam and valproic acid. Results: Our GWAS of AED response revealed suggestive evidence for association at 29 genomic loci (p <10-5) but no significant association reflecting its limited power. The suggestive associations highlight candidate genes that are implicated in epileptogenesis and neurodevelopment. Conclusion: This first GWAS of AED response in GGE provides a comprehensive reference of SNP associations for hypothesis-driven candidate gene analyses in upcoming pharmacogenetic studies.
Einleitung: Die akute Tonsillitis gehört zu den Infektionen der oberen Atemwege und ist eine sehr häufige Erkrankung in einer Kinder- und Jugendarztpraxis. Ziel unserer Untersuchung war es, das virale und bakterielle Erregerspektrum der akuten Tonsillitis, ihre saisonale Verteilung, ihre Altersverteilung, die klinische Symptomatik und den Einfluss einer Rauchexposition zu untersuchen. Gleichzeitig sollte erneut die Sensitivität und Spezifität des angewandten StrepA ST überprüft werden.
Methoden: In drei Kinder- und Jugendarztpraxen im Rhein-Main Gebiet wurden zwischen April 2009 und Mai 2010 insgesamt 1720 Patienten mit akuten Halsschmerzen untersucht. Mit einem Anamnesebogen wurden Alter, klinische Symptomatik und die Rauchexposition erfasst. Bei allen Patienten wurde ein StrepA ST durchgeführt. In einer Praxis (Praxis 1) wurden bei 306 Patienten zusätzlich ein Abstrich für eine bakterielle Kultur und für eine Multiplex PCR auf Viren durchgeführt.
Resultate: In 84% der Fälle tritt die GAS Tonsillitis im Alter zwischen 2 und 12 Jahren auf. Es konnte keine saisonale Häufung der GAS nachgewiesen werden. Mit 64 (42%) StrepA ST positiven Patienten von 152 Raucher-Familien und 74 (37%) von 200 Nichtraucher-Raucher-Familien zeigt sich kein signifikant erhöhtes Risiko an einer GAS Tonsillitis zu erkranken, wenn mindestens ein Elternteil raucht. Bei 306 Rachenabstrichen konnten 145 (47,5%) mal Streptokokken nachgewiesen werden. Davon waren mit 133 vorwiegend GAS (92%). Die anderen Streptokokken der Gruppen C (4,8%), G (2,1%) und B (1,4%) kommen deutlich seltener vor und spielen eine untergeordnete Rolle. Die Sensitivität und Spezifität des StrepA ST war mit 89,9% und 94,1% ausgezeichnet. Bei 306 Tonsillitiden gelang bei 110 Patienten (35,8%) ein Virusnachweis. Wie erwartet fanden sich doppelt so viele Virusnachweise (46%) bei Patienten ohne GAS Nachweis als Ko-Infektionen bei einer GAS (24%). Der Anteil der Entero-/Rhinoviren unter den nachgewiesenen Viren war mit 54% am höchsten. Adenoviren waren mit 15% und Influenza- 9% die nächst häufigen Viren, Para- und Coronaviren bildeten kleinere Gruppen. Während Entero-/Rhinoviren ganzjährig vorkommen sind Influenzaviren eher in der kalten Jahreszeit für akute Tonsillitiden verantwortlich. Die Rolle der Ko-Infektion in der Entstehung und im Verlauf der akuten Tonsillitis muss in weiteren Untersuchungen erforscht werden.
Schätzungen zufolge sind weltweit etwa 71 Millionen Menschen chronisch mit dem Hepatitis-C-Virus (HCV) infiziert. Im Jahre 2016 sind rund 400.000 Menschen an einer HCV-bedingten Lebererkrankung gestorben, insbesondere aufgrund der Entwicklung von Leberzirrhose und Lebertumoren. Trotz der großen Unterschiede in den Prävalenzschätzungen und der Qualität der epidemiologischen Daten zeigt die jüngste weltweite Bewertung, dass die virämische Ausbreitung der HCV-Infektion (Prävalenz der HCV-RNA) in den meisten Industrieländern, einschließlich der USA, weniger als 1,0% beträgt (www .cdc.gov / Hepatitis / HCV). In einigen osteuropäischen Ländern wie Lettland (2,2%) oder Russland (3,3%) und bestimmten Ländern in Afrika, Ägypten (6,3%) und Gabun (7,0%) oder im Nahen Osten Syriens (3,0%) ist die Prävalenz bemerkenswert höher. In den USA und den am weitesten entwickelten Ländern gilt die gemeinsame Nutzung von Werkzeugezur Herstellung von Arzneimitteln und zur Injektion von Medikamenten (Nadeln) als die häufigste derzeitige Übertragungsart. Die vorherrschende Übertragungsart in Ländern, in denen die Ausbreitung von HCV-Infektionen im Vergleich zu den Industrieländern höher ist, beruht jedoch auf schlechten Methoden zur Infektionskontrolle und unsicherer Handhabung von Injektionsnadeln.
Wenn die chronische Infektion unbehandelt bleibt, kann sich im fortschreitenden Verlauf eine Zirrhose oder ein hepatozelluläres Karzinom bilden (Alter H. J. und Seef L. B. 2000). Die Doppeltherapie, bei der es sich um eine Kombination aus pegyliertem Interferon-α (PEG IFNα) und Ribavirin (riba) handelt, war in einigen Ländern der Dritten Welt bis vor kurzem der goldene Standard für die Behandlung von Patienten mit chronischer Hepatitis C und hat eine anhaltende virologische Reaktion erzielt. Mit nur 50% der mit HCV-Genotyp 1 infizierten Patienten (der häufigere) im Vergleich zu 80% mit Genotyp 2 oder 3, obwohl sie kostspielig und langwierig sind (z. B. 24-48 Wochen) und zahlreiche harte Nebenwirkungen aufweisen, die schwer zu bekämpfen sind tolerieren (Erklärung der National Institutes of Health Consensus Development Conference: Management von Hepatitis C: 2002 - 10.-12. Juni 2002 2002). Die Identifizierung des JFH1 (japanische fulminante Hepatitis Typ 1) -Isolats wurde in einigen in vitro-Studien zu HCV als wichtiger Durchbruch bei der HCV-Behandlung angesehen. Die Verwendung dieses Isolats führte nachfolgend zu einem besseren Verständnis des HCV-Lebenszyklus und der 3D-Strukturen der viralen Proteine. Basierend auf dieser Erkenntnis konnten die ersten direkt wirkenden antiviralen Mittel (DAAs) entwickelt werden, die spezifisch virale Proteine beeinflussen. Die beiden Proteasehemmer (PI) Telaprevir und Boceprevir hemmen die virale NS3-4A-Protease und wurden 2011 als Kombinationstherapie mit PEG IFNα und Ribavirin zugelassen, was die anhaltende virologische Reaktion auf 67-75% erhöhte (Pawlotsky et al. 2015).
Die Optimierung der gegenwärtigen Arzneimittelregime, die Einschränkung des Problems der Mutationsresistenz, die Gestaltung einer individualisierten Therapie, der Zugang zu diesen therapeutischen antiviralen Arzneimitteln und ihr hoher Preis bleiben weiterhin eine Herausforderung (Pawlotsky 2016; Pawlotsky et al. 2015; Sarrazin 2016). Die Entwicklung eines Impfstoffs wird jedoch als größte Herausforderung für die weltweite Kontrolle von HCV angesehen (Bukh 2016). Aus diesem Grund ist es wichtig, weiterhin mehr über den HCV-Lebenszyklus und die Faktoren zu erfahren, die sich auf die Replikation und den gesamten Lebenszyklus auswirken können, um effiziente, qualitativ hochwertige und vor allem leicht zugängliche Behandlungen für alle Menschen weltweit zu entwickeln.
Der Lipidstoffwechsel und insbesondere das Cholesteringleichgewicht werden durch die HCV-Infektion beeinflusst. Die Korrelation zwischen Lipidstoffwechsel und HCV wurde klinisch seit langem beobachtet. In den Leberbiopsien von mit HCV infizierten Patienten wurde ein Anstieg der in den Lipidtröpfchen im Cytosol akkumulierten neutralen Lipide festgestellt (Dienes et al. 1982). Das Hepatitis-C-Virus wurde auch von Hypobetalipoproteinämie, Hypocholesterinämie und Lebersteatose begleitet (Schaefer und Chung 2013). Die Leber ist der primäre Ort für die Synthese, Speicherung und Oxidation von Lipiden und anderen Makromolekülen. Daher ist der Fettstoffwechsel in der Leber für die Aufrechterhaltung der systemischen Nährstoffhomöostase von wesentlicher Bedeutung. Eine Dysregulation des Leberlipidstoffwechsels ist ein Kennzeichen mehrerer Krankheiten wie Diabetes, alkoholische und nichtalkoholische Fettlebererkrankungen sowie parasitäre und virale Infektionen, einschließlich einer HCV-Infektion. (Erklärung der National Institutes of Health Consensus Development Conference: Management von Hepatitis C: 2002 - 10.-12. Juni 2002 2002; Fon Tacer und Rozman 2011; Chen et al. 2013; Reddy und Rao 2006; Visser et al. 2013; Wu und Parhofer 2014)
...
Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases
(2020)
Simple Summary: The prognosis for patients with breast cancer that has spread to the brain is poor, and survival for these women hasn’t improved over the last few decades. We do not currently test for asymptomatic brain metastases in breast cancer patients, although this does happen in some other types of cancer. In this study we wanted to find out more about breast cancer that has spread to the brain and in particular to see whether there might be any advantage to spotting brain metastases before the development of neurological symptoms. Overall, our results suggest that women could be better off if their brain metastases are diagnosed before they begin to cause symptoms. We now need to carry out a clinical trial to see what happens if we screen high-risk breast cancer patients for brain metastases. This will verify whether doing so could increase survival, symptom control or quality of life.
Abstract: Background: Brain metastases (BM) have become a major challenge in patients with metastatic breast cancer. Methods: The aim of this analysis was to characterize patients with asymptomatic BM (n = 580) in the overall cohort of 2589 patients with BM from our Brain Metastases in Breast Cancer Network Germany (BMBC) registry. Results: Compared to symptomatic patients, asymptomatic patients were slightly younger at diagnosis (median age: 55.5 vs. 57.0 years, p = 0.01), had a better performance status at diagnosis (Karnofsky index 80–100%: 68.4% vs. 57%, p < 0.001), a lower number of BM (>1 BM: 56% vs. 70%, p = 0.027), and a slightly smaller diameter of BM (median: 1.5 vs. 2.2 cm, p < 0.001). Asymptomatic patients were more likely to have extracranial metastases (86.7% vs. 81.5%, p = 0.003) but were less likely to have leptomeningeal metastasis (6.3% vs. 10.9%, p < 0.001). Asymptomatic patients underwent less intensive BM therapy but had a longer median overall survival (statistically significant for a cohort of HER2-positive patients) compared to symptomatic patients (10.4 vs. 6.9 months, p < 0.001). Conclusions: These analyses show a trend that asymptomatic patients have less severe metastatic brain disease and despite less intensive local BM therapy still have a better outcome (statistically significant for a cohort of HER2-positive patients) than patients who present with symptomatic BM, although a lead time bias of the earlier diagnosis cannot be ruled out. Our analysis is of clinical relevance in the context of potential trials examining the benefit of early detection and treatment of BM.
The ecological validity of neuropsychological testing (NT) has been questioned in the sports environment. A frequent criticism is that NT, mostly consisting of pen and paper or digital assessments, lacks relevant bodily movement. This study aimed to identify the determinants of a newly developed testing battery integrating both cognitive and motor demands. Twenty active individuals (25 ± 3 years, 11 males) completed the new motor-cognitive testing battery (MC), traditional NT (Stroop test, Trail Making test, Digit Span test) and isolated assessments of motor function (MF; Y-balance test, 20m-sprint, counter-movement jump). Kendal’s tau and partial Spearman correlations were used to detect associations between MC and NT/MF. Except for two items (Reactive Agility A and counter-movement jump; Run-Decide and sprint time; r = 0.37, p < 0.05), MC was not related to MF. Similarly, MC and NT were mostly unrelated, even when controlling for the two significant motor covariates (p > 0.05). The only MC item with (weak to moderate) associations to NT was the Memory Span test (Digit Span backwards and composite; r = 0.43–0.54, p < 0.05). In sum, motor-cognitive function appears to be largely independent from its two assumed components NT and MF and may represent a new parameter in performance diagnostics.
Background: A large number of idiosyncratic drug induced liver injury (iDILI) and herb induced liver injury(HILI) cases of variable quality has been published but some are a matter of concern if the cases were not evaluated for causality using a robust causality assessment method (CAM) such as RUCAM (Roussel Uclaf Causality Assessment Method) as diagnostiinjuryc algorithm. The purpose of this analysis was to evaluate the worldwide use of RUCAM in iDILI and HILI cases. Methods: The PubMed database (1993–30 June 2020) was searched for articles by using the following key terms: Roussel Uclaf Causality Assessment Method; RUCAM; Idiosyncratic drug induced liver injury; iDILI; Herb induced liver injury; HILI. Results: Considering reports published worldwide since 1993, our analysis showed the use of RUCAM for causality assessment in 95,885 cases of liver injury including 81,856 cases of idiosyncratic DILI and 14,029 cases of HILI. Among the top countries providing RUCAM based DILI cases were, in decreasing order, China, the US, Germany, Korea, and Italy, with China, Korea, Germany, India, and the US as the top countries for HILI. Conclusion: Since 1993 RUCAM is certainly the most widely used method to assess causality in IDILI and HILI. This should encourage practitioner, experts, and regulatory agencies to use it in order to reinforce their diagnosis and to take sound decisions.
Colorectal cancer (CRC) is one of the most frequently diagnosed tumor in humans and one of the most common causes of cancer-related death worldwide. The pathogenesis of CRC follows a multistage process which together with somatic gene mutations is mainly attributed to the dysregulation of signaling pathways critically involved in the maintenance of homeostasis of epithelial integrity in the intestine. A growing number of studies has highlighted the critical impact of members of the tripartite motif (TRIM) protein family on most types of human malignancies including CRC. In accordance, abundant expression of many TRIM proteins has been observed in CRC tissues and is frequently correlating with poor survival of patients. Notably, some TRIM members can act as tumor suppressors depending on the context and the type of cancer which has been assessed. Mechanistically, most cancer-related TRIMs have a critical impact on cell cycle control, apoptosis, epithelial–mesenchymal transition (EMT), metastasis, and inflammation mainly through directly interfering with diverse oncogenic signaling pathways. In addition, some recent publications have emphasized the emerging role of some TRIM members to act as transcription factors and RNA-stabilizing factors thus adding a further level of complexity to the pleiotropic biological activities of TRIM proteins. The current review focuses on oncogenic signaling processes targeted by different TRIMs and their particular role in the development of CRC. A better understanding of the crosstalk of TRIMs with these signaling pathways relevant for CRC development is an important prerequisite for the validation of TRIM proteins as novel biomarkers and as potential targets of future therapies for CRC.
Hypertonie stellt in der westlichen Welt die Haupttodesursache dar, obwohl sie im Hinblick auf die pharmakologischen Therapieoptionen gut behandelbar ist. Hauptursächlich ist hierfür eine, vor allem durch eine Non-Adhärenz (u.a. bedingt durch den asymptomatischen Charakter) und in selteneren Fällen eine aufgrund einer therapieresistente Hypertonie (TRH) verursachte, unzureichende Blutdruckkontrolle. Eine Möglichkeit zur Überprüfung der Therapietreue in der antihypertensiven Therapie ist der qualitative Nachweis der Arzneistoffe im Blut oder Urin. Unklar ist, inwiefern die Substanzen in einer biologischen Probe innerhalb des Dosierungsintervalls oder darüber hinaus nachweisbar sind und es zu einer Falschbeurteilung kommen kann.
Daher wurde eine quantitative chromatographisch-tandem-massenspektrometrische Methode für das Therapeutische Drug Monitoring von blutdrucksenkenden Arzneistoffen entwickelt und analytisch vollständig validiert. Bei 38 Patienten mit überwachter Medikamenteneinnahme wurde die Aussagekraft der Methode hinsichtlich der Bestätigung einer Adhärenz zunächst mittels zweier Wirkstoffkonzentrationen im Serum (Tal- und Spitzenspiegel) überprüft. Zur Bewertung der Konzentrationen wurden zwei Konzepte evaluiert. Einerseits wurde die untere Grenze des therapeutischen Referenzbereiches (TRR, Literaturdaten) und andererseits die mittels Rechenmodell (Daten pharmakokinetischer Studien) individuell ermittelte, dosisbezogene Arzneimittelkonzentration (DRC) evaluiert. In einem zweiten Studienansatz wurde diese neue quantitative Methode an einem Kollektiv von 36 ambulanten Patienten (ohne überwachte Medikamenteneinnahme) angewendet und zur Überprüfung der Aussagekraft mit Ergebnissen des etablierten Urinscreenings verglichen.
Die gemessenen Wirkstoffkonzentrationen von Atenolol (64 bis 564 ng/ml), Bisoprolol (2,5 bis 53 ng/ml), Metoprolol (5,8 bis 110 ng/ml), Nebivolol (0,32 bis 3,4 ng/ml), Hydrochlorothiazid (15 bis 606 ng/ml), Furosemid (22 ng/ml), Torasemid (17 bis 1829 ng/ml), Canrenon (25 bis 221 ng/ml), Amlodipin (2,4 bis 35 ng/ml), Lercanidipin (0,24 bis 21 ng/ml), Candesartan (6,0 bis 268 ng/ml), Telmisartan (22 bis 375 ng/ml) und Valsartan (115 bis 7962 ng/ml) haben gezeigt, dass die quantitative Analyse von Antihypertensiva in Serumproben und deren Auswertung auf Basis der individuell berechneten unteren DRC in der Beurteilung einer Adhärenz vielversprechend ist.
Die Auswertung auf Basis der unteren Grenze des TRR signalisierte bei den stationären Patienten (überwachte Einnahme) innerhalb der Substanzklasse der Diuretika (ohne Torasemid) bei 16,7 %, der β-Blocker bei 29,4 %, der Calciumkanal-Blocker bei 14,8 % und der AT1-Antagonisten bei 25 % fälschlicherweise eine Non-Adhärenz.
Die rein qualitative Urinanalyse zeigte im Falle der β-Blocker Atenolol, Bisoprolol und des Diuretikums HCT aufgrund einer hohen Bioverfügbarkeit, einer langen Halbwertszeit oder einer überwiegend renalen Ausscheidung der Muttersubstanz ein Nachweisfenster über das Dosierungsintervall hinaus, was bedingt, dass einige Patienten fälschlicherweise als adhärent gewertet wurden. Ein anderes Problem zeigte sich bei einigen Patienten, die mit dem AT1-Antagonist Candesartan oder dem Calciumkanal-Blocker Lercanidipin behandelt wurden und die als non-adhärent eingestuft wurden. Eine geringe Bioverfügbarkeit, eine hohe Metabolisierungsrate oder geringe renale Ausscheidung der unveränderten Arzneistoffe lies auf eine mangelhafte Nachweisbarkeit innerhalb des Dosierungsintervalls und damit auf eine eingeschränkte Beurteilbarkeit schließen.
Aus den Untersuchungen ergibt sich, dass es bei Anwendung qualitativer Nachweismethoden aufgrund besonderer Pharmakokinetiken einzelner antihypertensiver Wirkstoffe zur Fehleinschätzung der Adhärenz kommen kann. Die neu entwickelte Methodik in Form einer quantitativen Serumanalyse ist unter Verwendung patientenindividueller Bewertungskriterien bei dieser Fragestellung überlegen.
Postoperative thrombotic thrombocytopenic purpura (TTP) shows clinical presentation similar to classical TTP, whereas exact pathophysiological contexts remain unexplained. In this study, we investigated intraoperative and postoperative changes in ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs, member 13), von Willebrand factor (VWF), large VWF multimers, and interleukin-6 (IL-6) in vascular surgery patients. The objective was to compare the impact of endovascular, peripheral, and aortic surgery on target parameters which are supposed to play a role in surgery-associated TTP. A total of 93 vascular surgery patients were included and divided into 4 groups according to the specific type of intervention they underwent. Blood samples were taken preoperatively, intraoperatively, and postoperatively on days 2 and 4. The ADAMTS-13 activity decreased significantly in 3 of the 4 groups during surgery (from median 81% to 49%, P < .001, in the group undergoing aortoiliacal interventions), whereas the percentage of large VWF multimers increased in all groups of patients. von Willebrand factor antigen increased significantly in all groups on postoperative day 2 and IL-6 increased significantly in the intraoperative and early postoperative period. There was no significant correlation between the intraoperative decrease in ADAMTS-13 and the increase in VWF or IL-6. No patient in this study showed clinical picture of TTP; the precise cause and clinical significance of moderately reduced ADAMTS-13 activity in the perioperative setting have not yet been definitely determined.
Background: Macrophage Migration Inhibitory Factor (MIF) is highly elevated after cardiac surgery and impacts the postoperative inflammation. The aim of this study was to analyze whether the polymorphisms CATT5–7 (rs5844572/rs3063368,“-794”) and G>C single-nucleotide polymorphism (rs755622,-173) in the MIF gene promoter are related to postoperative outcome. Methods: In 1116 patients undergoing cardiac surgery, the MIF gene polymorphisms were analyzed and serum MIF was measured by ELISA in 100 patients. Results: Patients with at least one extended repeat allele (CATT7) had a significantly higher risk of acute kidney injury (AKI) compared to others (23% vs. 13%; OR 2.01 (1.40–2.88), p = 0.0001). Carriers of CATT7 were also at higher risk of death (1.8% vs. 0.4%; OR 5.12 (0.99–33.14), p = 0.026). The GC genotype was associated with AKI (20% vs. GG/CC:13%, OR 1.71 (1.20–2.43), p = 0.003). Multivariate analyses identified CATT7 predictive for AKI (OR 2.13 (1.46–3.09), p < 0.001) and death (OR 5.58 (1.29–24.04), p = 0.021). CATT7 was associated with higher serum MIF before surgery (79.2 vs. 50.4 ng/mL, p = 0.008). Conclusion: The CATT7 allele associates with a higher risk of AKI and death after cardiac surgery, which might be related to chronically elevated serum MIF. Polymorphisms in the MIF gene may constitute a predisposition for postoperative complications and the assessment may improve risk stratification and therapeutic guidance.